CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><script src="https://cmp.osano.com/6olh2SicG0V81Mlk/1f9d883d-3834-40b9-9a96-6f89a1cda98b/osano.js"></script><title>Research and Opportunities at the 2024 ASCP Annual Meeting</title><meta name="description" content="Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more."/><meta property="og:url" content="https://www.psychiatrictimes.com/view/research-and-opportunities-at-the-2024-ascp-annual-meeting "/><meta property="og:title" content="Research and Opportunities at the 2024 ASCP Annual Meeting"/><meta property="og:image" content="https://cdn.sanity.io/images/0vv8moc6/psychtimes/8ddbdd713f36df89e072d6a475712b13a7521d5f-6000x4000.jpg?fit=crop&auto=format"/><meta property="og:site_name" content="Psychiatric Times"/><meta property="og:description" content="Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more."/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Research and Opportunities at the 2024 ASCP Annual Meeting"/><meta name="twitter:image" content="https://cdn.sanity.io/images/0vv8moc6/psychtimes/8ddbdd713f36df89e072d6a475712b13a7521d5f-6000x4000.jpg?fit=crop&auto=format"/><meta name="twitter:site" content="@@PsychTimes"/><meta name="twitter:description" content="Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more."/><meta name="robots" content="max-image-preview:large"/><meta name="robots" content="max-video-preview:-1"/><link rel="preconnect dns-prefetch" href="https://cmp.osano.com"/><link rel="preconnect dns-prefetch" href="https://res.lassomarketing.io"/><link rel="preconnect dns-prefetch" href="https://www.lightboxcdn.com"/><link rel="preconnect dns-prefetch" href="https://pub.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.segment.com"/><link rel="preconnect dns-prefetch" href="https://securepubads.g.doubleclick.net"/><link rel="preconnect dns-prefetch" href="https://pagead2.googlesyndication.com"/><link rel="preconnect dns-prefetch" href="https://cdn.sanity.io"/><link rel="preconnect dns-prefetch" href="https://www.google-analytics.com"/><link rel="preconnect dns-prefetch" href="https://www.googletagmanager.com"/><link rel="preconnect dns-prefetch" href="https://player.vimeo.com"/><link rel="preconnect dns-prefetch" href="https://youtube.com"/><link rel="preconnect dns-prefetch" href="https://connect.facebook.net"/><link rel="preconnect dns-prefetch" href="https://www.facebook.com"/><link rel="preconnect dns-prefetch" href="https://static.ads-twitter.com"/><link rel="preconnect dns-prefetch" href="https://ad.doubleclick.net"/><link rel="preload" href="https://securepubads.g.doubleclick.net/tag/js/gpt.js"/><link rel="preload" href="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"/><link rel="icon" href="/favicon.ico"/><script async="" src="https://securepubads.g.doubleclick.net/tag/js/gpt.js"></script><script src="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"></script><script src="https://one.psychiatrictimes.com/tagmanager/scripts/one.js"></script><script>window.dataLayer = window.dataLayer || []; window.dataLayer.push({ event: "page_dimensions", pageTitle: "Research and Opportunities at the 2024 ASCP Annual Meeting", dimension9: "", dimension11: "ascp", dimension12: "", dimension13: "Articles", dimension14: "Erin Crown, MHS, PA-C, Psych-CAQ", dimension15: "research-and-opportunities-at-the-2024-ascp-annual-meeting", dimension18: "2024-05-30T16:45:07.968Z", dimension19: "", dimension20: "", });</script><script type="module"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5V9L5PL'); </script><script type="module"> var ALGOLIA_INSIGHTS_SRC = "https://cdn.jsdelivr.net/npm/search-insights@2.4.0"; !function(e,a,t,n,s,i,c){e.AlgoliaAnalyticsObject=s,e[s]=e[s]||function(){ (e[s].queue=e[s].queue||[]).push(arguments)},i=a.createElement(t),c=a.getElementsByTagName(t)[0], i.async=1,i.src=n,c.parentNode.insertBefore(i,c) }(window,document,"script",ALGOLIA_INSIGHTS_SRC,"aa");</script><link rel="canonical" href="https://www.psychiatrictimes.com/view/research-and-opportunities-at-the-2024-ascp-annual-meeting"/><link rel="preload" as="image" imagesrcset="/_next/image?url=%2FPsychiatricTimes_40yrs_ko%201.png&w=256&q=75 1x, /_next/image?url=%2FPsychiatricTimes_40yrs_ko%201.png&w=640&q=75 2x"/><meta name="robots" content="max-image-preview:large"/><meta name="robots" content="max-video-preview:-1"/><meta name="next-head-count" content="13"/><link rel="preconnect" href="https://res.lassomarketing.io"/><script async="" type="text/javascript" src="https://www.lightboxcdn.com/static/lightbox_mjh.js"></script><script defer="" src="https://res.lassomarketing.io/scripts/lasso-imp-id-min.js" type="text/javascript"></script> <script defer="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js"></script> <script type="module"> !function(){var analytics=window.analytics=window.analytics||[];if(!analytics.initialize)if(analytics.invoked)window.console&&console.error&&console.error("Segment snippet included twice.");else{analytics.invoked=!0;analytics.methods=["trackSubmit","trackClick","trackLink","trackForm","pageview","identify","reset","group","track","ready","alias","debug","page","once","off","on","addSourceMiddleware","addIntegrationMiddleware","setAnonymousId","addDestinationMiddleware"];analytics.factory=function(e){return function(){var t=Array.prototype.slice.call(arguments);t.unshift(e);analytics.push(t);return analytics}};for(var e=0;e<analytics.methods.length;e++){var key=analytics.methods[e];analytics[key]=analytics.factory(key)}analytics.load=function(key,e){var t=document.createElement("script");t.type="text/javascript";t.async=!0;t.src="https://cdn.segment.com/analytics.js/v1/" + key + "/analytics.min.js";var n=document.getElementsByTagName("script")[0];n.parentNode.insertBefore(t,n);analytics._loadOptions=e};analytics.SNIPPET_VERSION="4.13.1"; window.LassoImpressionID = lassoImpID(); analytics.load("BBbKMoOjmhsxPnbd2nO6osz3zq67DzuN"); analytics.page({ 'LassoImpressionID': window.LassoImpressionID }); }}(); </script> <script src="https://www.googleoptimize.com/optimize.js?id=OPT-NVFJRDN"></script><link rel="preload" href="/_next/static/css/0bba0d4f7f215be5.css" as="style"/><link rel="stylesheet" href="/_next/static/css/0bba0d4f7f215be5.css" data-n-g=""/><link rel="preload" href="/_next/static/css/1fd9d1dcb68b7a42.css" as="style"/><link rel="stylesheet" href="/_next/static/css/1fd9d1dcb68b7a42.css" data-n-p=""/><link rel="preload" href="/_next/static/css/159521ba7be98a3c.css" as="style"/><link rel="stylesheet" href="/_next/static/css/159521ba7be98a3c.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="/_next/static/chunks/webpack-1bcda9c6c92045bc.js" defer=""></script><script src="/_next/static/chunks/framework-45ce3d09104a2cae.js" defer=""></script><script src="/_next/static/chunks/main-c1ce322a402d266c.js" defer=""></script><script src="/_next/static/chunks/pages/_app-99f1ce586bb59b05.js" defer=""></script><script src="/_next/static/chunks/69bd6bf3-c7219ac9ecb38ac9.js" defer=""></script><script src="/_next/static/chunks/f36c6662-e730e1316f9aa347.js" defer=""></script><script src="/_next/static/chunks/8eec4907-bd18a9d50c17fbc1.js" defer=""></script><script src="/_next/static/chunks/065a3ddb-42216585c327b2a5.js" defer=""></script><script src="/_next/static/chunks/72585f70-0d4479e14d41a365.js" defer=""></script><script src="/_next/static/chunks/9814d858-cb162ab048445baf.js" defer=""></script><script src="/_next/static/chunks/59b4e022-7c8a205b41eac8c0.js" defer=""></script><script src="/_next/static/chunks/aeb74aa0-4e0b515016d20a9f.js" defer=""></script><script src="/_next/static/chunks/e1efa4cc-06e900eb45581c19.js" defer=""></script><script src="/_next/static/chunks/5553-adcf0734802bcf9d.js" defer=""></script><script src="/_next/static/chunks/4346-1ca981691e341246.js" defer=""></script><script src="/_next/static/chunks/7107-6cabb37a1b6db405.js" defer=""></script><script src="/_next/static/chunks/5737-bbed1e27037a005b.js" defer=""></script><script src="/_next/static/chunks/6469-ae787191eae770ba.js" defer=""></script><script src="/_next/static/chunks/7707-7156dc278e0d847c.js" defer=""></script><script src="/_next/static/chunks/1574-ac454c7851064c9b.js" defer=""></script><script src="/_next/static/chunks/4978-94b1ec955a833def.js" defer=""></script><script src="/_next/static/chunks/pages/view/%5B...slug%5D-ec4d2dd06ef1142e.js" defer=""></script><script src="/_next/static/aMxshKRZGxbHXjz6zV8Pm/_buildManifest.js" defer=""></script><script src="/_next/static/aMxshKRZGxbHXjz6zV8Pm/_ssgManifest.js" defer=""></script><style id="__jsx-1661e6713d4eb9b5">.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:90px;background:#fff}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5{}@media screen and (min-width:768px){.leader-fixed.jsx-1661e6713d4eb9b5{position:fixed;margin-top:1rem;z-index:999999}}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5 div[id*="google_ads_iframe"].jsx-1661e6713d4eb9b5:empty{height:0px!important}@media screen and (max-width:668px){.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:0px;position:fixed;background:white;left:0;right:0;top:55px;padding-top:.5rem;padding-bottom:.25rem;z-index:9999}}</style><style id="__jsx-19ede9f0a5a45918">.jsx-19ede9f0a5a45918::-webkit-scrollbar{display:none}</style><style id="__jsx-ad50481d5ee26850">@media(min-width:980px)and (max-width:1200px){.article-detail.jsx-ad50481d5ee26850{width:47%}}@media(min-width:1201px)and (max-width:1400px){.article-detail.jsx-ad50481d5ee26850{width:55%}}</style></head><body><div id="__next" data-reactroot=""><div class="-mb-6"><div id="frame-nav" class="sticky top-0 left-0 bg-main-nav-bg text-main-nav-text z-[9948010]"><div class="container px-4 mx-auto flex justify-between items-center h-[65px] pl-4 pr-4" id="frame-mob-nav"><div class="block lg:hidden"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 20 20" aria-hidden="true" class="text-3xl" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="M3 5a1 1 0 011-1h12a1 1 0 110 2H4a1 1 0 01-1-1zM3 10a1 1 0 011-1h12a1 1 0 110 2H4a1 1 0 01-1-1zM3 15a1 1 0 011-1h12a1 1 0 110 2H4a1 1 0 01-1-1z" clip-rule="evenodd"></path></svg></div><div class="flex-auto hidden w-auto text-sm text-left lg:flex"><div class="relative flex items-center cursor-pointer lg:px-2"><a target="_self" class="whitespace-nowrap flex items-center" href="/news">News</a></div><div class="relative flex items-center cursor-pointer lg:px-2"><div class="whitespace-nowrap flex items-center">Media<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div><div id="div_sub_menu_dropdown_desktop_1" class="absolute bg-main-nav-item-bg text-main-nav-item-text z-[9999999999] border hidden max-h-[1000px]" style="top:30px;left:0;min-width:180px"><a target="_self" href="/around-the-practice"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Around the Practice</div></a><a target="_self" href="/between-the-lines"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Between the Lines</div></a><a target="_self" href="/psych-view"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">PsychView</div></a><a target="_self" href="/expert-perspectives?page=1"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Expert Perspectives</div></a><a target="_self" href="/case-based-psych-perspectives"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Case-Based Psych Perspectives</div></a><a target="_self" href="/clinical-case-collective?page=1"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Clinical Case Collective</div></a><a target="_self" href="/dialogues"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Dialogues</div></a><a target="_self" href="/payer-provider-perspective"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Payer-Provider Perspective</div></a><a target="_self" href="/slideshows"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Slideshows</div></a><a target="_self" href="/videos"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Videos</div></a><a target="_self" href="/viewpoints"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Viewpoints</div></a></div></div><div class="relative flex items-center cursor-pointer lg:px-2"><div class="whitespace-nowrap flex items-center">Conferences<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div><div id="div_sub_menu_dropdown_desktop_2" class="absolute bg-main-nav-item-bg text-main-nav-item-text z-[9999999999] border hidden max-h-[1000px]" style="top:30px;left:0;min-width:180px"><a target="_self" href="/latest-conference"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Conference Coverage</div></a><a target="_self" href="/conferences"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Conference Listing</div></a></div></div><div class="relative flex items-center cursor-pointer lg:px-2"><div class="whitespace-nowrap flex items-center">Publication<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div><div id="div_sub_menu_dropdown_desktop_3" class="absolute bg-main-nav-item-bg text-main-nav-item-text z-[9999999999] border hidden max-h-[1000px]" style="top:30px;left:0;min-width:180px"><a target="_self" href="/journals/psychiatric-times"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Psychiatric Times</div></a></div></div><div class="relative flex items-center cursor-pointer lg:px-2"><a target="_blank" class="whitespace-nowrap flex items-center" href="http://jobs.modernmedicine.com/index.php">Job Board</a></div><div class="relative flex items-center cursor-pointer lg:px-2"><a target="_self" class="whitespace-nowrap flex items-center" href="/continuing-education">CME/CE</a></div><div class="relative flex items-center cursor-pointer lg:px-2"><a target="_self" class="whitespace-nowrap flex items-center" href="/sap-partner">Partners</a></div><div class="relative flex items-center cursor-pointer lg:px-2"><a target="_self" class="whitespace-nowrap flex items-center" href="/editorial-info">Editorial</a></div><div class="relative flex items-center cursor-pointer lg:px-2"><div class="whitespace-nowrap flex items-center">Resources<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div><div id="div_sub_menu_dropdown_desktop_8" class="absolute bg-main-nav-item-bg text-main-nav-item-text z-[9999999999] border hidden max-h-[1000px]" style="top:30px;left:0;min-width:180px"><a target="_self" href="/clinical-consult"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Clinical Consult</div></a><a target="_self" href="/resources/clinical-scales"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Clinical Scales</div></a><a target="_self" href="/interactive-tools"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Interactive Tools</div></a><a target="_self" href="/partner-perspectives"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Partner Perspectives</div></a><a target="_self" href="/resources/q-a"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Q&A</div></a><a target="_self" href="/resources/quizzes"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Quizzes</div></a><a target="_self" href="/series"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Series</div></a><a target="_self" href="/special-reports"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Special Reports</div></a><a target="_self" href="/resources/sponsored-resources"><div style="white-space:nowrap" class="w-full px-4 py-2 hover:bg-main-nav-item-hover-bg hover:text-main-nav-item-hover-text">Sponsored</div></a></div></div><div class="relative flex items-center cursor-pointer lg:px-2"><a target="_blank" class="whitespace-nowrap flex items-center" href="https://one.psychiatrictimes.com/subscribe">Subscribe</a></div></div><div class="flex flex-wrap items-center flex-none md:relative md:flex-nowrap"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 512 512" class="hidden md:block text-2xl cursor-pointer mr-[0.125rem] mt-[0.125rem] focus:border focus:border-primary" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M505 442.7L405.3 343c-4.5-4.5-10.6-7-17-7H372c27.6-35.3 44-79.7 44-128C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c48.3 0 92.7-16.4 128-44v16.3c0 6.4 2.5 12.5 7 17l99.7 99.7c9.4 9.4 24.6 9.4 33.9 0l28.3-28.3c9.4-9.4 9.4-24.6.1-34zM208 336c-70.7 0-128-57.2-128-128 0-70.7 57.2-128 128-128 70.7 0 128 57.2 128 128 0 70.7-57.2 128-128 128z"></path></svg><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 512 512" class="block md:hidden text-2xl cursor-pointer mr-[0.125rem] mt-[0.125rem] focus:border focus:border-primary" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M505 442.7L405.3 343c-4.5-4.5-10.6-7-17-7H372c27.6-35.3 44-79.7 44-128C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c48.3 0 92.7-16.4 128-44v16.3c0 6.4 2.5 12.5 7 17l99.7 99.7c9.4 9.4 24.6 9.4 33.9 0l28.3-28.3c9.4-9.4 9.4-24.6.1-34zM208 336c-70.7 0-128-57.2-128-128 0-70.7 57.2-128 128-128 70.7 0 128 57.2 128 128 0 70.7-57.2 128-128 128z"></path></svg><a rel="noopener" class="hidden pr-1 lg:block" target="_self" href="https://twitter.com/psychtimes/"><p> <svg xmlns='http://www.w3.org/2000/svg' version='1.1' width='25' height='25' viewBox='1.41 1.41 252.9 252.9'> <g transform='translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)'> <polygon points='24.89,23.01 57.79,66.99 65.24,66.99 32.34,23.01' fill='#FFFFFF' transform='matrix(1 0 0 1 0 0)' /> <path d='M 45 0 L 45 0 C 20.147 0 0 20.147 0 45 v 0 c 0 24.853 20.147 45 45 45 h 0 c 24.853 0 45 -20.147 45 -45 v 0 C 90 20.147 69.853 0 45 0 z M 56.032 70.504 L 41.054 50.477 L 22.516 70.504 h -4.765 L 38.925 47.63 L 17.884 19.496 h 16.217 L 47.895 37.94 l 17.072 -18.444 h 4.765 L 50.024 40.788 l 22.225 29.716 H 56.032 z' fill='#FFFFFF' transform='matrix(1 0 0 1 0 0)' strokeLinecap='round' /> </g> </svg> </p></a><a rel="noreferrer noopener" class="hidden pr-1 lg:block" target="_blank" href="https://www.facebook.com/psychtimes/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='facebook' fill='#FFFFFF' fillRule='nonzero'> <path d='M512,256 C512,114.6 397.4,0 256,0 C114.6,0 0,114.6 0,256 C0,397.4 114.6,512 256,512 C257.5,512 259,512 260.5,511.9 L260.5,312.7 L205.5,312.7 L205.5,248.6 L260.5,248.6 L260.5,201.4 C260.5,146.7 293.9,116.9 342.7,116.9 C366.1,116.9 386.2,118.6 392,119.4 L392,176.6 L358.4,176.6 C331.9,176.6 326.7,189.2 326.7,207.7 L326.7,248.5 L390.2,248.5 L381.9,312.6 L326.7,312.6 L326.7,502.1 C433.7,471.4 512,372.9 512,256 Z' id='Path' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="hidden pr-1 lg:block" target="_blank" href="https://www.linkedin.com/company/psychiatric-times/posts/?feedView=all"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='linkedin' fill='#FFFFFF' fillRule='nonzero'> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M181.609375,387 L119.261719,387 L119.261719,199.425781 L181.609375,199.425781 L181.609375,387 Z M150.4375,173.8125 L150.03125,173.8125 C129.109375,173.8125 115.578125,159.410156 115.578125,141.410156 C115.578125,123.003906 129.523438,109 150.851562,109 C172.179688,109 185.304688,123.003906 185.710938,141.410156 C185.710938,159.410156 172.179688,173.8125 150.4375,173.8125 Z M406.421875,387 L344.082031,387 L344.082031,286.652344 C344.082031,261.433594 335.054688,244.234375 312.496094,244.234375 C295.273438,244.234375 285.015625,255.835938 280.507812,267.035156 C278.859375,271.042969 278.457031,276.644531 278.457031,282.25 L278.457031,387 L216.113281,387 C216.113281,387 216.929688,217.023438 216.113281,199.425781 L278.457031,199.425781 L278.457031,225.984375 C286.742188,213.203125 301.566406,195.023438 334.644531,195.023438 C375.664062,195.023438 406.421875,221.832031 406.421875,279.445312 L406.421875,387 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="hidden pr-1 lg:block" target="_blank" href="/rss"><p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:svgjs="http://svgjs.com/svgjs" version="1.1" width="25px" height="25px" x="0" y="0" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512" xml:space="preserve"> <g> <path xmlns="http://www.w3.org/2000/svg" d="m437.019531 74.980469c-48.351562-48.351563-112.640625-74.980469-181.019531-74.980469s-132.667969 26.628906-181.019531 74.980469c-48.351563 48.351562-74.980469 112.640625-74.980469 181.019531s26.628906 132.667969 74.980469 181.019531c48.351562 48.351563 112.640625 74.980469 181.019531 74.980469s132.667969-26.628906 181.019531-74.980469c48.351563-48.351562 74.980469-112.640625 74.980469-181.019531s-26.628906-132.667969-74.980469-181.019531zm-267.757812 292.957031c-13.730469 0-24.90625-11.171875-24.90625-24.90625s11.175781-24.90625 24.90625-24.90625c13.734375 0 24.90625 11.171875 24.90625 24.90625s-11.171875 24.90625-24.90625 24.90625zm80.277343 4.925781c-8.28125 0-15-6.714843-15-15 0-44.171875-35.9375-80.109375-80.109374-80.109375-8.285157 0-15-6.71875-15-15 0-8.285156 6.714843-15 15-15 60.714843 0 110.109374 49.394532 110.109374 110.109375 0 8.285157-6.714843 15-15 15zm67.09375 0c-8.285156 0-15-6.714843-15-15 0-81.167969-66.035156-147.203125-147.203124-147.203125-8.285157 0-15-6.714844-15-15s6.714843-15 15-15c97.710937 0 177.203124 79.492188 177.203124 177.203125 0 8.285157-6.714843 15-15 15zm66.292969 0c-8.28125 0-15-6.714843-15-15 0-117.722656-95.773437-213.496093-213.496093-213.496093-8.285157 0-15-6.714844-15-15 0-8.285157 6.714843-15 15-15 65.039062 0 126.1875 25.328124 172.179687 71.316406 45.988281 45.992187 71.316406 107.140625 71.316406 172.179687 0 8.285157-6.714843 15-15 15zm0 0" fill="#ffffff" data-original="#000000" style=""/> </g> </svg></p></a><div id="div_search_box" class="hidden flex-none md:absolute top-[50px] w-full md:w-[400px] md:left-[-400px] z-50 bg-search-box-bg p-2 rounded-xl"><form method="GET" action="/search" class="flex items-center justify-between w-full"><input type="text" name="searchTerm" placeholder="SEARCH" class="bg-white p-1 rounded-md border-0 w-[80%] text-black" required=""/><input type="submit" value="SEARCH" class="ml-2 cursor-pointer bg-search-box-button-bg text-search-box-button-text hover:bg-search-box-button-hover-bg hover:text-search-box-button-hover-text ronded rounded-md p-1 font-bold w-[20%]"/></form></div></div></div><div id="div_search_box_mobile" class="hidden flex-none md:absolute top-[50px] md:w-[400px] md:left-[-400px] z-50 bg-search-box-bg p-2 rounded-xl"><form method="GET" action="/search" class="flex items-center justify-between w-full"><input type="text" name="searchTerm" placeholder="SEARCH" class="bg-white p-1 rounded-md border-0 w-[80%] text-black" required=""/><input type="submit" value="SEARCH" class="ml-2 bg-search-box-button-bg text-search-box-button-text ronded rounded-md p-1 font-bold w-[20%]"/></form></div><div class="hidden fixed w-full top-0 modal h-[100vh] overflow-y-scroll z-[9999] max-h-screen" id="div_mobile_main_menu_0"><div class="bg-primary h-full w-[80%] "><div class="pb-10 container text-white max-h-screen overflow-auto pt-4"><div class="flex items-center py-4 px-2 relative "><div class="text-3xl w-[18%] xs:ml-8 text-left"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 512 512" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M289.94 256l95-95A24 24 0 00351 127l-95 95-95-95a24 24 0 00-34 34l95 95-95 95a24 24 0 1034 34l95-95 95 95a24 24 0 0034-34z"></path></svg></div><div class="mx-auto w-[70%] text-center pt-2 absolute top-1/2 left-1/2 -translate-x-1/2 -translate-y-1/2"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27220%27%20height=%2749%27/%3e"/></span><img alt="logo" srcSet="/_next/image?url=%2FPsychiatricTimes_40yrs_ko%201.png&w=256&q=75 1x, /_next/image?url=%2FPsychiatricTimes_40yrs_ko%201.png&w=640&q=75 2x" src="/_next/image?url=%2FPsychiatricTimes_40yrs_ko%201.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/></span></div></div><div class="border-b border-[rgba(0,0,0,.20)] mx-2 pb-2"></div><div class="relative border-b border-[rgba(0,0,0,.20)] mx-2 py-2"><div class="flex items-center justify-between p-2"><div class="flex items-center w-full justify-between">Spotlight<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div></div><div class="hidden bg-nav-secondary -mx-2 " id="div_sub_menu_dropdown_mobile_0"><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/clinical-case-collective/expanding-possibilities-in-mdd-exploring-rapid-acting-therapeutic-options?utm_source=website&utm_medium=spotlight&utm_campaign=MDD-CCC_Sept24">Expanding Possibilities in MDD: Exploring Rapid-Acting Therapeutic Options</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/topics/major-depressive-disorder">Major Depressive Disorder</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/topics/schizophrenia">Schizophrenia/Psychosis </a></div></div><div class="relative border-b border-[rgba(0,0,0,.20)] mx-2 py-2"><div class="flex items-center justify-between p-2"><div class="flex items-center w-full justify-between">Commentary<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div></div><div class="hidden bg-nav-secondary -mx-2 " id="div_sub_menu_dropdown_mobile_1"><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/commentary/couch-in-crisis">Couch In Crisis</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/commentary/early-career-psychiatry">Early Career Psychiatry</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/commentary/history-of-psychiatry">History of Psychiatry</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/commentary/residents">Residents Corner</a></div></div><div class="relative border-b border-[rgba(0,0,0,.20)] mx-2 py-2"><div class="flex items-center justify-between p-2"><div class="flex items-center w-full justify-between">Cultural Corner<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div></div><div class="hidden bg-nav-secondary -mx-2 " id="div_sub_menu_dropdown_mobile_2"><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/cultural-corner/film-and-book-reviews">Film and Book Reviews</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/cultural-corner/poetry">Poetry</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/cultural-corner/writers-contest">Writers Contest</a></div></div><div class="relative border-b border-[rgba(0,0,0,.20)] mx-2 py-2"><div class="flex items-center justify-between p-2"><div class="flex items-center w-full justify-between">Psychiatric Practice<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div></div><div class="hidden bg-nav-secondary -mx-2 " id="div_sub_menu_dropdown_mobile_3"><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/psychiatric-practice/burnout">Burnout</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/psychiatric-practice/careers">Careers</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/psychiatric-practice/coding">Coding</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/psychiatric-practice/guidelines">Guidelines</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/psychiatric-practice/risk-management">Risk Management</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/psychiatric-practice/telepsychiatry">Telepsychiatry</a></div></div><div class="relative border-b border-[rgba(0,0,0,.20)] mx-2 py-2"><div class="flex items-center justify-between p-2"><div class="flex items-center w-full justify-between">Series<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></div></div><div class="hidden bg-nav-secondary -mx-2 " id="div_sub_menu_dropdown_mobile_4"><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/series/climate-change">Climate Change</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/series/critical-conversations-in-psychiatry">Critical Conversations in Psychiatry</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/series/portraits">Portraits</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/series/psychiatric-views-on-the-daily-news">Psychiatric Views on the Daily News</a><a class="block w-full pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,0.1)]" href="/series/tales-new-asylum">Tales from the New Asylum</a></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.1)] mx-2"><div class="flex items-center p-2 " href="/news"><span class="flex items-center w-full justify-between">News</span></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.20)] mx-2"><button aria-controls="div_main_menu_dropdown_mobile_1" class="flex items-center p-2 w-full "><span class="flex items-center w-full justify-between">Media<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></span></button><div class="hidden bg-nav-secondary -mx-2" id="div_main_menu_dropdown_mobile_1"><a href="/around-the-practice"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Around the Practice</div></a><a href="/between-the-lines"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Between the Lines</div></a><a href="/psych-view"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">PsychView</div></a><a href="/expert-perspectives?page=1"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Expert Perspectives</div></a><a href="/case-based-psych-perspectives"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Case-Based Psych Perspectives</div></a><a href="/clinical-case-collective?page=1"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Clinical Case Collective</div></a><a href="/dialogues"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Dialogues</div></a><a href="/payer-provider-perspective"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Payer-Provider Perspective</div></a><a href="/slideshows"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Slideshows</div></a><a href="/videos"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Videos</div></a><a href="/viewpoints"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Viewpoints</div></a></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.20)] mx-2"><button aria-controls="div_main_menu_dropdown_mobile_2" class="flex items-center p-2 w-full "><span class="flex items-center w-full justify-between">Conferences<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></span></button><div class="hidden bg-nav-secondary -mx-2" id="div_main_menu_dropdown_mobile_2"><a href="/latest-conference"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Conference Coverage</div></a><a href="/conferences"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Conference Listing</div></a></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.20)] mx-2"><button aria-controls="div_main_menu_dropdown_mobile_3" class="flex items-center p-2 w-full "><span class="flex items-center w-full justify-between">Publication<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></span></button><div class="hidden bg-nav-secondary -mx-2" id="div_main_menu_dropdown_mobile_3"><a href="/journals/psychiatric-times"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Psychiatric Times</div></a></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.1)] mx-2"><div class="flex items-center p-2 " href="http://jobs.modernmedicine.com/index.php"><span class="flex items-center w-full justify-between">Job Board</span></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.1)] mx-2"><div class="flex items-center p-2 " href="/continuing-education"><span class="flex items-center w-full justify-between">CME/CE</span></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.1)] mx-2"><div class="flex items-center p-2 " href="/sap-partner"><span class="flex items-center w-full justify-between">Partners</span></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.1)] mx-2"><div class="flex items-center p-2 " href="/editorial-info"><span class="flex items-center w-full justify-between">Editorial</span></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.20)] mx-2"><button aria-controls="div_main_menu_dropdown_mobile_8" class="flex items-center p-2 w-full "><span class="flex items-center w-full justify-between">Resources<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></span></button><div class="hidden bg-nav-secondary -mx-2" id="div_main_menu_dropdown_mobile_8"><a href="/clinical-consult"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Clinical Consult</div></a><a href="/resources/clinical-scales"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Clinical Scales</div></a><a href="/interactive-tools"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Interactive Tools</div></a><a href="/partner-perspectives"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Partner Perspectives</div></a><a href="/resources/q-a"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Q&A</div></a><a href="/resources/quizzes"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Quizzes</div></a><a href="/series"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Series</div></a><a href="/special-reports"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Special Reports</div></a><a href="/resources/sponsored-resources"><div class=" pt-2 pb-2 pl-6 pr-6 hover:bg-secondary text-sm border-b border-[rgba(0,0,0,.20)]">Sponsored</div></a></div></div><div class="relative py-2 border-b border-[rgba(0,0,0,.1)] mx-2"><div class="flex items-center p-2 " href="https://one.psychiatrictimes.com/subscribe"><span class="flex items-center w-full justify-between">Subscribe</span></div></div></div></div></div><div class="w-full h-[2px] bg-main-nav-border-bg"></div></div><div class="container top-ad-div px-4 mx-auto pl-2 pr-2 sm:h-[98px] sm:w-[728px]"><div id="leaderboardWrapper" class="jsx-1661e6713d4eb9b5 leaderboardAdWrapper mx-auto mt-1 flex min-h-0 md:min-h-[90px] justify-center items-center flex-col relative z-[99999] "><div class="jsx-1661e6713d4eb9b5 bg-white md:-translate-x-4"><div class="jsx-1661e6713d4eb9b5 text-[8px] text-center text-gray-600 hidden relative">Advertisement</div><div id="div-gpt-ad-top" class="jsx-1661e6713d4eb9b5 AD728x90 mx-auto text-center x"></div></div></div></div><nav class=" relative bg-white text-gray-900 mb-6 mt-4 w-full hidden md:block" id="mega-menu"><div class="container mx-auto flex flex-col pl-4 items-center"><div class="sm:flex w-full hidden text-sm border-b border-menu-border"><div id="" class="headers w-[93%] h-5 overflow-hidden flex flex-row flex-wrap undefined my-4 ml-0 z-[9999]"><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/adhd"> ADHD </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/addiction-suds-compulsive"> | Addiction & Substance Use </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/alzheimer-disease"> | Alzheimer Disease </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/anxiety"> | Anxiety & Stress Disorders </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/bipolar"> | Bipolar Disorder </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/covid-19"> | COVID-19 </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/cannabis"> | Cannabis </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/case-discussions"> | Case Discussions </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/child-adolescent-psychiatry"> | Child & Adolescent Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/climate-change"> | Climate Change </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/comorbidity"> | Comorbidity </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/compulsive-disorders"> | Compulsive Disorders </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/cultural-psychiatry"> | Cultural Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/digital-therapeutics"> | Digital Therapeutics </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/dei"> | Diversity, Equity, Inclusion </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/drug-watch"> | Drug Watch </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/eating-disorders"> | Eating Disorders </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/emergency-psychiatry"> | Emergency Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/ethics"> | Ethics </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/forensic"> | Forensic Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/geriatric-psychiatry"> | Geriatric Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/integrative-psychiatry"> | Integrative Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/major-depressive-disorder"> | Major Depressive Disorder </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/media-psychiatry"> | Media & Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/mental-health-awareness"> | Mental Health Awareness Month </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/mood-disorders"> | Mood Disorders </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/neuropsychiatry"> | Neuropsychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/ptsd"> | PTSD </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/personality-disorders"> | Personality Disorders </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/postpartum"> | Postpartum Depression </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/psychedelics"> | Psychedelics </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/psychopharmacology"> | Psychopharmacology </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/psychosomatics"> | Psychosomatics </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/psychotherapy"> | Psychotherapy </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/schizophrenia"> | Schizophrenia/Psychosis </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/sleep-disorders"> | Sleep Disorders </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/special-populations"> | Special Populations </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/view/topics/topics/sports-psychiatry"> | Sports Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/suicide"> | Suicide </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/tardive-dyskinesia"> | Tardive Dyskinesia </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/tech-psychiatry"> | Technology & Psychiatry </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-main-nav-item-text hover:underline px-2 pb-3 hover:text-primary border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/transcranial-magnetic-stimulation"> | Transcranial Magnetic Stimulation </a><div class="mt-4 max-w-[125px]"></div></div></div><div class="group w-[10%] text-center subnav-view-all mx-auto mt-4 text-sm"><div class="cursor-pointer text-main-nav-item-text hover:opacity-80 text-right">View All >></div><div class="w-full z-[99999] h-megamenu-height overflow-x-auto right-0 p-6 mega-menu group-hover:block hidden pt-8 mb-16 sm:mb-0 shadow-xl bg-white absolute"><ul class="container w-[80%] m-auto flex flex-col flex-wrap h-full"><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/adhd">ADHD</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/addiction-suds-compulsive">Addiction & Substance Use</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/alzheimer-disease">Alzheimer Disease</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/anxiety">Anxiety & Stress Disorders</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/bipolar">Bipolar Disorder</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/covid-19">COVID-19</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/cannabis">Cannabis</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/case-discussions">Case Discussions</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/child-adolescent-psychiatry">Child & Adolescent Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/climate-change">Climate Change</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/comorbidity">Comorbidity</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/compulsive-disorders">Compulsive Disorders</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/cultural-psychiatry">Cultural Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/digital-therapeutics">Digital Therapeutics</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/dei">Diversity, Equity, Inclusion</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/drug-watch">Drug Watch</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/eating-disorders">Eating Disorders</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/emergency-psychiatry">Emergency Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/ethics">Ethics</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/forensic">Forensic Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/geriatric-psychiatry">Geriatric Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/integrative-psychiatry">Integrative Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/major-depressive-disorder">Major Depressive Disorder</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/media-psychiatry">Media & Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/mental-health-awareness">Mental Health Awareness Month</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/mood-disorders">Mood Disorders</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/neuropsychiatry">Neuropsychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/ptsd">PTSD</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/personality-disorders">Personality Disorders</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/postpartum">Postpartum Depression</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/psychedelics">Psychedelics</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/psychopharmacology">Psychopharmacology</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/psychosomatics">Psychosomatics</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/psychotherapy">Psychotherapy</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/schizophrenia">Schizophrenia/Psychosis</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/sleep-disorders">Sleep Disorders</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/special-populations">Special Populations</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/view/topics/topics/sports-psychiatry">Sports Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/suicide">Suicide</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/tardive-dyskinesia">Tardive Dyskinesia</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/tech-psychiatry">Technology & Psychiatry</a></li><li class=" text-left m-1 p-2 ml-8 hover:opacity-80 hover:underline hover:text-primary"><a class=" " href="/topics/transcranial-magnetic-stimulation">Transcranial Magnetic Stimulation</a></li></ul></div></div></div><div class="sm:flex w-full hidden text-sm border-menu-border"><p class="my-auto flex font-bold text-primary w-auto ">SPOTLIGHT <span class="font-normal">-</span></p><div id="" class="headers w-[90%] h-5 overflow-hidden flex flex-row flex-wrap undefined my-4 ml-0 z-[9999]"><div class=""><a class="block cursor-pointer text-primary hover:underline px-2 pb-3 hover:text-black border-l border-current pl-auto first:border-none first:pl-0 " href="/clinical-case-collective/expanding-possibilities-in-mdd-exploring-rapid-acting-therapeutic-options?utm_source=website&utm_medium=spotlight&utm_campaign=MDD-CCC_Sept24"> Expanding Possibilities in MDD: Exploring Rapid-Acting Therapeutic Options </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-primary hover:underline px-2 pb-3 hover:text-black border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/major-depressive-disorder"> | Major Depressive Disorder </a><div class="mt-4 max-w-[125px]"></div></div><div class=""><a class="block cursor-pointer text-primary hover:underline px-2 pb-3 hover:text-black border-l border-current pl-auto first:border-none first:pl-0 " href="/topics/schizophrenia"> | Schizophrenia/Psychosis </a><div class="mt-4 max-w-[125px]"></div></div></div></div></div></nav><div id="research-and-opportunities-at-the-2024-ascp-annual-meeting" class="container mx-auto flex m-1 min-h-[57vh] px-4"><div class="flex-auto w-[calc(100%-300px)] pr-0 md:pr-6 mt-16 sm:mt-0"><div class="m-2 md:my-2 md:ml-2 md:pr-12"><div class="hidden md:block fixed"><div class="md:absolute md:left-[557px] lg:left-[742px] xl:left-[942px] flex flex-col justify-center bg-white h-fit w-fit py-3 px-[.35rem] border border-[#DDDDDD] rounded-full"><button class="group mt-1"><button aria-label="linkedin" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" style="color:#818285;margin-bottom:6px;cursor:pointer" height="1.25rem" width="1.25rem" xmlns="http://www.w3.org/2000/svg"><path d="M100.28 448H7.4V148.9h92.88zM53.79 108.1C24.09 108.1 0 83.5 0 53.8a53.79 53.79 0 0 1 107.58 0c0 29.7-24.1 54.3-53.79 54.3zM447.9 448h-92.68V302.4c0-34.7-.7-79.2-48.29-79.2-48.29 0-55.69 37.7-55.69 76.7V448h-92.78V148.9h89.08v40.8h1.3c12.4-23.5 42.69-48.3 87.88-48.3 94 0 111.28 61.9 111.28 142.3V448z"></path></svg></button></button><button class="group"><button aria-label="facebook" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg stroke="currentColor" fill="currentColor" stroke-width="0" version="1.2" baseProfile="tiny" viewBox="0 0 24 24" style="color:#818285;margin-bottom:6px;cursor:pointer" height="32" width="32" xmlns="http://www.w3.org/2000/svg"><path d="M13 10h3v3h-3v7h-3v-7h-3v-3h3v-1.255c0-1.189.374-2.691 1.118-3.512.744-.823 1.673-1.233 2.786-1.233h2.096v3h-2.1c-.498 0-.9.402-.9.899v2.101z"></path></svg></button></button><button class="group"><button aria-label="twitter" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 512 512" style="color:#818285;margin-bottom:10px;cursor:pointer" height="1.25rem" width="1.25rem" xmlns="http://www.w3.org/2000/svg"><path d="M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z"></path></svg></button></button><button class="group"><button aria-label="email" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" style="color:#818285;margin-bottom:6px;cursor:pointer" height="1.25rem" width="1.25rem" xmlns="http://www.w3.org/2000/svg"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M22 6c0-1.1-.9-2-2-2H4c-1.1 0-2 .9-2 2v12c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6zm-2 0l-8 4.99L4 6h16zm0 12H4V8l8 5 8-5v10z"></path></svg></button></button><button class="group mb-4 "><a class="cursor-pointer flex justify-center"><svg stroke="currentColor" fill="none" stroke-width="2" viewBox="0 0 24 24" stroke-linecap="round" stroke-linejoin="round" style="color:#818285;margin-bottom:6px;background:white;cursor:pointer" height="1.25rem" width="1.25rem" xmlns="http://www.w3.org/2000/svg"><polyline points="6 9 6 2 18 2 18 9"></polyline><path d="M6 18H4a2 2 0 0 1-2-2v-5a2 2 0 0 1 2-2h16a2 2 0 0 1 2 2v5a2 2 0 0 1-2 2h-2"></path><rect x="6" y="14" width="12" height="8"></rect></svg></a></button></div></div><div><div class="flex flex-wrap"><p class=" text-primary font-semibold">News</p><div class="h-[16px] border-l-2 border-gray-400 mt-1 mx-1"></div><p class=" text-primary font-semibold">Article</p><div class="h-[16px] border-l-2 border-gray-400 mt-1 mx-1 "></div><time class="text-gray-500 " dateTime="2024-05-30T16:45:07.968">May 30, 2024</time></div><h1 class="text-[26px] font-medium leading-8">Research and Opportunities at the 2024 ASCP Annual Meeting</h1><div class="py-3 text-gray-600 md:flex flex-col md:justify-between"><div class="flex flex-col xs:flex-row"><p class="mr-1 self-start">Author(s):</p><div class="flex flex-col xs:flex-row mb-3 md:mb-0"><div class="flex flex-wrap"><span class="text-md mr-2"><a class="text-author text-gray-500 hover:text-primary underline hover:no-underline decoration-gray-400" href="/authors/erin-crown-mhs-pa-c">Erin Crown, MHS, PA-C, Psych-CAQ</a></span></div></div></div><div class="max-w-full"><div class="flex flex-wrap sm:flex-nowrap items-center w-fit my-2"></div><div class="w-full flex flex-col sm:flex-row justify-between mt-2"><div class="block md:hidden "><div class="mt-2 flex items-center max-w-fit"><button title="Research and Opportunities at the 2024 ASCP Annual Meeting" aria-label="facebook" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg viewBox="0 0 64 64" width="32" height="32"><circle cx="32" cy="32" r="31" fill="#3b5998"></circle><path d="M34.1,47V33.3h4.6l0.7-5.3h-5.3v-3.4c0-1.5,0.4-2.6,2.6-2.6l2.8,0v-4.8c-0.5-0.1-2.2-0.2-4.1-0.2 c-4.1,0-6.9,2.5-6.9,7V28H24v5.3h4.6V47H34.1z" fill="white"></path></svg></button><button aria-label="twitter" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg fill="#DC7633" xmlns="http://www.w3.org/2000/svg" width="32" zoomAndPan="magnify" viewBox="0 0 375 374.9999" height="32" preserveAspectRatio="xMidYMid meet" version="1.0"><defs><path d="M 7.09375 7.09375 L 367.84375 7.09375 L 367.84375 367.84375 L 7.09375 367.84375 Z M 7.09375 7.09375 " fill="#000000"></path></defs><g><path d="M 187.46875 7.09375 C 87.851562 7.09375 7.09375 87.851562 7.09375 187.46875 C 7.09375 287.085938 87.851562 367.84375 187.46875 367.84375 C 287.085938 367.84375 367.84375 287.085938 367.84375 187.46875 C 367.84375 87.851562 287.085938 7.09375 187.46875 7.09375 " fill-opacity="1" fill-rule="nonzero" fill="#000000"></path></g><g transform="translate(85, 75)"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" version="1.1" height="215" width="215"><path d="M18.244 2.25h3.308l-7.227 8.26 8.502 11.24H16.17l-5.214-6.817L4.99 21.75H1.68l7.73-8.835L1.254 2.25H8.08l4.713 6.231zm-1.161 17.52h1.833L7.084 4.126H5.117z" fill="#ffffff"></path></svg> </g></svg></button><button aria-label="linkedin" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg viewBox="0 0 64 64" width="32" height="32"><circle cx="32" cy="32" r="31" fill="#007fb1"></circle><path d="M20.4,44h5.4V26.6h-5.4V44z M23.1,18c-1.7,0-3.1,1.4-3.1,3.1c0,1.7,1.4,3.1,3.1,3.1 c1.7,0,3.1-1.4,3.1-3.1C26.2,19.4,24.8,18,23.1,18z M39.5,26.2c-2.6,0-4.4,1.4-5.1,2.8h-0.1v-2.4h-5.2V44h5.4v-8.6 c0-2.3,0.4-4.5,3.2-4.5c2.8,0,2.8,2.6,2.8,4.6V44H46v-9.5C46,29.8,45,26.2,39.5,26.2z" fill="white"></path></svg></button><button title="Research and Opportunities at the 2024 ASCP Annual Meeting" aria-label="pinterest" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg viewBox="0 0 64 64" width="32" height="32"><circle cx="32" cy="32" r="31" fill="#cb2128"></circle><path d="M32,16c-8.8,0-16,7.2-16,16c0,6.6,3.9,12.2,9.6,14.7c0-1.1,0-2.5,0.3-3.7 c0.3-1.3,2.1-8.7,2.1-8.7s-0.5-1-0.5-2.5c0-2.4,1.4-4.1,3.1-4.1c1.5,0,2.2,1.1,2.2,2.4c0,1.5-0.9,3.7-1.4,5.7 c-0.4,1.7,0.9,3.1,2.5,3.1c3,0,5.1-3.9,5.1-8.5c0-3.5-2.4-6.1-6.7-6.1c-4.9,0-7.9,3.6-7.9,7.7c0,1.4,0.4,2.4,1.1,3.1 c0.3,0.3,0.3,0.5,0.2,0.9c-0.1,0.3-0.3,1-0.3,1.3c-0.1,0.4-0.4,0.6-0.8,0.4c-2.2-0.9-3.3-3.4-3.3-6.1c0-4.5,3.8-10,11.4-10 c6.1,0,10.1,4.4,10.1,9.2c0,6.3-3.5,11-8.6,11c-1.7,0-3.4-0.9-3.9-2c0,0-0.9,3.7-1.1,4.4c-0.3,1.2-1,2.5-1.6,3.4 c1.4,0.4,3,0.7,4.5,0.7c8.8,0,16-7.2,16-16C48,23.2,40.8,16,32,16z" fill="white"></path></svg></button><button aria-label="email" class="react-share__ShareButton" style="background-color:transparent;border:none;padding:0;font:inherit;color:inherit;cursor:pointer"><svg viewBox="0 0 64 64" width="32" height="32"><circle cx="32" cy="32" r="31" fill="#7f7f7f"></circle><path d="M17,22v20h30V22H17z M41.1,25L32,32.1L22.9,25H41.1z M20,39V26.6l12,9.3l12-9.3V39H20z" fill="white"></path></svg></button><a class="print-wrap flex justify-center items-center cursor-pointer"><svg id="print" xmlns="http://www.w3.org/2000/svg" width="24" height="24" fill="currentColor" class="print bi bi-printer" viewBox="0 0 16 16"> <path d="M2.5 8a.5.5 0 1 0 0-1 .5.5 0 0 0 0 1z"></path> <path d="M5 1a2 2 0 0 0-2 2v2H2a2 2 0 0 0-2 2v3a2 2 0 0 0 2 2h1v1a2 2 0 0 0 2 2h6a2 2 0 0 0 2-2v-1h1a2 2 0 0 0 2-2V7a2 2 0 0 0-2-2h-1V3a2 2 0 0 0-2-2H5zM4 3a1 1 0 0 1 1-1h6a1 1 0 0 1 1 1v2H4V3zm1 5a2 2 0 0 0-2 2v1H2a1 1 0 0 1-1-1V7a1 1 0 0 1 1-1h12a1 1 0 0 1 1 1v3a1 1 0 0 1-1 1h-1v-1a2 2 0 0 0-2-2H5zm7 2v3a1 1 0 0 1-1 1H5a1 1 0 0 1-1-1v-3a1 1 0 0 1 1-1h6a1 1 0 0 1 1 1z"></path></svg></a></div><style> .print-wrap { width: 32px; height: 32px; background: #7F7F7F; border-radius: 100%; } .print { background: #7F7F7F; color: white; padding: 2px; border-radius: 100%; } </style></div></div></div></div><div class=" lg:w-full flex flex-col lg:flex-row lg:items-center lg:justify-end"><div class="related-landing sm:w-auto md:max-w-fit lg:w-[auto] md:text-center my-2 md:my-0 undefined"><a class="" href="/conferences/ascp"><div class="mt-6"><span class="text-primary text-sm">Conferences</span><span class="mx-1 text-sm">|</span><span class="text-sm text-blue-700 underline">ASCP</span></div></a></div></div><p class="py-2 mb-2 text-sm italic text-gray-600">Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.</p><div class="py-2"><div class="blockText_blockContent__TbCXh"><div class="relative"><div class="brightcove-fluid" autoplay=""></div></div><p class="pb-2"><strong>CONFERENCE REPORTER</strong></p><p class="pb-2">In this Mental Health Minute, Erin Crown, MHS, PA-C, <em>joins Psychiatric Times</em>® live from <em>the </em><a rel="nofollow noreferrer noopener" target="_blank" href="https://ascpp.org/ascp-meetings/ascp-annual-meeting/">2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting</a> and shares her thoughts on ASCP, the meeting, and an upcoming panel presentation she is excited to attend. The full transcript is below.</p><p class="pb-2"></p><p class="pb-2">Hi, my name is Erin Crown. I am a psychiatric physician assistant from State College, Pennsylvania. I do outpatient medication management, but I am also the owner of Future Options Research, and have recently become a primary investigator in clinical trials.</p><p class="pb-2">As a primary investigator, I think that it is really important for me to come to ASCP for networking opportunities and to really get a firsthand look at the topics that we are talking about in research right now, and to just kind of get my sea legs under me as I grow this next portion of my career.</p><p class="pb-2">There is a session that is going to be happening about pseudospecific vs transdiagnostic symptom targeting in pharmacotherapy that I am very interested in. I know Drs Goldberg and McIntyre will both be presenting in that session, and I am very excited to hear what they have to teach me.</p><p class="pb-2">I just think ASCP is a really intimate and nice conference. It is smaller than many other conferences that I have been to for other kinds of reasons, and so it has been a nice change of pace and a great learning environment. I am really excited to finish out the rest of the week and see what all there is to offer.</p><p class="pb-2"></p><p class="pb-2"><strong>Ms Crown </strong><em>is a psychiatric physician assistant at State College, Pennsylvania, and owner of Future Options Research.</em></p><p class="pb-2"></p><p class="pb-2">Note: The panel presentation referenced in this video is “Pseudospecific Versus Transdiagnostic Symptom Targeting in Pharmacotherapy Trials: Agitation, Attention, Anhedonia, and Mood Instability,” which takes place Thursday, May 30, at 2:15 PM EST. See a preview of the presentation by panel chair and co-presenter Joseph F. Goldberg, MD, <a target="_blank" href="https://www.psychiatrictimes.com/view/pseudospecific-and-transdiagnostic-symptom-targeting-in-clinical-trials">here</a>.</p><p class="pb-2"></p><p class="pb-2"><em>Follow the </em>Psychiatric Times<em> coverage of the 2024 ASCP Annual Meeting, and stay up-to-date on news related to research on promising new interventions and developments in the treatment of a wide variety of psychiatric disorders, at <a target="_blank" href="https://www.psychiatrictimes.com/">psychiatrictimes.com</a>.</em></p><p class="pb-2"></p></div></div><div class="flex items-center lg:w-3/4 mb-4 pb-12"></div><div class="jsx-19ede9f0a5a45918 py-4 relative bg-primary md:px-8 -ml-6 xs:ml-0 w-screen xs:w-auto"><div class="jsx-19ede9f0a5a45918 px-4 sm:px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none sm:border-b border-secondary"><div class="text-3xl text-white text-lg sm:text-3xl">Related Videos</div></div></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-full pl-4"><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/examples-of-quality-of-life-improvement-for-patients-with-tardive-dyskinesia"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="tardive dyskinesia" title="tardive dyskinesia" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="tardive dyskinesia" title="tardive dyskinesia" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/designing-an-effective-treatment-strategy-for-tardive-dyskinesia"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="tardive dyskinesia" title="tardive dyskinesia" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="tardive dyskinesia" title="tardive dyskinesia" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F647c4feb1336c4441a62c8168309482962a587f5-5944x3871.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/teasing-out-tardive-dyskinesia"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="tardive dyskinesia" title="tardive dyskinesia" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="tardive dyskinesia" title="tardive dyskinesia" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/managing-medication-side-effects-what-to-share-with-your-patients"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="meds pills" title="meds pills" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="meds pills" title="meds pills" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fbb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/covid-19-the-advent-of-virtual-psychiatry"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="covid" title="covid" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="covid" title="covid" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Ffa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/factors-when-choosing-an-adhd-treatment"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="ADHD" title="ADHD" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="ADHD" title="ADHD" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/research-on-pause-covid-19-s-impact-on-drug-development"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="covid-19" title="covid-19" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="covid-19" title="covid-19" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/gauging-adhd-treatment-success-improvement-in-quality-of-life"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="ADHD" title="ADHD" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="ADHD" title="ADHD" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fd8ac56994505f64acb8a96030cedacd7d9404054-5750x3830.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/the-importance-of-mattering-in-the-wake-of-the-pandemic"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="covid" title="covid" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="covid" title="covid" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2Fa9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a><a id="" class="w-[200px] h-fit space-y-3 flex-none select-none no-underline" style="scroll-snap-align:center;text-decoration:none" href="/view/whole-person-care-choosing-an-adhd-treatment"><div class="w-full shadow-md shadow-gray-800 overflow-hidden relative bg-white aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="ADHD" title="ADHD" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain"/><noscript><img alt="ADHD" title="ADHD" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=30 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=30 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=30 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=30 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=30 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=30 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=30 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fpsychtimes%2F25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" loading="lazy"/></noscript></span></div><div class="w-full flex-wrap text-center text-sm mt-4 font-light no-underline text-white"></div></a></div></div><div class="relative block sm:hidden"><div class="mt-4 overflow-hidden"><div class="flex justify-between"><div class="flex items-center clear-both pt-4 pb-2 text-3xl lg:text-2xl xl:text-3xl min-w-fit ">Related Content </div><div class="hidden lg:flex w-full flex-col justify-end items-end"><div class="hidden w-full lg:flex flex-wrap pb-2 gap-x-2 gap-y-1 justify-end items-end"></div></div></div><div class="w-full mb-2 border border-secondary"></div><div class="lg:hidden flex flex-wrap items-center"></div><div class="lg:grid grid-cols-2 gap-x-12"><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-1"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072.jpg?fit=crop&auto=format" alt="MADNI/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 17th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748.jpg?fit=crop&auto=format" alt="Tasty Cat/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 14th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584.jpg?fit=crop&auto=format" alt="LFK/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 13th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956.jpg?fit=crop&auto=format" alt="Berit Kessler/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 13th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/23b63d5745365091b73bc1cfc08e2d806bfd17e3-5824x3264.jpg?fit=crop&auto=format" alt="Sebastien Montier/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 12th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/ab7da8966014ad1be562e621a9f5b7a2397b9d28-5824x3264.jpg?fit=crop&auto=format" alt="Yuparet/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 12th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div></div></div></div><div class="relative hidden sm:block"><div class="mt-4 overflow-hidden"><div class="flex justify-between"><div class="flex items-center clear-both pt-4 pb-2 text-3xl lg:text-2xl xl:text-3xl min-w-fit ">Related Content </div><div class="hidden lg:flex w-full flex-col justify-end items-end"><div class="hidden w-full lg:flex flex-wrap pb-2 gap-x-2 gap-y-1 justify-end items-end"></div></div></div><div class="w-full mb-2 border border-secondary"></div><div class="lg:hidden flex flex-wrap items-center"></div><div class="lg:grid grid-cols-2 gap-x-12"><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-1"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072.jpg?fit=crop&auto=format" alt="MADNI/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 17th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748.jpg?fit=crop&auto=format" alt="Tasty Cat/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 14th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584.jpg?fit=crop&auto=format" alt="LFK/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 13th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956.jpg?fit=crop&auto=format" alt="Berit Kessler/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 13th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/23b63d5745365091b73bc1cfc08e2d806bfd17e3-5824x3264.jpg?fit=crop&auto=format" alt="Sebastien Montier/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 12th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 gap-x-4"><a class="jsx-ad50481d5ee26850" href="/view/spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"><img src="https://cdn.sanity.io/images/0vv8moc6/psychtimes/ab7da8966014ad1be562e621a9f5b7a2397b9d28-5824x3264.jpg?fit=crop&auto=format" alt="Yuparet/AdobeStock" width="288" class="jsx-ad50481d5ee26850 lg:w-[110px] lg:h-[100px] xl:w-[135px] xl:h-[125px] xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full xl:w-[70%]"><span class="jsx-ad50481d5ee26850 article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">February 12th 2025</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent">SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#00ADEF] underline text-sm italic" href="/authors/megan-mcsweeney">Megan McSweeney</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms?utm_source=www.psychiatrictimes.com&utm_medium=relatedContent"></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div></div></div></div><div class="pb-24"></div></div><script type="application/ld+json">{"@context":"https://schema.org","@type":"NewsArticle","headline":"Research and Opportunities at the 2024 ASCP Annual Meeting","datePublished":"2024-05-30T16:45:07.968Z","dateModified":"2024-06-05T19:58:26Z","inLanguage":"en-US","image":"https://cdn.sanity.io/images/0vv8moc6/psychtimes/8ddbdd713f36df89e072d6a475712b13a7521d5f-6000x4000.jpg?fit=crop&auto=format","mainEntityOfPage":{"@type":"WebPage","@id":"https://www.psychiatrictimes.com/view/research-and-opportunities-at-the-2024-ascp-annual-meeting"},"publisher":{"@type":"Organization","name":"Psychiatric Times","logo":{"@type":"ImageObject","url":"https://www.psychiatrictimes.com/PsychiatricTimes_40yrs_ko 1.png"}},"articleBody":"\n\nCONFERENCE REPORTER\n\nIn this Mental Health Minute, Erin Crown, MHS, PA-C, joins Psychiatric Times® live from the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting and shares her thoughts on ASCP, the meeting, and an upcoming panel presentation she is excited to attend. The full transcript is below.\n\n\n\nHi, my name is Erin Crown. I am a psychiatric physician assistant from State College, Pennsylvania. I do outpatient medication management, but I am also the owner of Future Options Research, and have recently become a primary investigator in clinical trials.\n\nAs a primary investigator, I think that it is really important for me to come to ASCP for networking opportunities and to really get a firsthand look at the topics that we are talking about in research right now, and to just kind of get my sea legs under me as I grow this next portion of my career.\n\nThere is a session that is going to be happening about pseudospecific vs transdiagnostic symptom targeting in pharmacotherapy that I am very interested in. I know Drs Goldberg and McIntyre will both be presenting in that session, and I am very excited to hear what they have to teach me.\n\nI just think ASCP is a really intimate and nice conference. It is smaller than many other conferences that I have been to for other kinds of reasons, and so it has been a nice change of pace and a great learning environment. I am really excited to finish out the rest of the week and see what all there is to offer.\n\n\n\nMs Crown is a psychiatric physician assistant at State College, Pennsylvania, and owner of Future Options Research.\n\n\n\nNote: The panel presentation referenced in this video is “Pseudospecific Versus Transdiagnostic Symptom Targeting in Pharmacotherapy Trials: Agitation, Attention, Anhedonia, and Mood Instability,” which takes place Thursday, May 30, at 2:15 PM EST. See a preview of the presentation by panel chair and co-presenter Joseph F. Goldberg, MD, here.\n\n\n\nFollow the Psychiatric Times coverage of the 2024 ASCP Annual Meeting, and stay up-to-date on news related to research on promising new interventions and developments in the treatment of a wide variety of psychiatric disorders, at psychiatrictimes.com.\n\n","description":"Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.","author":[{"@type":"Person","name":"Erin Crown, MHS, PA-C, Psych-CAQ"}]}</script></div></div><div class="flex-none w-[300px] z-[9999] relative hidden md:block"><div style="top:5rem" class="sticky custom-spacing"><div class="collapse-container " style="overflow:hidden;max-height:900px;transition:max-height .4s ease-in-out"></div></div></div></div><div id="div-gpt-ad-pixel" style="width:1px;height:1px" class=""></div><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5V9L5PL" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="footerOuterWrap" class="w-full bg-primary flex flex-col items-center justify-center"><div class="container w-[1340px]"><div id="footerInnerWrap" class="bg-primary w-full py-12"><div class="py-4 pl-4 flex flex-row items-center"><div class="flex flex-row flex-wrap w-[55%] h-full"><div class="w-[33%] p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/about">About</a></div><div class="w-[33%] p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/advertise">Advertise</a></div><div class="w-[33%] p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/contact-us">Contact Us</a></div><div class="w-[33%] p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/editorial-info">Editorial</a></div><div class="w-[33%] p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/terms">Terms and Conditions</a></div><div class="w-[33%] p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/privacy">Privacy Policy</a></div><div class="w-[33%] p-1 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_blank" href="https://www.mjhlifesciences.com/ccpa?domain=www.psychiatrictimes.com">Do Not Sell My Personal Information</a></div></div><div class="w-[45%] flex flex-row"><div class="w-[1px] bg-footer-vertical-rule"></div><div class="text-center flex w-[50%] flex-col gap-4 px-8 text-footer-text-color"><div class="py-2 text-xl">Contact Info</div><div class="mx-auto"><div class="flex flex-row gap-4 mb-4"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" class="text-footer-icon-color" font-size="30" style="margin-top:0.2rem" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path fill="none" d="M0 0h24v24H0z"></path><path d="M12 2C8.13 2 5 5.13 5 9c0 1.74.5 3.37 1.41 4.84.95 1.54 2.2 2.86 3.16 4.4.47.75.81 1.45 1.17 2.26.26.55.47 1.5 1.26 1.5s1-.95 1.25-1.5c.37-.81.7-1.51 1.17-2.26.96-1.53 2.21-2.85 3.16-4.4C18.5 12.37 19 10.74 19 9c0-3.87-3.13-7-7-7zm0 9.75a2.5 2.5 0 010-5 2.5 2.5 0 010 5z"></path></svg><p class="text-left text-sm">2 Commerce Drive <br/>Cranbury, NJ 08512</p></div><div class="flex flex-row gap-4 mb-4"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 16 16" class="text-footer-icon-color ml-2" font-size="25" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="M1.885.511a1.745 1.745 0 0 1 2.61.163L6.29 2.98c.329.423.445.974.315 1.494l-.547 2.19a.678.678 0 0 0 .178.643l2.457 2.457a.678.678 0 0 0 .644.178l2.189-.547a1.745 1.745 0 0 1 1.494.315l2.306 1.794c.829.645.905 1.87.163 2.611l-1.034 1.034c-.74.74-1.846 1.065-2.877.702a18.634 18.634 0 0 1-7.01-4.42 18.634 18.634 0 0 1-4.42-7.009c-.362-1.03-.037-2.137.703-2.877L1.885.511z"></path></svg><p class="text-sm"><a href="tel:609-716-7777">609-716-7777</a></p></div></div></div><div class="w-[1px] bg-footer-vertical-rule"></div><div class="flex flex-col gap-8 items-center justify-center" style="margin:0 auto"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27200%27%20height=%2733%27/%3e"/></span><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" srcSet="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=256&q=75 1x, /_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75 2x" src="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span><div class="flex flex-wrap self-start pt-6 pl-2"><a href="https://twitter.com/psychtimes/" class="social-icon mx-0.5 mb-1" target="_self" rel="noopener noreferrer" style="display:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle" aria-label="x"><span class="social-container" style="position:absolute;top:0;left:0;width:100%;height:100%"><svg role="img" aria-label="x social icon" class="social-svg" viewBox="0 0 64 64" style="position:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd"><g class="social-svg-icon" style="transition:fill 170ms ease-in-out;fill:white"><path d="M0,0H64V64H0ZM0 0v64h64V0zm16 17.537h10.125l6.992 9.242 8.084-9.242h4.908L35.39 29.79 48 46.463h-9.875l-7.734-10.111-8.85 10.11h-4.908l11.465-13.105zm5.73 2.783 17.75 23.205h2.72L24.647 20.32z"></path></g><g class="social-svg-mask" style="transition:fill 170ms ease-in-out;fill:#000000"><path d="M0 0v64h64V0zm16 17.537h10.125l6.992 9.242 8.084-9.242h4.908L35.39 29.79 48 46.463h-9.875l-7.734-10.111-8.85 10.11h-4.908l11.465-13.105zm5.73 2.783 17.75 23.205h2.72L24.647 20.32z"></path></g></svg></span></a><a href="https://www.facebook.com/psychtimes/" class="social-icon mx-0.5 mb-1" target="_blank" rel="noopener noreferrer" style="display:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle" aria-label="facebook"><span class="social-container" style="position:absolute;top:0;left:0;width:100%;height:100%"><svg role="img" aria-label="facebook social icon" class="social-svg" viewBox="0 0 64 64" style="position:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd"><g class="social-svg-icon" style="transition:fill 170ms ease-in-out;fill:white"><path d="M0,0H64V64H0ZM0 0v64h64V0zm39.6 22h-2.8c-2.2 0-2.6 1.1-2.6 2.6V28h5.3l-.7 5.3h-4.6V47h-5.5V33.3H24V28h4.6v-4c0-4.6 2.8-7 6.9-7 2 0 3.6.1 4.1.2z"></path></g><g class="social-svg-mask" style="transition:fill 170ms ease-in-out;fill:#3b5998"><path d="M0 0v64h64V0zm39.6 22h-2.8c-2.2 0-2.6 1.1-2.6 2.6V28h5.3l-.7 5.3h-4.6V47h-5.5V33.3H24V28h4.6v-4c0-4.6 2.8-7 6.9-7 2 0 3.6.1 4.1.2z"></path></g></svg></span></a><a href="https://www.linkedin.com/company/psychiatric-times/posts/?feedView=all" class="social-icon mx-0.5 mb-1" target="_blank" rel="noopener noreferrer" style="display:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle" aria-label="linkedin"><span class="social-container" style="position:absolute;top:0;left:0;width:100%;height:100%"><svg role="img" aria-label="linkedin social icon" class="social-svg" viewBox="0 0 64 64" style="position:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd"><g class="social-svg-icon" style="transition:fill 170ms ease-in-out;fill:white"><path d="M0,0H64V64H0ZM0 0v64h64V0zm25.8 44h-5.4V26.6h5.4zm-2.7-19.7c-1.7 0-3.1-1.4-3.1-3.1s1.4-3.1 3.1-3.1 3.1 1.4 3.1 3.1-1.4 3.1-3.1 3.1M46 44h-5.4v-8.4c0-2 0-4.6-2.8-4.6s-3.2 2.2-3.2 4.5V44h-5.4V26.6h5.2V29h.1c.7-1.4 2.5-2.8 5.1-2.8 5.5 0 6.5 3.6 6.5 8.3V44z"></path></g><g class="social-svg-mask" style="transition:fill 170ms ease-in-out;fill:#007fb1"><path d="M0 0v64h64V0zm25.8 44h-5.4V26.6h5.4zm-2.7-19.7c-1.7 0-3.1-1.4-3.1-3.1s1.4-3.1 3.1-3.1 3.1 1.4 3.1 3.1-1.4 3.1-3.1 3.1M46 44h-5.4v-8.4c0-2 0-4.6-2.8-4.6s-3.2 2.2-3.2 4.5V44h-5.4V26.6h5.2V29h.1c.7-1.4 2.5-2.8 5.1-2.8 5.5 0 6.5 3.6 6.5 8.3V44z"></path></g></svg></span></a><a href="/rss" class="social-icon mx-0.5 mb-1" target="_blank" rel="noopener noreferrer" style="display:inline-block;width:30px;height:30px;position:relative;overflow:hidden;vertical-align:middle" aria-label="rss"><span class="social-container" style="position:absolute;top:0;left:0;width:100%;height:100%"><svg role="img" aria-label="rss social icon" class="social-svg" viewBox="0 0 64 64" style="position:absolute;top:0;left:0;width:100%;height:100%;border-radius:50%;fill-rule:evenodd"><g class="social-svg-icon" style="transition:fill 170ms ease-in-out;fill:white"><path d="M0,0H64V64H0ZM0 0v64h64V0zm24 44c-2.2 0-4-1.8-4-4s1.8-4 4-4 4 1.8 4 4-1.8 4-4 4m11-1c-1.1 0-2-.9-2-2 0-5.5-4.5-10-10-10-1.1 0-2-.9-2-2s.9-2 2-2c7.7 0 14 6.3 14 14 0 1.1-.9 2-2 2m9 0c-1.1 0-2-.9-2-2 0-10.5-8.5-19-19-19-1.1 0-2-.9-2-2s.9-2 2-2c12.7 0 23 10.3 23 23 0 1.1-.9 2-2 2"></path></g><g class="social-svg-mask" style="transition:fill 170ms ease-in-out;fill:#EF8733"><path d="M0 0v64h64V0zm24 44c-2.2 0-4-1.8-4-4s1.8-4 4-4 4 1.8 4 4-1.8 4-4 4m11-1c-1.1 0-2-.9-2-2 0-5.5-4.5-10-10-10-1.1 0-2-.9-2-2s.9-2 2-2c7.7 0 14 6.3 14 14 0 1.1-.9 2-2 2m9 0c-1.1 0-2-.9-2-2 0-10.5-8.5-19-19-19-1.1 0-2-.9-2-2s.9-2 2-2c12.7 0 23 10.3 23 23 0 1.1-.9 2-2 2"></path></g></svg></span></a></div></div></div></div></div></div><div class="w-full bg-secondary flex justify-center"><div class="bg-secondary w-[85%] text-subfooter-text-color text-sm font-bold"><div class="flex flex-col gap-8 md:flex-row justify-between p-4 md:py-4 md:px-12"><div>© 2025 MJH Life Sciences <br/> <br/> All rights reserved.</div><div class="flex flex-column" style="gap:2rem;align-items:center"></div></div></div></div></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"pageProps":{},"cache":{"main_menu":[{"sortOrder":0,"url":"/news","name":"News","subQuery":[],"is_active":true,"_createdAt":"2023-01-12T21:37:12Z","_updatedAt":"2023-01-12T21:37:12Z","_rev":"c0yE3Bu5KElxUwrEaznFHf","_type":"mainNavigation","_id":"1843e321-488e-4669-93ca-cab2440aed6d","navParent":null},{"is_active":true,"sortOrder":2,"navParent":null,"_rev":"snQqhhB4O8T5bi1viURsgs","name":"Media","_updatedAt":"2020-05-29T13:44:24Z","_createdAt":"2020-03-19T16:02:04Z","subQuery":[{"_type":"mainNavigation","_updatedAt":"2021-12-22T16:26:33Z","_createdAt":"2021-09-21T13:28:00Z","sortOrder":1,"navParent":{"_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147","_type":"reference"},"_rev":"ChnBnF2xw1R5u2UJAWSuuF","url":"/around-the-practice","is_active":true,"children":[],"name":"Around the Practice","_id":"de72718f-4e22-471c-abe0-8b043ef92406"},{"_createdAt":"2021-12-22T16:26:36Z","sortOrder":2,"_type":"mainNavigation","name":"Between the Lines","_rev":"36kaxChiThYqCLNeM3hhVp","children":[],"is_active":true,"navParent":{"_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147","_type":"reference"},"_id":"c5a4d211-1b2f-40fe-ae07-abfb539fc598","_updatedAt":"2021-12-22T16:49:00Z","url":"/between-the-lines"},{"is_active":true,"_type":"mainNavigation","children":[],"sortOrder":3,"_rev":"fHJeXuT6UrG2EzoqzYEGVy","_id":"979bbc49-d8e6-43ac-a127-9e69bd520019","navParent":{"_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147","_type":"reference"},"_createdAt":"2021-05-27T15:56:49Z","name":"PsychView","_updatedAt":"2021-05-27T15:57:03Z","url":"/psych-view"},{"_type":"mainNavigation","_id":"105f3bcc-920b-4ff7-a249-06f884e59f75","navParent":{"_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147","_type":"reference"},"_createdAt":"2023-05-25T18:00:26Z","children":[],"_updatedAt":"2023-05-25T18:01:08Z","url":"/expert-perspectives?page=1","is_active":true,"sortOrder":5,"_rev":"9AI7T3W4gDT22gBLmTo0As","name":"Expert Perspectives"},{"_type":"mainNavigation","name":"Case-Based Psych Perspectives","_rev":"rJWQJ3YdV4iXBwE4Cgb60n","is_active":true,"navParent":{"_type":"reference","_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147"},"children":[],"url":"/case-based-psych-perspectives","_id":"84644adf-8708-4065-9312-ba1e741adfbb","_updatedAt":"2021-02-02T13:28:39Z","blank":false,"_createdAt":"2020-12-02T22:08:30Z"},{"_updatedAt":"2024-09-24T12:59:50Z","is_active":true,"_createdAt":"2024-09-24T12:59:29Z","name":"Clinical Case Collective","children":[],"_type":"mainNavigation","_rev":"AO7SV74IIejg0KBxJQrVAT","_id":"9c1882bf-8a3a-43d6-9238-e73c41eaeeff","url":"/clinical-case-collective?page=1","navParent":{"_type":"reference","_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147"}},{"_rev":"MqLNOsFfWNrEK75cxC5vlV","name":"Dialogues","_updatedAt":"2023-11-07T16:21:56Z","is_active":true,"navParent":{"_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147","_type":"reference"},"children":[],"_id":"721c996b-f6c8-46f7-becc-ca1a61c6aa05","url":"/dialogues","_type":"mainNavigation","_createdAt":"2023-11-07T16:21:45Z"},{"_updatedAt":"2022-08-11T20:44:23Z","url":"/payer-provider-perspective","children":[],"_createdAt":"2022-08-11T20:44:23Z","_rev":"ssa5UxKU775yMCmhdm7Dli","name":"Payer-Provider Perspective","is_active":true,"navParent":{"_type":"reference","_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147"},"_type":"mainNavigation","_id":"ed6715e2-25b1-45f3-a8eb-b9a1fafee934"},{"navParent":{"_type":"reference","_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147"},"_type":"mainNavigation","name":"Slideshows","_updatedAt":"2023-01-11T20:45:02Z","_id":"0302b195-9741-4a3f-8c23-a8fd8df8dcdb","_rev":"fSrtE9SUG7ytm1P8Db4nKr","is_active":true,"_createdAt":"2020-05-20T08:15:17Z","url":"/slideshows","children":[]},{"_createdAt":"2020-03-19T16:02:22Z","is_active":true,"_rev":"IlP9l41tH9jB20SbSpvPeM","_type":"mainNavigation","name":"Videos","children":[],"_updatedAt":"2020-06-10T19:43:38Z","_id":"418d0610-56dc-4f7f-90ba-7fe942ae1135","url":"/videos","navParent":{"_type":"reference","_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147"}},{"_id":"6a9888b6-102a-4ede-bc6b-a7068ffa1f4a","_updatedAt":"2020-12-01T21:40:56Z","_type":"mainNavigation","url":"/viewpoints","is_active":true,"_rev":"kv47vbxDVlS4qhKkRLYuFx","name":"Viewpoints","_createdAt":"2020-12-01T21:40:10Z","navParent":{"_ref":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147","_type":"reference"},"children":[]}],"_type":"mainNavigation","_id":"d8e0ba32-9f66-4c8e-b6eb-e4c285b62147"},{"_id":"395dfdb3-82e2-44c9-a54d-183ecbb75220","_updatedAt":"2024-03-14T17:28:34Z","is_active":true,"sortOrder":3,"_rev":"GE1zs3WNkZAi8NNFHblOnd","_type":"mainNavigation","subQuery":[{"_createdAt":"2020-08-28T15:15:10Z","_rev":"GE1zs3WNkZAi8NNFHbliyX","name":"Conference Coverage","_updatedAt":"2024-03-14T17:30:06Z","url":"/latest-conference","is_active":true,"navParent":{"_ref":"395dfdb3-82e2-44c9-a54d-183ecbb75220","_type":"reference"},"_id":"e2672269-cacc-43a5-8977-3a14ffd1384e","children":[],"_type":"mainNavigation"},{"_createdAt":"2020-08-28T15:14:51Z","_id":"f2d6a179-8a80-4257-b8e2-d66f19e1fc57","_updatedAt":"2024-03-14T17:30:23Z","is_active":true,"navParent":{"_ref":"395dfdb3-82e2-44c9-a54d-183ecbb75220","_type":"reference"},"_rev":"GE1zs3WNkZAi8NNFHblpwL","_type":"mainNavigation","name":"Conference Listing","url":"/conferences","children":[]}],"_createdAt":"2024-03-14T17:28:12Z","name":"Conferences","navParent":null},{"name":"Publication","_createdAt":"2020-03-24T08:13:09Z","sortOrder":4,"_type":"mainNavigation","subQuery":[{"_type":"mainNavigation","url":"/journals/psychiatric-times","_rev":"IlP9l41tH9jB20SbSpvPnI","name":"Psychiatric Times","_id":"9e6ca761-b435-40b5-96b5-9aa62d02379c","_createdAt":"2020-03-26T11:50:06Z","navParent":{"_ref":"6da3da6b-2f68-4b25-8a15-149c821f807a","_type":"reference"},"sortOrder":1,"_updatedAt":"2020-06-10T19:43:38Z","is_active":true,"children":[]}],"_rev":"GE1zs3WNkZAi8NNFHblv2P","url":"/journals","is_active":true,"_id":"6da3da6b-2f68-4b25-8a15-149c821f807a","navParent":null,"_updatedAt":"2024-03-14T17:30:34Z"},{"_createdAt":"2020-06-05T12:39:51Z","_type":"mainNavigation","navParent":null,"url":"http://jobs.modernmedicine.com/index.php","is_active":true,"sortOrder":5,"name":"Job Board","_id":"65c10b12-2c79-434e-8f72-8bf7a190a789","_updatedAt":"2024-03-14T17:31:13Z","_rev":"GE1zs3WNkZAi8NNFHbm6xN","blank":true,"subQuery":[]},{"url":"/continuing-education","_rev":"GE1zs3WNkZAi8NNFHbm7tF","_type":"mainNavigation","_createdAt":"2020-03-19T16:19:20Z","sortOrder":6,"subQuery":[],"_updatedAt":"2024-03-14T17:31:20Z","_id":"387a9885-df6d-429a-a5b5-7c1a0c00a1d9","name":"CME/CE","is_active":true,"navParent":null},{"url":"/sap-partner","navParent":null,"subQuery":[],"_createdAt":"2021-10-14T20:21:59Z","sortOrder":7,"_type":"mainNavigation","is_active":true,"_rev":"GE1zs3WNkZAi8NNFHbmCur","name":"Partners","_id":"458a06a9-a0a8-4ba9-b0c1-14e3107be838","_updatedAt":"2024-03-14T17:31:36Z"},{"navParent":null,"sortOrder":8,"_type":"mainNavigation","_updatedAt":"2024-03-14T17:32:05Z","name":"Editorial","_id":"4b098fae-43cf-4a67-9400-e0fc1b55195a","url":"/editorial-info","subQuery":[],"is_active":true,"_createdAt":"2024-03-14T17:31:47Z","_rev":"u8GFRcAIyRJ3mDD0auyX3j"},{"_rev":"GE1zs3WNkZAi8NNFHbmDhp","url":"/resources","navParent":null,"_createdAt":"2020-03-19T16:26:53Z","_type":"mainNavigation","_updatedAt":"2024-03-14T17:31:42Z","_id":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8","subQuery":[{"is_active":true,"_rev":"YnHcRrfS97TenynEl03ID1","_id":"6bdc0dbb-645f-4eac-a8c1-567d9dd72d76","blank":false,"navParent":{"_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8","_type":"reference"},"_updatedAt":"2024-05-31T17:02:16Z","_createdAt":"2024-05-31T17:01:59Z","_type":"mainNavigation","name":"Clinical Consult","url":"/clinical-consult","children":[]},{"_createdAt":"2020-03-24T08:07:34Z","url":"/resources/clinical-scales","navParent":{"_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8","_type":"reference"},"_rev":"IlP9l41tH9jB20SbSpvPeM","_type":"mainNavigation","name":"Clinical Scales","_id":"27d4f862-fad0-4e4c-921d-e9b5f1ca0aa9","is_active":true,"_updatedAt":"2020-06-10T19:43:38Z","children":[]},{"is_active":true,"navParent":{"_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8","_type":"reference"},"url":"/interactive-tools","_createdAt":"2021-03-10T19:42:37Z","_rev":"m02m7wCFelmJf04sT3Dcyu","_id":"22784626-75df-4699-9c39-cadec66c00a1","_updatedAt":"2021-03-10T19:42:37Z","name":"Interactive Tools","children":[],"_type":"mainNavigation","blank":false},{"is_active":true,"_createdAt":"2024-09-06T17:10:36Z","_rev":"KzS6kYoWzDJY07Cgj1zNlS","url":"/partner-perspectives","navParent":{"_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8","_type":"reference"},"_type":"mainNavigation","_id":"b938bf02-028f-489d-9725-79982289ad00","_updatedAt":"2024-09-06T17:10:51Z","blank":false,"name":"Partner Perspectives","children":[]},{"_updatedAt":"2020-06-10T19:43:38Z","url":"/resources/q-a","_rev":"IlP9l41tH9jB20SbSpvPeM","_type":"mainNavigation","name":"Q\u0026A","_id":"22e9b11e-a818-4534-9f69-eb4690e7000a","_createdAt":"2020-03-24T08:08:55Z","is_active":true,"navParent":{"_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8","_type":"reference"},"children":[]},{"is_active":true,"_rev":"snQqhhB4O8T5bi1viUShjg","name":"Quizzes","_updatedAt":"2020-06-10T19:43:38Z","navParent":{"_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8","_type":"reference"},"children":[],"_id":"fdc93267-d2f7-4a70-a0cc-8553106902bb","_type":"mainNavigation","url":"/resources/quizzes","_createdAt":"2020-03-24T08:09:11Z"},{"_type":"mainNavigation","name":"Series","is_active":true,"_id":"c647a9af-83e7-441e-b3f8-01f3ce388f97","navParent":{"_type":"reference","_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8"},"_createdAt":"2023-01-16T14:55:47Z","url":"/series","children":[],"_rev":"6v9gXhKVIkpZE4xQ8o8RSp","_updatedAt":"2023-01-16T14:57:17Z"},{"navParent":{"_type":"reference","_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8"},"_createdAt":"2020-03-24T08:09:30Z","_id":"31beecbb-9280-47c1-80c6-b3aedfe52542","_rev":"IlP9l41tH9jB20SbSpvPeM","children":[],"_updatedAt":"2020-06-10T19:43:38Z","_type":"mainNavigation","is_active":true,"name":"Special Reports","url":"/special-reports"},{"_id":"dbab3601-30b7-4ff8-b9ad-cd563cf0d149","children":[],"name":"Sponsored","is_active":true,"_type":"mainNavigation","_rev":"xbchpXbFe07Cgtkdynd1WF","_updatedAt":"2021-02-08T18:04:22Z","url":"/resources/sponsored-resources","navParent":{"_ref":"9d1d3280-79c1-4f3c-86dd-fe8d9dcfcdd8","_type":"reference"},"_createdAt":"2020-03-24T08:09:55Z"}],"is_active":true,"sortOrder":8,"name":"Resources"},{"_rev":"Ar19jrAZ1MlIiaihL3HN64","name":"Subscribe","sortOrder":9,"navParent":null,"blank":true,"_type":"mainNavigation","_id":"bbf146ea-82b5-4669-9bfa-336d093ee93e","url":"https://one.psychiatrictimes.com/subscribe","is_active":true,"_createdAt":"2020-05-29T13:43:21Z","subQuery":[],"_updatedAt":"2024-04-08T16:08:41Z"}],"sub_menu":[{"_createdAt":"2020-04-09T16:05:12Z","sortOrder":1,"_id":"c0b83ec2-95cb-4420-afbd-fcc8b5b34c32","navParent":null,"_type":"subNavigation","name":"Spotlight","url":"/topics","_rev":"dsDuJ8RgDkZe5YdVQL0T1F","_updatedAt":"2020-07-02T14:18:45Z","is_active":true,"subQuery":[{"_rev":"0Mkb5FQxU5FAKeDVsgc25x","_updatedAt":"2025-02-03T15:21:36Z","navParent":{"_ref":"c0b83ec2-95cb-4420-afbd-fcc8b5b34c32","_type":"reference"},"is_active":true,"url":"/clinical-case-collective/expanding-possibilities-in-mdd-exploring-rapid-acting-therapeutic-options?utm_source=website\u0026utm_medium=spotlight\u0026utm_campaign=MDD-CCC_Sept24","children":[],"_type":"subNavigation","_id":"14a8b7ca-aeba-4d14-ad8a-885b416dde30","_createdAt":"2025-02-03T14:49:44Z","sortOrder":1,"name":"Expanding Possibilities in MDD: Exploring Rapid-Acting Therapeutic Options"},{"sortOrder":2,"_updatedAt":"2025-02-03T15:36:14Z","url":"/topics/major-depressive-disorder","is_active":true,"_createdAt":"2022-12-22T20:49:42Z","_rev":"0Mkb5FQxU5FAKeDVsglDr6","_id":"0586180c-22ee-475e-a116-6e033e13e3ad","navParent":{"_ref":"c0b83ec2-95cb-4420-afbd-fcc8b5b34c32","_type":"reference"},"name":"Major Depressive Disorder","_type":"subNavigation","children":[]},{"is_active":true,"_rev":"fZt50Occ15DCCqvI8Fgruj","_createdAt":"2024-04-23T14:47:05Z","name":"Schizophrenia/Psychosis ","_id":"10bddb17-c39b-453e-b1ba-33771ee28934","children":[],"_updatedAt":"2025-02-03T15:36:22Z","sortOrder":3,"_type":"subNavigation","url":"/topics/schizophrenia","navParent":{"_ref":"c0b83ec2-95cb-4420-afbd-fcc8b5b34c32","_type":"reference"}}]},{"sortOrder":2,"_updatedAt":"2020-05-19T17:17:01Z","navParent":null,"is_active":true,"name":"Commentary","url":"/commentary","_createdAt":"2020-03-24T14:31:58Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"subNavigation","_id":"d525cee2-75c5-4b12-858b-d17aab33821f","subQuery":[{"_type":"subNavigation","url":"/commentary/couch-in-crisis","children":[],"is_active":true,"_id":"10e59262-5310-4126-9220-ec546ba4d151","navParent":{"_ref":"d525cee2-75c5-4b12-858b-d17aab33821f","_type":"reference"},"_createdAt":"2020-04-01T21:50:43Z","name":"Couch In Crisis","_updatedAt":"2020-06-10T19:43:38Z","_rev":"IlP9l41tH9jB20SbSpvPeM"},{"_createdAt":"2020-04-01T21:51:01Z","_type":"subNavigation","_updatedAt":"2020-06-10T19:43:38Z","url":"/commentary/early-career-psychiatry","is_active":true,"_rev":"IlP9l41tH9jB20SbSpvPeM","name":"Early Career Psychiatry","_id":"8c04af33-26cd-4fb3-8bf3-07ea17fd2880","navParent":{"_ref":"d525cee2-75c5-4b12-858b-d17aab33821f","_type":"reference"},"children":[]},{"is_active":true,"_updatedAt":"2020-06-10T19:43:38Z","navParent":{"_ref":"d525cee2-75c5-4b12-858b-d17aab33821f","_type":"reference"},"children":[],"name":"History of Psychiatry","_id":"59b44890-e52e-444b-b9cc-258f4a7a0a98","url":"/commentary/history-of-psychiatry","_createdAt":"2020-04-01T21:51:19Z","_rev":"IlP9l41tH9jB20SbSpvPeM","_type":"subNavigation"},{"_id":"4991b8d9-e319-48b7-b441-5c30bb2ee29e","url":"/commentary/residents","is_active":true,"navParent":{"_ref":"d525cee2-75c5-4b12-858b-d17aab33821f","_type":"reference"},"_rev":"IlP9l41tH9jB20SbSpvPeM","_createdAt":"2020-04-01T21:51:34Z","_updatedAt":"2020-06-10T19:43:38Z","children":[],"_type":"subNavigation","name":"Residents Corner"}]},{"_updatedAt":"2020-05-19T17:17:13Z","navParent":null,"_type":"subNavigation","name":"Cultural Corner","_id":"6d311f61-f270-4a24-b269-705bcb5d7ba0","url":"/cultural-corner","sortOrder":3,"subQuery":[{"_id":"d8402029-d770-4704-913e-ea45d3779a7c","_updatedAt":"2020-06-10T19:43:38Z","url":"/cultural-corner/film-and-book-reviews","navParent":{"_ref":"6d311f61-f270-4a24-b269-705bcb5d7ba0","_type":"reference"},"children":[],"_rev":"IlP9l41tH9jB20SbSpvPnI","_type":"subNavigation","is_active":true,"sortOrder":1,"name":"Film and Book Reviews","_createdAt":"2020-03-24T14:29:26Z"},{"_id":"cd5112ce-340b-4cd7-a63e-5db49067c729","url":"/cultural-corner/poetry","blank":false,"children":[],"_createdAt":"2020-03-24T14:29:49Z","sortOrder":2,"_rev":"IlP9l41tH9jB20SbSpvPnI","_type":"subNavigation","_updatedAt":"2020-06-10T19:43:38Z","navParent":{"_ref":"6d311f61-f270-4a24-b269-705bcb5d7ba0","_type":"reference"},"name":"Poetry","is_active":true},{"name":"Writers Contest","_type":"subNavigation","sortOrder":3,"_rev":"IlP9l41tH9jB20SbSpvPeM","_id":"2555f011-792e-4edd-a3a2-9b8275a55043","_updatedAt":"2020-06-10T19:43:38Z","url":"/cultural-corner/writers-contest","navParent":{"_ref":"6d311f61-f270-4a24-b269-705bcb5d7ba0","_type":"reference"},"children":[],"_createdAt":"2020-03-24T14:30:58Z","is_active":true}],"is_active":true,"_createdAt":"2020-03-24T14:29:12Z","_rev":"snQqhhB4O8T5bi1viURsgs"},{"name":"Psychiatric Practice","url":"/psychiatric-practice","navParent":null,"_createdAt":"2020-04-01T21:39:49Z","_rev":"snQqhhB4O8T5bi1viURsgs","_id":"1bea9f4b-4597-4c81-a1ab-8d4afea5ddc9","sortOrder":4,"_type":"subNavigation","is_active":true,"_updatedAt":"2020-05-19T17:16:51Z","subQuery":[{"_type":"subNavigation","url":"/psychiatric-practice/burnout","children":[],"is_active":true,"navParent":{"_ref":"1bea9f4b-4597-4c81-a1ab-8d4afea5ddc9","_type":"reference"},"_createdAt":"2020-04-01T21:40:05Z","_updatedAt":"2020-06-10T19:43:38Z","_rev":"IlP9l41tH9jB20SbSpvPeM","name":"Burnout","_id":"3390661b-0619-4f29-939e-eace8faae992"},{"children":[],"navParent":{"_ref":"1bea9f4b-4597-4c81-a1ab-8d4afea5ddc9","_type":"reference"},"name":"Careers","_type":"subNavigation","url":"/psychiatric-practice/careers","is_active":true,"_createdAt":"2020-04-01T21:40:23Z","_updatedAt":"2020-06-10T19:43:38Z","_rev":"IlP9l41tH9jB20SbSpvPeM","_id":"4ceccc05-3c24-4261-bebe-cad9ee5530df"},{"_createdAt":"2020-05-19T14:36:43Z","_rev":"IlP9l41tH9jB20SbSpvPnI","navParent":{"_ref":"1bea9f4b-4597-4c81-a1ab-8d4afea5ddc9","_type":"reference"},"name":"Coding","_id":"d71f55d5-a867-426e-ba4b-c28c798cb245","_type":"subNavigation","_updatedAt":"2020-06-10T19:43:38Z","url":"/psychiatric-practice/coding","is_active":true,"children":[]},{"navParent":{"_ref":"1bea9f4b-4597-4c81-a1ab-8d4afea5ddc9","_type":"reference"},"_createdAt":"2020-05-19T14:36:26Z","name":"Guidelines","_updatedAt":"2020-06-10T19:43:38Z","children":[],"_rev":"IlP9l41tH9jB20SbSpvPeM","_id":"8ccdfe96-24f0-4daa-9011-6e4d8ceb4a93","url":"/psychiatric-practice/guidelines","is_active":true,"_type":"subNavigation"},{"navParent":{"_ref":"1bea9f4b-4597-4c81-a1ab-8d4afea5ddc9","_type":"reference"},"_rev":"ZMYcYT2CLb3vZFFgs0psbG","_type":"subNavigation","name":"Risk Management","url":"/psychiatric-practice/risk-management","is_active":true,"_createdAt":"2020-05-19T14:36:09Z","children":[],"_id":"b9e2c00e-9cf8-41a1-81c8-9c9ae622cd10","_updatedAt":"2020-06-14T14:20:02Z"},{"is_active":true,"url":"/psychiatric-practice/telepsychiatry","navParent":{"_ref":"1bea9f4b-4597-4c81-a1ab-8d4afea5ddc9","_type":"reference"},"children":[],"_createdAt":"2020-05-19T14:35:50Z","_updatedAt":"2020-06-10T19:43:38Z","_rev":"IlP9l41tH9jB20SbSpvPeM","_type":"subNavigation","name":"Telepsychiatry","_id":"7a80afad-0ac8-48ab-b711-b6602380b38a"}]},{"_updatedAt":"2020-05-19T17:14:56Z","navParent":null,"subQuery":[{"navParent":{"_ref":"790fcafc-0d49-4d10-927a-c003531095c0","_type":"reference"},"_type":"subNavigation","children":[],"_id":"56d70f3b-0dbb-4a76-b93d-32a15c60459b","url":"/series/climate-change","_rev":"IlP9l41tH9jB20SbSpvPeM","_updatedAt":"2020-06-10T19:43:38Z","is_active":true,"_createdAt":"2020-05-19T17:15:22Z","name":"Climate Change"},{"_rev":"IlP9l41tH9jB20SbSpvPeM","_createdAt":"2020-05-19T17:15:44Z","name":"Critical Conversations in Psychiatry","_updatedAt":"2020-06-10T19:43:38Z","url":"/series/critical-conversations-in-psychiatry","navParent":{"_ref":"790fcafc-0d49-4d10-927a-c003531095c0","_type":"reference"},"is_active":true,"_id":"14f817fa-5837-4aa4-82e4-7d32ae19149b","_type":"subNavigation","children":[]},{"_type":"subNavigation","url":"/series/portraits","navParent":{"_ref":"790fcafc-0d49-4d10-927a-c003531095c0","_type":"reference"},"_rev":"IlP9l41tH9jB20SbSpvPnI","_id":"aaf583e3-d77e-4b92-9272-0fd976813d1b","children":[],"name":"Portraits","_updatedAt":"2020-06-10T19:43:38Z","is_active":true,"_createdAt":"2020-05-19T17:15:53Z"},{"children":[],"url":"/series/psychiatric-views-on-the-daily-news","_createdAt":"2021-10-28T16:35:03Z","_rev":"BXHEdz19TlV0w95nuSkK0S","is_active":true,"name":"Psychiatric Views on the Daily News","_type":"subNavigation","_updatedAt":"2021-10-28T16:35:03Z","navParent":{"_ref":"790fcafc-0d49-4d10-927a-c003531095c0","_type":"reference"},"_id":"4d8c2e30-6795-4853-8a3e-6effc976f071"},{"_type":"subNavigation","is_active":true,"children":[],"_id":"28f3773f-8f99-4b53-933b-d5c569416077","_updatedAt":"2020-06-10T19:43:38Z","url":"/series/tales-new-asylum","navParent":{"_ref":"790fcafc-0d49-4d10-927a-c003531095c0","_type":"reference"},"name":"Tales from the New Asylum","_createdAt":"2020-05-19T17:16:20Z","_rev":"IlP9l41tH9jB20SbSpvPeM"}],"is_active":true,"_id":"790fcafc-0d49-4d10-927a-c003531095c0","_createdAt":"2020-05-19T17:14:56Z","sortOrder":5,"_rev":"snQqhhB4O8T5bi1viURsgs","_type":"subNavigation","url":"/series","name":"Series"}],"site_setting":{"siteURL":"www.psychiatrictimes.com","creativeLayoutLatestNews":null,"footerLinks":[{"_type":"urlArray","_key":"2087aaeb2ba19093221f839004d60d38","title":"About","url":"/about"},{"title":"Advertise","url":"/advertise","_type":"urlArray","_key":"bdbfed9283cd"},{"_type":"urlArray","_key":"15464e4eca0f","title":"Contact Us","url":"/contact-us","blank":false},{"_key":"b9910177c702","title":"Editorial","url":"/editorial-info","_type":"urlArray"},{"url":"/terms","_type":"urlArray","_key":"21f996ea3e94","title":"Terms and Conditions"},{"url":"/privacy","_type":"urlArray","_key":"04fd2bebcf00","title":"Privacy Policy"},{"title":"Do Not Sell My Personal Information","url":"https://www.mjhlifesciences.com/ccpa?domain=www.psychiatrictimes.com","blank":true,"_type":"urlArray","_key":"fe4a3b0871aa"}],"_rev":"1zZEGxR9lz85RWEelqBK8y","_type":"siteSettings","salesforceDMPId":"uvi8wzngz","name":"Psychiatric Times","_id":"siteSettings","redisConfig":{"cachePurgeDomain":"https://www2.psychiatrictimes.com","redisURL":"https://global-current-seahorse-30408.upstash.io","redisPWD":"AXbIASQgOGM4NDU0ZWMtMjA2YS00NDM4LTg5ZmQtMTBkNDc5ZTY1NWVlMTk3MjMxN2JmNTRkNGRkODhjY2U0NzY3NjRmNzRhYWI="},"enableSanity2":true,"gaID":"UA-155582410-43,UA-630614-1","_updatedAt":"2025-01-22T20:27:47Z","creativeLayout":null,"socialLinks":[{"_key":"8d7532457054","title":"X","url":"https://twitter.com/psychtimes/","blank":false,"_type":"urlArray"},{"url":"https://www.facebook.com/psychtimes/","blank":true,"_type":"urlArray","_key":"a573173a4c8a","title":"Facebook"},{"title":"LinkedIn","url":"https://www.linkedin.com/company/psychiatric-times/posts/?feedView=all","blank":true,"_type":"urlArray","_key":"fd1668a909ff"},{"_type":"urlArray","_key":"23a37f7661a2","title":"RSS","url":"/rss","blank":true}],"_createdAt":"2020-02-21T05:35:48Z"},"clinicalData":[{"identifier":"topics/adhd","sortOrder":9999,"children":[],"_id":"pst_taxonomy_8_adhd","name":"ADHD"},{"sortOrder":9999,"children":[{"_id":"pst_taxonomy_175_gambling","name":"Gambling","identifier":"topics/gambling","sortOrder":null},{"_id":"pst_taxonomy_288_opioidrelateddisorders","name":"Opioid Related Disorders","identifier":"topics/opioid","sortOrder":null},{"_id":"pst_taxonomy_29_alcoholabuse","name":"Alcohol Abuse","identifier":"topics/alcohol-abuse","sortOrder":null},{"_id":"pst_taxonomy_34_amphetaminerelateddisorders","name":"Amphetamine Related Disorders","identifier":"topics/amphetamine-related-disorders","sortOrder":null},{"_id":"pst_taxonomy_394_substanceusedisorder","name":"Substance Use Disorder","identifier":"topics/substance-use-disorder","sortOrder":null}],"_id":"pst_taxonomy_254_addictionsubstanceuse","name":"Addiction \u0026 Substance Use","identifier":"topics/addiction-suds-compulsive"},{"_id":"pst_taxonomy_149_alzheimerdisease","name":"Alzheimer Disease","identifier":"topics/alzheimer-disease","sortOrder":9999,"children":[]},{"_id":"pst_taxonomy_119_anxietystressdisorders","name":"Anxiety \u0026 Stress Disorders","identifier":"topics/anxiety","sortOrder":9999,"children":[{"_id":"pst_taxonomy_143_disasterpsychiatry","name":"Disaster Psychiatry","identifier":"topics/disaster-psychiatry","sortOrder":null},{"_id":"pst_taxonomy_296_panicdisorder","name":"Panic Disorder","identifier":"topics/panic","sortOrder":null},{"_id":"pst_taxonomy_415_traumaandviolence","name":"Trauma And Violence","identifier":"topics/trauma-and-violence","sortOrder":null},{"_id":"pst_taxonomy_416_traumaticstressdisorders","name":"Traumatic Stress Disorders","identifier":"topics/traumatic-stress-disorders","sortOrder":null}]},{"identifier":"topics/bipolar","sortOrder":9999,"children":[{"_id":"pst_taxonomy_241_mania","name":"Mania","identifier":"topics/mania","sortOrder":null}],"_id":"pst_taxonomy_52_bipolardisorder","name":"Bipolar Disorder"},{"name":"COVID-19","identifier":"topics/covid-19","sortOrder":9999,"children":[],"_id":"f159c13f-564a-44fe-a9ef-9bb704b05b1d"},{"_id":"634d24b6-a345-4f1a-9f9f-dbf3abd45d8a","name":"Cannabis","identifier":"topics/cannabis","sortOrder":9999,"children":[]},{"_id":"pst_taxonomy_767_casediscussions","name":"Case Discussions","identifier":"topics/case-discussions","sortOrder":9999,"children":[]},{"_id":"pst_taxonomy_89_childadolescentpsychiatry","name":"Child \u0026 Adolescent Psychiatry","identifier":"topics/child-adolescent-psychiatry","sortOrder":9999,"children":[]},{"_id":"a2be30ac-7b19-4ec4-92e2-27e180b2455e","name":"Climate Change","identifier":"topics/climate-change","sortOrder":9999,"children":[]},{"_id":"pst_taxonomy_120_comorbidity","name":"Comorbidity","identifier":"topics/comorbidity","sortOrder":9999,"children":[]},{"_id":"pst_taxonomy_280_compulsivedisorders","name":"Compulsive Disorders","identifier":"topics/compulsive-disorders","sortOrder":9999,"children":[]},{"name":"Cultural Psychiatry","identifier":"topics/cultural-psychiatry","sortOrder":9999,"children":[],"_id":"pst_taxonomy_128_culturalpsychiatry"},{"name":"Digital Therapeutics","identifier":"topics/digital-therapeutics","sortOrder":9999,"children":[],"_id":"150ff356-9cf5-4634-86ca-acbaeaa9a998"},{"identifier":"topics/dei","sortOrder":9999,"children":[],"_id":"3015942b-5d84-4549-a34c-c5d4cd50d946","name":"Diversity, Equity, Inclusion"},{"_id":"01583c5c-f3f9-433a-a948-ce2d3bbdc164","name":"Drug Watch","identifier":"topics/drug-watch","sortOrder":9999,"children":[]},{"sortOrder":9999,"children":[],"_id":"pst_taxonomy_150_eatingdisorders","name":"Eating Disorders","identifier":"topics/eating-disorders"},{"children":[],"_id":"pst_taxonomy_334_psychiatricemergencies","name":"Emergency Psychiatry","identifier":"topics/emergency-psychiatry","sortOrder":9999},{"_id":"3f005629-ac29-46f4-b4f1-49ffa396908b","name":"Ethics","identifier":"topics/ethics","sortOrder":9999,"children":[]},{"name":"Forensic Psychiatry","identifier":"topics/forensic","sortOrder":9999,"children":[{"_id":"pst_taxonomy_261_munchausensyndrome","name":"Munchausen Syndrome","identifier":"topics/munchausen-syndrome","sortOrder":null},{"_id":"pst_taxonomy_371_sexualoffenses","name":"Sexual Offenses","identifier":"topics/sexual-offenses","sortOrder":null}],"_id":"pst_taxonomy_173_forensicpsychiatry"},{"identifier":"topics/geriatric-psychiatry","sortOrder":9999,"children":[],"_id":"pst_taxonomy_184_geriatricpsychiatry","name":"Geriatric Psychiatry"},{"_id":"pst_taxonomy_214_integrativepsychiatry","name":"Integrative Psychiatry","identifier":"topics/integrative-psychiatry","sortOrder":9999,"children":[]},{"_id":"pst_taxonomy_238_majordepressivedisorder","name":"Major Depressive Disorder","identifier":"topics/major-depressive-disorder","sortOrder":9999,"children":[]},{"sortOrder":9999,"children":[],"_id":"cc759323-2eb8-4a57-affd-58701b288a82","name":"Media \u0026 Psychiatry","identifier":"topics/media-psychiatry"},{"_id":"33300c16-1d5e-48d8-bf27-16706480c6c5","name":"Mental Health Awareness Month","identifier":"topics/mental-health-awareness","sortOrder":9999,"children":[]},{"name":"Mood Disorders","identifier":"topics/mood-disorders","sortOrder":9999,"children":[],"_id":"pst_taxonomy_253_mooddisorders"},{"identifier":"topics/neuropsychiatry","sortOrder":9999,"children":[{"_id":"pst_taxonomy_115_cognitivedisorders","name":"Cognitive Disorders","identifier":"topics/cognitive-disorders","sortOrder":null},{"_id":"pst_taxonomy_132_dementia","name":"Dementia","identifier":"topics/dementia","sortOrder":null},{"_id":"pst_taxonomy_45_autism","name":"Autism","identifier":"topics/autism","sortOrder":null}],"_id":"pst_taxonomy_35_neuropsychiatry","name":"Neuropsychiatry"},{"name":"PTSD","identifier":"topics/ptsd","sortOrder":9999,"children":[],"_id":"pst_taxonomy_339_ptsd"},{"_id":"pst_taxonomy_310_personalitydisorders","name":"Personality Disorders","identifier":"topics/personality-disorders","sortOrder":9999,"children":[{"_id":"pst_taxonomy_122_compulsivepersonalitydisorder","name":"Compulsive Personality Disorder","identifier":"topics/compulsive-personality-disorder","sortOrder":null},{"_id":"pst_taxonomy_134_dependentpersonalitydisorder","name":"Dependent Personality Disorder","identifier":"topics/dependent-personality-disorder","sortOrder":null},{"_id":"pst_taxonomy_145_dissociativeidentitydisorder","name":"Dissociative Identity Disorder","identifier":"topics/dissociative-identity-disorder","sortOrder":null},{"_id":"pst_taxonomy_198_histrionicpersonalitydisorder","name":"Histrionic Personality Disorder","identifier":"topics/histrionic-personality-disorder","sortOrder":null},{"_id":"pst_taxonomy_361_schizoidpersonalitydisorder","name":"Schizoid Personality Disorder","identifier":"topics/schizoid-personality-disorder","sortOrder":null},{"_id":"pst_taxonomy_36_antisocialpersonalitydisorder","name":"Antisocial Personality Disorder","identifier":"topics/antisocial-personality-disorder","sortOrder":null},{"_id":"pst_taxonomy_65_borderlinepersonality","name":"Borderline Personality","identifier":"topics/borderline-personality","sortOrder":null}]},{"_id":"1880d7c4-6501-4ce5-a0bf-866838092a1f","name":"Postpartum Depression","identifier":"topics/postpartum","sortOrder":9999,"children":[]},{"name":"Psychedelics","identifier":"topics/psychedelics","sortOrder":9999,"children":[],"_id":"ac6c86f4-3fb2-4bb9-b7e5-3ed6f20ac45a"},{"_id":"pst_taxonomy_336_psychopharmacology","name":"Psychopharmacology","identifier":"topics/psychopharmacology","sortOrder":9999,"children":[]},{"_id":"pst_taxonomy_351_psychosomatics","name":"Psychosomatics","identifier":"topics/psychosomatics","sortOrder":9999,"children":[{"_id":"pst_taxonomy_129_delirium","name":"Delirium","identifier":"topics/delirium","sortOrder":null},{"_id":"pst_taxonomy_247_metabolicdisorders","name":"Metabolic Disorders","identifier":"topics/metabolic-disorders","sortOrder":null},{"_id":"pst_taxonomy_384_somatoformdisorder","name":"Somatoform Disorder","identifier":"topics/somatoform-disorder","sortOrder":null}]},{"sortOrder":9999,"children":[{"_id":"pst_taxonomy_114_cognitivebehavioraltherapy","name":"Cognitive Behavioral Therapy","identifier":"topics/cognitive-behavioral-therapy","sortOrder":null}],"_id":"pst_taxonomy_337_psychotherapy","name":"Psychotherapy","identifier":"topics/psychotherapy"},{"_id":"pst_taxonomy_362_schizophreniapsychosis","name":"Schizophrenia/Psychosis","identifier":"topics/schizophrenia","sortOrder":9999,"children":[{"_id":"pst_taxonomy_299_paranoidschizophrenia","name":"Paranoid Schizophrenia","identifier":"topics/paranoid-schizophrenia","sortOrder":null},{"_id":"pst_taxonomy_338_psychoticaffectivedisorders","name":"Psychotic Affective Disorders","identifier":"topics/psychotic-affective-disorders","sortOrder":null},{"_id":"pst_taxonomy_360_schizoaffective","name":"Schizoaffective","identifier":"topics/schizoaffective","sortOrder":null},{"_id":"pst_taxonomy_363_schizophreniapsychoticfeatures","name":"Schizophrenia Psychotic Features","identifier":"topics/schizophrenia","sortOrder":null},{"_id":"pst_taxonomy_364_schizotypalpersonalitydisorder","name":"Schizotypal Personality Disorder","identifier":"topics/schizotypal-personality-disorder","sortOrder":null},{"_id":"pst_taxonomy_85_catatonicschizophrenia","name":"Catatonic Schizophrenia","identifier":"topics/catatonic-schizophrenia","sortOrder":null}]},{"children":[{"_id":"pst_taxonomy_272_nocturnalparoxysmaldystonia","name":"Nocturnal Paroxysmal Dystonia","identifier":"topics/nocturnal-paroxysmal-dystonia","sortOrder":null},{"_id":"pst_taxonomy_379_sleepdeprivation","name":"Sleep Deprivation","identifier":"topics/sleep-deprivation","sortOrder":null},{"_id":"pst_taxonomy_380_sleepwaketransition","name":"Sleep Wake Transition","identifier":"topics/sleep-wake-transition","sortOrder":null},{"_id":"pst_taxonomy_95_circadianrhythmsleepdisorders","name":"Circadian Rhythm Sleep Disorders","identifier":"topics/circadian-rhythm-sleep-disorders","sortOrder":null}],"_id":"pst_taxonomy_694_sleepdisorders","name":"Sleep Disorders","identifier":"topics/sleep-disorders","sortOrder":9999},{"name":"Special Populations","identifier":"topics/special-populations","sortOrder":9999,"children":[{"_id":"43325cb4-0ee9-4642-bdda-e378111c2bf0","name":"Pervasive Developmental Disorder","identifier":"topics/pervasive-developmental-disorder","sortOrder":null},{"_id":"pst_taxonomy_180_genderissues","name":"Gender Issues","identifier":"topics/gender","sortOrder":null},{"_id":"pst_taxonomy_249_militarymentalhealth","name":"Military Mental Health","identifier":"topics/military","sortOrder":null}],"_id":"pst_taxonomy_53201_specialpopulations"},{"name":"Sports Psychiatry","identifier":"/topics/sports-psychiatry","sortOrder":9999,"children":[],"_id":"0eef0dc5-3910-4a2a-9ca1-410022b90972"},{"identifier":"topics/suicide","sortOrder":9999,"children":[],"_id":"pst_taxonomy_395_suicide","name":"Suicide"},{"identifier":"topics/tardive-dyskinesia","sortOrder":9999,"children":[],"_id":"pst_taxonomy_49771_tardivedyskinesia","name":"Tardive Dyskinesia"},{"identifier":"topics/tech-psychiatry","sortOrder":9999,"children":[],"_id":"pst_taxonomy_407_digitalpsychiatry","name":"Technology \u0026 Psychiatry"},{"_id":"b160eca8-057d-49f5-a06e-962599380ee9","name":"Transcranial Magnetic Stimulation","identifier":"topics/transcranial-magnetic-stimulation","sortOrder":9999,"children":[]}],"seo_data":[],"recent_news":[{"_id":"bb70f5f7-1256-48b1-b1a4-151f873f4a12","title":"Planned Induction of Labor in a Patient With Acute Late-Pregnancy Psychosis: A Case Report ","url":{"current":"planned-induction-of-labor-in-a-patient-with-acute-late-pregnancy-psychosis-a-case-report","_type":"slug"},"published":"2025-02-18T16:00:00.000Z","authorMapping":{"_type":"author","url":{"_type":"slug","current":"cecilia-a-westbrook-md-phd"},"authorType":"author","_rev":"sqn82GeejNhxQc9bet6Xm3","_id":"038bfe74-9e25-494e-a787-fd5644fd8474","biography":[{"markDefs":[],"children":[{"marks":["strong"],"text":"Dr Westbrook ","_key":"8740ae840fff","_type":"span"},{"_type":"span","marks":["em"],"text":"is a board-certified psychiatrist in Pittsburgh, PA, affiliated with UPMC Presbyterian.","_key":"5f4a2f1a1f2e"}],"_type":"block","style":"normal","_key":"d17131a1ad14"}],"_updatedAt":"2025-02-17T20:44:56Z","displayName":"Cecilia A. Westbrook, MD, PhD","_createdAt":"2025-02-17T20:44:56Z"},"factCheckAuthorMapping":null,"summary":"Consideration of both practical and ethical concerns, as well as an interdisciplinary approach, can lead to better outcomes for pregnant patients with psychosis. ","thumbnail":{"asset":{"_ref":"image-2bb56ac82e597ddb7c4240a7a28596e8a2617548-5424x3051-jpg","_type":"reference"},"_type":"mainImage","alt":"pregnancy","caption":"Gajus/AdobeStock"},"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","_updatedAt":"2020-02-25T09:35:56Z","_createdAt":"2020-02-06T09:15:47Z","_rev":"snQqhhB4O8T5bi1viURsgs"}},{"_id":"909ec995-c476-4c4f-bdd5-9b47eb024d04","title":"Using CBT to Empower Black Patients","summary":"Judith S. Beck, PhD, and Janeé M. Steele, PhD, engage in a conversation about how clinicians from all backgrounds can address issues of race in session and also empower Black patients with a sense of personal pride in their identities.","published":"2025-02-18T15:00:14.498Z","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","_updatedAt":"2020-02-25T09:35:56Z","_createdAt":"2020-02-06T09:15:47Z","_rev":"snQqhhB4O8T5bi1viURsgs"},"thumbnail":{"_type":"mainImage","alt":"black woman therapy","caption":"Ms_Tali/AdobeStock","asset":{"_ref":"image-4cbfd53a31aed17b6685dad782f81fce90945e67-5462x3051-jpg","_type":"reference"}},"url":{"current":"using-cbt-to-empower-black-patients","_type":"slug"},"authorMapping":{"_rev":"tP8j57NH9sOhICdpnMAwGr","_type":"author","company":"KAISER PERMANTE","biography":[{"style":"normal","_key":"44c1579165ae","markDefs":[],"children":[{"text":"Dr Beck","_key":"7884a356c1fe0","_type":"span","marks":["strong"]},{"_type":"span","marks":[],"text":" ","_key":"7884a356c1fe1"},{"marks":["em"],"text":"is president of Beck Institute for Cognitive Behavior Therapy in Bala Cynwyd, Pennsylvania, and a clinical professor of psychology in psychiatry at the University of Pennsylvania in Philadelphia.","_key":"7884a356c1fe2","_type":"span"}],"_type":"block"}],"profileImage":{"_type":"mainImage","asset":{"_ref":"image-d9471b4f884761d153257be6ceb21eec249096dd-513x768-jpg","_type":"reference"}},"address1":"PO BOX 601098","displayName":"Judith S. Beck, PhD","_createdAt":"2020-02-21T11:23:21Z","_updatedAt":"2024-10-07T17:11:59Z","url":{"current":"judith-s-beck-phd","_type":"slug"},"profileThumbnail":{"_type":"mainImage","asset":{"_ref":"image-d9471b4f884761d153257be6ceb21eec249096dd-513x768-jpg","_type":"reference"}},"_id":"pst_author_325304"},"factCheckAuthorMapping":null},{"_id":"a6dd60b8-ef2f-4bcc-8420-0288e0135e97","thumbnail":{"caption":"MADNI/AdobeStock","asset":{"_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg","_type":"reference"},"_type":"mainImage","alt":"MADNI/AdobeStock"},"url":{"current":"conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update","_type":"slug"},"contentCategory":{"_updatedAt":"2020-02-25T09:35:56Z","_createdAt":"2020-02-06T09:15:47Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb"},"title":"Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update","summary":"Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.","published":"2025-02-17T21:45:27.773Z","authorMapping":{"biography":[{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ms McSweeney","_key":"67ccf07444ee"},{"marks":[],"text":" ","_key":"3e163b408efc","_type":"span"},{"_key":"b70df96f70e5","_type":"span","marks":["em"],"text":"is an assistant editor at "},{"_type":"span","marks":[],"text":"Psychiatric Times","_key":"52d2e41075d5"},{"_type":"span","marks":["em"],"text":".","_key":"85b80e6c3bc5"}],"_type":"block","style":"normal","_key":"37d6c0564341"}],"url":{"current":"megan-mcsweeney","_type":"slug"},"_createdAt":"2024-11-25T16:17:55Z","_rev":"HG9itg5Um8jvM5zF8KyjU8","_type":"author","displayName":"Megan McSweeney","_id":"0dd98119-9102-491d-98b5-9cd27b8be6f7","_updatedAt":"2024-11-25T16:17:55Z","firstName":"Megan","lastName":"McSweeney","authorType":"author"},"factCheckAuthorMapping":null},{"_id":"a8450db1-107a-4d16-a890-f2ebec783b0a","title":"Psychiatric Times Welcomes Media \u0026 Psychiatry Section Editor: Mena Mirhom, MD, FAPA","published":"2025-02-17T16:00:00.000Z","authorMapping":{"lastName":"Kuntz","_createdAt":"2020-10-06T13:25:26Z","_rev":"AHAMphbTGS6uc0RcJHCpre","_id":"eae211d2-ac5b-40d6-9e4b-b25ee06057f2","_updatedAt":"2020-10-06T13:25:26Z","url":{"current":"leah-kuntz","_type":"slug"},"firstName":"Leah","displayName":"Leah Kuntz","_type":"author"},"factCheckAuthorMapping":null,"summary":"Psychiatric Times is pleased to present a brand-new section on media and psychiatry, and section editor, Mena Mirhom, MD, FAPA. ","thumbnail":{"hotspot":{"height":0.5388452341180099,"_type":"sanity.imageHotspot","width":1,"x":0.5,"y":0.39107744994199367},"_type":"mainImage","asset":{"_ref":"image-e285ae97747d01e67b03a5acd10d0363392b02ab-3248x4872-jpg","_type":"reference"},"crop":{"right":0,"top":0.1216548328829887,"left":0,"bottom":0.3394999329990014,"_type":"sanity.imageCrop"}},"url":{"current":"psychiatric-times-welcomes-media-psychiatry-section-editor-mena-mirhom-md-fapa","_type":"slug"},"contentCategory":{"name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","_updatedAt":"2020-02-25T09:35:56Z","_createdAt":"2020-02-06T09:15:47Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory"}}],"isLiveSite":true,"host":"www.psychiatrictimes.com","settings":{"title":"Psychiatric Times","networkID":"4688","adUnit":"cmpm.psychiatrictimes","liveDomain":"www.psychiatrictimes.com","publicationName":"Psychiatric Times","logo":"/PsychiatricTimes_40yrs_ko 1.png","mobile_logo":"/PsychiatricTimes_40yrs_ko 1.png","white_logo":"/PsychiatricTimes_40yrs_ko 1.png","enableEdgeCache":false,"sMaxAge":300,"staleWhileRevalidate":359,"logoWidth":"220px","mobileLogoWidth":"220px","logoHeight":"49px","mobileLogoHeight":"49px","logoBannerHeight":"80","logoPadding":"2","megaMenuTaxName":"topics","sharingImageUrl":"https://www.psychiatrictimes.com/PT_share_logo.png","twitterHandle":"@PsychTimes","publicationMapping":"journals","marginRightFromLogo":"3rem","gateEnabled":"modal","redesignDetail":true}},"targeting":{"content_placement":[],"document_url":["research-and-opportunities-at-the-2024-ascp-annual-meeting"],"document_group":["ascp"],"content_group":[],"rootDocumentGroup":["conferences"],"issue_url":[],"publication_url":[],"tags":[],"hostname":"www.psychiatrictimes.com"},"statusCode":200,"data":{"page":{"disableEpisode":null,"parent":null,"cmeConfig":null,"searchConfig":{"baseUrl":"/view/"},"videoPlayerConfig":null,"useV3":null,"pageType":"Article Detail","taxonomy":null,"labelRequired":false,"featureContent":null,"orderDesc":null,"content":null,"externalLinks":null,"articleDetailConfig":{"brightcovePlayerID":"cv3eRkzu9","drupalleadBaseURL":"https://drupalleads.mjh.group/injectablewebform/output/","issueMapping":"/journals","enableSegmentRecommend":false,"brightcoveAccountID":"10203567001","downloadCitation":false,"shareOptions":{"twitterHandle":"@psychtimes","siteName":"psychiatrictimes","hideFacebook":false,"SocialIconSize":32,"twitterSiteName":"psychtimes","hidePinterest":false,"shareSubject":"Check out this article!","thumbnail":{"asset":{"_ref":"image-8ddbdd713f36df89e072d6a475712b13a7521d5f-6000x4000-jpg","_type":"reference"},"_type":"mainImage","alt":"Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.","caption":"THANANIT AdobeStock"}}},"title":"View","creativeLayoutDetail":null,"docGroup":null,"relatedMegaMenu":false,"creativeLayout":null,"filterRequired":false,"linkedPage":null,"archived":false,"filters":null,"theme":"default","pages":null,"pageSliders":null,"contentCategories":null,"url":{"current":"/view","_type":"slug"},"intro":null,"franchise":null,"fixIdentifier":null,"excludeFromSitemap":false,"identifier":null,"creativeLayoutLatestNews":null,"contentCategory":null,"hasSubCategory":false,"label":null,"styling":{"imageControl":{"_type":"imageControl","showImage":true,"thumbnailRadius":{"bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem","topRight":"0rem"}},"divider":{"_type":"divider","dividerSize":1},"columns":"2","titleOptions":{"_type":"titleOptions","titleSize":"1rem"},"border":{"borderRadius":{"bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem","topRight":"0rem"},"_type":"border","borderSize":0},"contentControl":{"showAuthor":true,"showSummary":false,"_type":"contentControl","showPublished":true,"readMore":false}},"isDsoGated":null,"gateCode":null},"pageData":{"article":{"contentCategory":{"_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","name":"Articles"},"documentGroup":{"parent":{"_updatedAt":"2021-10-07T14:43:42Z","identifier":{"current":"conferences","_type":"slug"},"_createdAt":"2020-03-26T06:12:02Z","parent":null,"_rev":"wprjukSzaYWKhfPX4FSqef","_type":"documentGroup","name":"Conferences","_id":"pst_documentGroup_53201_conferences"},"_createdAt":"2024-06-04T17:24:13Z","_type":"documentGroup","_updatedAt":"2024-06-04T21:47:10Z","name":"ASCP","docGroupArchive":false,"externalURL":"https://www.psychiatrictimes.com/conferences/ascp","identifier":{"current":"ascp","_type":"slug"},"_rev":"NjcgaUZeSNUWzq2QL4nENm","_id":"416d7790-5dab-4702-b1f8-76ddf93117f9","pixelTrackingCode":null},"published":"2024-05-30T16:45:07.968Z","documentGroupMapping":null,"taxonomyMapping":[{"parent":null,"pixelTrackingCode":null,"identifier":"conferences","name":"Conferences","_id":"pst_taxonomy_439_conferences","_updatedAt":"2020-09-11T15:24:41Z","_createdAt":"2020-03-26T06:11:21Z","_rev":"A1SshklVZqV0BxeqIqEcIX","_type":"taxonomy"},{"_type":"taxonomy","name":"Videos","_createdAt":"2020-03-26T06:11:21Z","pixelTrackingCode":null,"_id":"pst_taxonomy_51523_expertinterviews","_updatedAt":"2020-05-29T12:51:27Z","identifier":"videos/expert-interviews","_rev":"IlP9l41tH9jB20SbSpsYNi","parent":null}],"url":{"current":"research-and-opportunities-at-the-2024-ascp-annual-meeting","_type":"slug"},"is_visible":true,"_rev":"xdQEau5fkY6kxamCwYchLe","_id":"72fc8e94-b0c8-4e74-a8fb-6f7e390a234d","authorMapping":[{"authorType":"author","displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","_createdAt":"2023-11-13T16:47:10Z","_type":"author","_id":"2270b229-89a6-41ec-bc1d-24c4f25de7bd","firstName":"Erin","lastName":"Crown","_rev":"w14ZFqLK3vmAl22uSW8PAZ","biography":[{"_type":"block","style":"normal","_key":"fc856dc557ca","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ms Crown","_key":"08477e92955d0"},{"_type":"span","marks":[],"text":" ","_key":"0d2add315389"},{"_key":"910c2addcd00","_type":"span","marks":["em"],"text":"is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials. "}]}],"_updatedAt":"2025-01-20T19:12:03Z","url":{"current":"erin-crown-mhs-pa-c","_type":"slug"}}],"_type":"article","contentGroup":null,"body":[{"_type":"video","upload_doc":null,"uploadAudio":null,"medias":null,"_key":"9df96e0fdd64","source":"brightcove","videoObject":{"thumbnail":{"asset":{"_ref":"image-b2495eaadeb74eb7883f74b7041e8c47c47fe1ab-2842x1580-png","_type":"reference"},"_type":"image"},"videoDuration":"1 minute, 37 seconds","videoDescription":"Crown ASCP Video","_type":"videoDetails","videoTitle":"Research and Opportunities at the 2024 ASCP Annual Meeting"},"videoID":"6353955346112","disableAutoPlayVideo":false},{"upload_doc":null,"uploadAudio":null,"medias":null,"_type":"block","style":"normal","_key":"2d1fb13e4e03","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"CONFERENCE REPORTER","_key":"61a7828faaf80"}]},{"uploadAudio":null,"medias":null,"markDefs":[{"blank":true,"_type":"link","href":"https://ascpp.org/ascp-meetings/ascp-annual-meeting/","_key":"8f13e0bedad2"}],"children":[{"_type":"span","marks":[],"text":"In this Mental Health Minute, Erin Crown, MHS, PA-C, ","_key":"87605f2fc4490"},{"_type":"span","marks":["em"],"text":"joins Psychiatric Times","_key":"87605f2fc4491"},{"text":"® live from ","_key":"87605f2fc4492","_type":"span","marks":[]},{"text":"the ","_key":"87605f2fc4493","_type":"span","marks":["em"]},{"_key":"87605f2fc4494","_type":"span","marks":["8f13e0bedad2"],"text":"2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting"},{"_type":"span","marks":[],"text":" and shares her thoughts on ASCP, the meeting, and an upcoming panel presentation she is excited to attend. ","_key":"87605f2fc4495"},{"marks":[],"text":"The full transcript is below.","_key":"28d4f860f80f","_type":"span"}],"_type":"block","style":"normal","_key":"e5514c4db835","upload_doc":null},{"medias":null,"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c7b16d3606380"}],"_type":"block","style":"normal","_key":"ef10aad1aeaa","upload_doc":null,"uploadAudio":null},{"_key":"d8b9ef0b4940","markDefs":[],"upload_doc":null,"uploadAudio":null,"medias":null,"children":[{"marks":[],"text":"Hi, my name is Erin Crown. I am a psychiatric physician assistant from State College, Pennsylvania. I do outpatient medication management, but I am also the owner of Future Options Research, and have recently become a primary investigator in clinical trials.","_key":"dc49c8f018570","_type":"span"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"As a primary investigator, I think that it is really important for me to come to ASCP for networking opportunities and to really get a firsthand look at the topics that we are talking about in research right now, and to just kind of get my sea legs under me as I grow this next portion of my career.","_key":"8ca87fffa41a0"}],"_type":"block","style":"normal","_key":"53c6c717a704","markDefs":[],"upload_doc":null,"uploadAudio":null,"medias":null},{"medias":null,"_type":"block","style":"normal","_key":"f837c0ce5c06","markDefs":[],"children":[{"_type":"span","marks":[],"text":"There is a session that is going to be happening about pseudospecific vs transdiagnostic symptom targeting in pharmacotherapy that I am very interested in. I know Drs Goldberg and McIntyre will both be presenting in that session, and I am very excited to hear what they have to teach me.","_key":"7eae771b42810"}],"upload_doc":null,"uploadAudio":null},{"children":[{"_type":"span","marks":[],"text":"I just think ASCP is a really intimate and nice conference. It is smaller than many other conferences that I have been to for other kinds of reasons, and so it has been a nice change of pace and a great learning environment. I am really excited to finish out the rest of the week and see what all there is to offer.","_key":"654e7622aa540"}],"_type":"block","style":"normal","_key":"d6a8a909148e","upload_doc":null,"uploadAudio":null,"medias":null,"markDefs":[]},{"_type":"block","style":"normal","upload_doc":null,"uploadAudio":null,"medias":null,"_key":"69d339f6bd0e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"d631798ba0d60"}]},{"children":[{"_key":"a91412cc2a070","_type":"span","marks":["strong"],"text":"Ms Crown "},{"_type":"span","marks":["em"],"text":"is a psychiatric physician assistant at State College, Pennsylvania, and owner of Future Options Research.","_key":"a91412cc2a071"}],"_type":"block","upload_doc":null,"uploadAudio":null,"medias":null,"style":"normal","_key":"97ad8817b9dd","markDefs":[]},{"upload_doc":null,"uploadAudio":null,"medias":null,"_key":"1686230b9126","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"499628b5068e0"}],"_type":"block","style":"normal"},{"uploadAudio":null,"medias":null,"children":[{"_type":"span","marks":[],"text":"Note: The panel presentation referenced in this video is “Pseudospecific Versus Transdiagnostic Symptom Targeting in Pharmacotherapy Trials: Agitation, Attention, Anhedonia, and Mood Instability,” which takes place Thursday, May 30, at 2:15 PM EST. See a preview of the presentation by panel chair and co-presenter Joseph F. Goldberg, MD, ","_key":"135d67b73e320"},{"marks":["9139d9cc2184"],"text":"here","_key":"135d67b73e321","_type":"span"},{"marks":[],"text":".","_key":"135d67b73e322","_type":"span"}],"_type":"block","style":"normal","_key":"68d1228fc80a","markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/view/pseudospecific-and-transdiagnostic-symptom-targeting-in-clinical-trials","_key":"9139d9cc2184"}],"upload_doc":null},{"style":"normal","_key":"82b02fe0e3ad","upload_doc":null,"uploadAudio":null,"medias":null,"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"19419782a6bc0"}],"_type":"block"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/","_key":"33fb09196081"}],"children":[{"_key":"35022318ea950","_type":"span","marks":["em"],"text":"Follow the "},{"_type":"span","marks":[],"text":"Psychiatric Times","_key":"35022318ea951"},{"_type":"span","marks":["em"],"text":" coverage of the 2024 ASCP Annual Meeting, and stay up-to-date on news related to research on promising new interventions and developments in the treatment of a wide variety of psychiatric disorders, at ","_key":"35022318ea952"},{"text":"psychiatrictimes.com","_key":"35022318ea953","_type":"span","marks":["33fb09196081","em"]},{"_type":"span","marks":["em"],"text":".","_key":"35022318ea954"}],"_type":"block","style":"normal","upload_doc":null,"uploadAudio":null,"medias":null,"_key":"407a66b43442"},{"upload_doc":null,"uploadAudio":null,"medias":null,"style":"normal","_key":"43dee7c6c85d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"b94730c31a24"}],"_type":"block"}],"_updatedAt":"2024-06-05T19:58:26Z","issueSection":null,"pdfUrl":null,"factCheckAuthorMapping":null,"issueGroup":null,"title":"Research and Opportunities at the 2024 ASCP Annual Meeting","filter":null,"articleType":"News","summary":"Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.","ExcludeFromPubMedXML":false,"_createdAt":"2024-05-30T16:30:19Z","thumbnail":{"asset":{"_ref":"image-8ddbdd713f36df89e072d6a475712b13a7521d5f-6000x4000-jpg","_type":"reference"},"_type":"mainImage","alt":"Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.","caption":"THANANIT AdobeStock"},"disableAds":false,"disableRelatedContent":false,"relatedArticles":[{"title":"Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update","audioUrl":"https://s3.us-east-1.amazonaws.com/ai-generated-audios/www.psychiatrictimes.com/a6dd60b8-ef2f-4bcc-8420-0288e0135e97_1739828805528.c746e8bd-fb11-43fe-b8e2-fb84f58ab37c.mp3","_id":"a6dd60b8-ef2f-4bcc-8420-0288e0135e97","summary":"Catch up on coverage from the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.","authors":[{"displayName":"Megan McSweeney","url":"megan-mcsweeney"}],"factCheckAuthors":null,"gptTakeaways":"• The EMERGENT-5 trial showed xanomeline and trospium significantly improved PANSS scores in schizophrenia over 52 weeks.\n\n• The treatment was well tolerated, with mild to moderate gastrointestinal issues as the most common adverse events.\n\n• Xanomeline and trospium were not associated with significant weight gain, with participants losing an average of 2.2 kg.\n\n• AXS-05 and SPN-820 demonstrated rapid and sustained efficacy in major depressive disorder, with manageable adverse effects.","articleType":"News","body":[{"alt":"MADNI/AdobeStock","alignment":"left","disableLightBox":true,"_type":"figure","asset":{"_type":"reference","_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg"},"disableTextWrap":false,"_key":"f09c8f18074e","widthP":50,"imgcaption":[{"_key":"e8877e805ac5","markDefs":[],"children":[{"_type":"span","marks":[],"text":"MADNI/AdobeStock","_key":"82799418eadd"}],"_type":"block","style":"normal"}]},{"_key":"f41780d297c0","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"CONFERENCE REPORTER","_key":"bf03327232f0"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"1395a5c767b7","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings","_key":"11a6137d4166"}]},{"_type":"block","style":"normal","_key":"041af52ba563","markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/view/long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings","_key":"7c20d51398b8"}],"children":[{"text":"The EMERGENT-5 trial, a 52-week open-label phase 3 study, evaluated the long-term efficacy and safety of xanomeline and trospium in adults with schizophrenia. Conducted across multiple centers, the trial included 277 participants with stable schizophrenia who had not previously been exposed to this treatment combination. Findings revealed significant and sustained improvements in key clinical measures, notably the Positive and Negative Syndrome Scale (PANSS) total score, the Clinical Global Impression–Severity scale, and PANSS subscale scores. The treatment was generally well tolerated; the most common adverse events were mild to moderate gastrointestinal issues, such as nausea (21.4%), vomiting (17.8%), and constipation (16.8%). Serious adverse events were rare, occurring in only 1.6% of participants. Importantly, the treatment was not associated with significant weight gain or metabolic disturbances; participants experienced an average weight reduction of 2.2 kg over the 52-week period. ","_key":"42b1d43ffab6","_type":"span","marks":[]},{"_type":"span","marks":["7c20d51398b8"],"text":"Read more","_key":"338bd2d5d4cc"},{"_type":"span","marks":[],"text":".","_key":"a447fe36fc9c"}]},{"children":[{"_type":"span","marks":[],"text":"","_key":"75aea5f468c8"}],"_type":"block","style":"normal","_key":"d45ba210ad05","markDefs":[]},{"_key":"7fd533bddecf","markDefs":[],"children":[{"text":"Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment","_key":"7ab47d173b6f","_type":"span","marks":["strong"]}],"_type":"block","style":"normal"},{"_key":"171005710c49","markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/view/xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment","_key":"259b2c537eb1"}],"children":[{"_type":"span","marks":[],"text":"The EMERGENT-4 trial, a 52-week open-label phase 3 study, evaluated the long-term efficacy and safety of xanomeline and trospium in adults with schizophrenia. This trial demonstrated sustained symptom improvement, with 68.6% of participants achieving a response, defined as a ≥30% reduction in the Positive and Negative Syndrome Scale (PANSS) total score. The treatment was generally well tolerated; the most common adverse events were mild to moderate gastrointestinal issues, such as nausea, vomiting, and constipation. Importantly, the treatment was not associated with significant weight gain or metabolic disturbances; participants experienced an average weight reduction of 1.9 kg over the 52-week period. ","_key":"06be739bcdab"},{"_type":"span","marks":["259b2c537eb1"],"text":"Read more","_key":"e042af6b167e"},{"text":".","_key":"d1bf0e6f5c0f","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"style":"normal","_key":"2166b71fc669","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"3b196e6154bd"}],"_type":"block"},{"markDefs":[],"children":[{"_key":"47142fb04268","_type":"span","marks":["strong"],"text":"Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis"}],"_type":"block","style":"normal","_key":"2b1d489f54e0"},{"_key":"2af375b4312c","markDefs":[{"href":"https://www.psychiatrictimes.com/view/xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis","_key":"3853bda081d9","blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"Recent analyses from the EMERGENT trials have demonstrated that the combination of xanomeline and trospium not only alleviates core symptoms of schizophrenia but also significantly enhances social functioning and life engagement in affected individuals. The initial 3 EMERGENT trials were 5-week, double-blind, placebo-controlled studies involving 640 participants experiencing acute exacerbations of schizophrenia. Participants were randomized to receive either the xanomeline-trospium combination (314 individuals) or a placebo (326 individuals), with dosages titrated up to 125 mg of xanomeline and 30 mg of trospium administered twice daily. Findings revealed that those treated with xanomeline and trospium exhibited significant improvements in social functioning, as evidenced by a notable reduction in prosocial factor scores compared with the placebo group. These results suggest that this therapeutic combination may offer 2 benefits for individuals with schizophrenia, with effective management of psychotic symptoms and meaningful enhancement of social engagement and quality of life. ","_key":"4cbc72649bad"},{"_type":"span","marks":["3853bda081d9"],"text":"Read more","_key":"a0107942131b"},{"_type":"span","marks":[],"text":".","_key":"69fa27e4eaa5"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"decd4219d7a2","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"a7c265733c97"}]},{"children":[{"_type":"span","marks":["strong"],"text":"AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment","_key":"2c8a80d760ea"}],"_type":"block","style":"normal","_key":"466bd5b71ee8","markDefs":[]},{"_key":"50a38113ce3c","markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/view/axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment","_key":"54b9f6180b8c"}],"children":[{"_type":"span","marks":[],"text":"A recent pooled analysis of 2 clinical trials has demonstrated that AXS-05, an investigational treatment for major depressive disorder (MDD), offers rapid and sustained reduction in depressive symptoms with a manageable safety profile. AXS-05 combines dextromethorphan and bupropion, functioning as an NMDA receptor antagonist and sigma-1 receptor agonist. Patients experienced significant symptom improvement within the first week of treatment, with sustained efficacy observed over a 6-week period. The most commonly reported adverse effects were dizziness, nausea, and headache, which were generally mild to moderate in severity. ","_key":"d67e958dc11e"},{"_type":"span","marks":["54b9f6180b8c"],"text":"Read more","_key":"08a0052305fe"},{"text":".","_key":"6e3367f5b371","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"9d573a607e0c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"eda7cc7d4c87"}]},{"style":"normal","_key":"f3b72a8cbe1c","markDefs":[],"children":[{"text":"SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms","_key":"349ead1b2553","_type":"span","marks":["strong"]}],"_type":"block"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/view/spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms","_key":"7695cb3b271a"}],"children":[{"_type":"span","marks":[],"text":"A recent phase 2, open-label clinical trial has demonstrated that SPN-820, a novel antidepressant, provides rapid and substantial improvement in adults with major depressive disorder (MDD). Patients taking SPN-820 alongside their existing antidepressant medication exhibited significant symptom relief within hours of administration, with continued improvement observed over the study period. The rapid onset of action is particularly notable, as conventional antidepressants often require weeks to show full therapeutic effects. The trial results indicate that SPN-820 was well tolerated, with most adverse events being mild to moderate in nature. The findings suggest that SPN-820 could represent a breakthrough in MDD treatment, particularly for individuals who do not respond adequately to standard antidepressants. ","_key":"8515ec763b14"},{"_type":"span","marks":["7695cb3b271a"],"text":"Read more","_key":"211204b95fe5"},{"_type":"span","marks":[],"text":".","_key":"960c63cbcdd6"}],"_type":"block","style":"normal","_key":"fc53a0556d1e"}],"taxonomyMapping":[{"_updatedAt":"2020-09-11T15:24:41Z","name":"Conferences","_createdAt":"2020-03-26T06:11:21Z","_rev":"A1SshklVZqV0BxeqIqEcIX","_type":"taxonomy","parent":null,"pixelTrackingCode":null,"_id":"pst_taxonomy_439_conferences","identifier":"conferences"},{"pixelTrackingCode":null,"parent":{"identifier":"topics","_createdAt":"2020-03-26T06:11:21Z","name":"Topics","_id":"pst_taxonomy_53202_clinical","isMainTopic":true,"_rev":"uvXJooXtzvjNOyx50HTt8m","_type":"taxonomy","_updatedAt":"2023-03-31T19:15:59Z","parent":null},"perKeywordMapping":["Psychiatry","Neurology"],"_type":"taxonomy","_id":"pst_taxonomy_238_majordepressivedisorder","_updatedAt":"2024-02-29T16:00:14Z","identifier":"topics/major-depressive-disorder","cmeType":"per","_createdAt":"2020-03-26T06:11:21Z","_rev":"r4Rkjy04WvWq5fuPdnwLCI","name":"Major Depressive Disorder"},{"perKeywordMapping":["Psychiatry","Neurology"],"_type":"taxonomy","parent":{"_updatedAt":"2023-03-31T19:15:59Z","isMainTopic":true,"_rev":"uvXJooXtzvjNOyx50HTt8m","parent":null,"name":"Topics","identifier":"topics","_createdAt":"2020-03-26T06:11:21Z","_type":"taxonomy","_id":"pst_taxonomy_53202_clinical"},"_createdAt":"2020-03-26T06:11:21Z","pixelTrackingCode":null,"_updatedAt":"2023-03-31T19:32:05Z","_rev":"77mZ7PORfofI3dBGfWfij5","name":"Schizophrenia/Psychosis","cmeType":"per","_id":"pst_taxonomy_362_schizophreniapsychosis","identifier":"topics/schizophrenia"}],"_rev":"WXRAdJOhAFvlN3sG0gnGkC","factCheckAuthorMapping":null,"_createdAt":"2025-02-17T21:46:34Z","_type":"article","ExcludeFromPubMedXML":false,"drugMentions":"{\"drug_mentions\": [\"Xanomeline\", \"Trospium\", \"AXS-05\", \"dextromethorphan\", \"bupropion\", \"SPN-820\"]}","authorMapping":[{"_type":"author","_updatedAt":"2024-11-25T16:17:55Z","firstName":"Megan","displayName":"Megan McSweeney","_createdAt":"2024-11-25T16:17:55Z","_rev":"HG9itg5Um8jvM5zF8KyjU8","url":{"current":"megan-mcsweeney","_type":"slug"},"lastName":"McSweeney","authorType":"author","_id":"0dd98119-9102-491d-98b5-9cd27b8be6f7","biography":[{"style":"normal","_key":"37d6c0564341","markDefs":[],"children":[{"marks":["strong"],"text":"Ms McSweeney","_key":"67ccf07444ee","_type":"span"},{"_type":"span","marks":[],"text":" ","_key":"3e163b408efc"},{"_type":"span","marks":["em"],"text":"is an assistant editor at ","_key":"b70df96f70e5"},{"_type":"span","marks":[],"text":"Psychiatric Times","_key":"52d2e41075d5"},{"_type":"span","marks":["em"],"text":".","_key":"85b80e6c3bc5"}],"_type":"block"}]}],"is_visible":true,"gptSummary":"The EMERGENT-5 trial assessed the long-term efficacy and safety of xanomeline and trospium in schizophrenia, showing significant improvements in clinical measures like PANSS scores. The treatment was well tolerated, with mild to moderate gastrointestinal issues as the most common adverse events. Importantly, it was not linked to significant weight gain or metabolic disturbances, with participants losing an average of 2.2 kg. Additionally, the combination improved social functioning and life engagement. AXS-05 and SPN-820 also demonstrated efficacy in major depressive disorder, with rapid symptom improvement and manageable adverse effects.","url":"conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update","_updatedAt":"2025-02-17T21:46:45Z","thumbnail":{"_type":"mainImage","alt":"MADNI/AdobeStock","caption":"MADNI/AdobeStock","asset":{"_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg","_type":"reference"}},"documentGroup":null,"documentGroupMapping":null,"contentCategory":{"_createdAt":"2020-02-06T09:15:47Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","_updatedAt":"2020-02-25T09:35:56Z"},"published":"2025-02-17T21:45:27.773Z","targeting":{"content_placement":["conferences","topics/major-depressive-disorder","topics/schizophrenia"],"document_url":["conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update"],"document_group":null,"rootDocumentGroup":[],"issue_url":"","publication_url":""},"relatedArticles":[{"title":"Planned Induction of Labor in a Patient With Acute Late-Pregnancy Psychosis: A Case Report ","url":{"current":"planned-induction-of-labor-in-a-patient-with-acute-late-pregnancy-psychosis-a-case-report","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"pregnancy","caption":"Gajus/AdobeStock","asset":{"_ref":"image-2bb56ac82e597ddb7c4240a7a28596e8a2617548-5424x3051-jpg","_type":"reference"}},"published":"2025-02-18T16:00:00.000Z"},{"title":"Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update","url":{"current":"conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"MADNI/AdobeStock","caption":"MADNI/AdobeStock","asset":{"_type":"reference","_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg"}},"published":"2025-02-17T21:45:27.773Z"},{"title":"Xanomeline-Trospium as a Novel Agent for Treatment of Psychosis in Schizophrenia","url":{"current":"xanomeline-trospium-as-a-novel-agent-for-treatment-of-psychosis-in-schizophrenia","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"schizophrenia","caption":"Kamonwan/AdobeStock","asset":{"_ref":"image-ab16f55a19460639646149c79950a844fb75612a-6144x3072-jpg","_type":"reference"}},"published":"2025-02-17T15:00:11.674Z"},{"title":"Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings","url":{"current":"long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Tasty Cat/AdobeStock","caption":"Tasty Cat/AdobeStock","asset":{"_ref":"image-10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748-jpg","_type":"reference"}},"published":"2025-02-14T15:45:38.972Z"},{"title":"Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment","url":{"_type":"slug","current":"xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment"},"thumbnail":{"caption":"LFK/AdobeStock","asset":{"_ref":"image-0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584-jpg","_type":"reference"},"_type":"mainImage","alt":"LFK/AdobeStock"},"published":"2025-02-13T21:57:15.688Z"},{"title":"Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis","url":{"current":"xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Berit Kessler/AdobeStock","caption":"Berit Kessler/AdobeStock","asset":{"_type":"reference","_ref":"image-200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956-jpg"}},"published":"2025-02-13T19:30:34.622Z"}]},{"documentGroup":null,"_rev":"WXRAdJOhAFvlN3sG0Mq4VL","title":"Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings","gptSummary":"A 52-week phase 3 trial, EMERGENT-5, demonstrated the long-term efficacy, safety, and tolerability of xanomeline and trospium in adults with schizophrenia. The study involved 277 participants and showed significant improvements in clinical measures, including PANSS scores, with 30% achieving a 30% reduction. Xanomeline acts as an M1/M4 muscarinic receptor agonist, while trospium reduces peripheral side effects. The treatment was well tolerated, with mild gastrointestinal issues as the most common adverse events. The trial supports xanomeline and trospium as a viable alternative to conventional antipsychotics.","ExcludeFromPubMedXML":false,"taxonomyMapping":[{"_type":"taxonomy","name":"Psychopharmacology","_createdAt":"2020-03-26T06:11:21Z","identifier":"topics/psychopharmacology","cmeType":"per","pixelTrackingCode":null,"_rev":"4roekEga8ZReQAdH6zkAp9","parent":{"_id":"pst_taxonomy_53202_clinical","isMainTopic":true,"_type":"taxonomy","parent":null,"name":"Topics","_updatedAt":"2023-03-31T19:15:59Z","identifier":"topics","_createdAt":"2020-03-26T06:11:21Z","_rev":"uvXJooXtzvjNOyx50HTt8m"},"perKeywordMapping":["Psychiatry","Neurology","New Drugs"],"_id":"pst_taxonomy_336_psychopharmacology","_updatedAt":"2023-03-31T19:23:25Z"},{"_rev":"A1SshklVZqV0BxeqIqEcIX","_type":"taxonomy","pixelTrackingCode":null,"name":"Conferences","identifier":"conferences","_createdAt":"2020-03-26T06:11:21Z","_id":"pst_taxonomy_439_conferences","_updatedAt":"2020-09-11T15:24:41Z","parent":null}],"articleType":"News","thumbnail":{"_type":"mainImage","alt":"Tasty Cat/AdobeStock","caption":"Tasty Cat/AdobeStock","asset":{"_ref":"image-10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748-jpg","_type":"reference"}},"drugMentions":"{\"drug_mentions\": [\"xanomeline\", \"trospium\"]}","gptTakeaways":"• The EMERGENT-5 trial confirmed xanomeline and trospium's long-term efficacy and safety in schizophrenia, with significant improvements in PANSS scores over 52 weeks.\n\n• Xanomeline's novel mechanism as an M1/M4 muscarinic receptor agonist, combined with trospium, offers a new treatment approach with reduced adverse effects.\n\n• The treatment was well tolerated, with mild gastrointestinal issues as the most common adverse events and no significant weight gain or metabolic disturbances.\n\n• The trial supports xanomeline and trospium as a viable alternative to conventional antipsychotics, with FDA approval reinforcing its potential in schizophrenia management.","contentCategory":{"_createdAt":"2020-02-06T09:15:47Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","_updatedAt":"2020-02-25T09:35:56Z"},"_id":"44956733-1804-4d62-a070-7b321a182b25","is_visible":true,"summary":"A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.","url":"long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings","_type":"article","_createdAt":"2025-02-14T15:10:35Z","documentGroupMapping":null,"audioUrl":"https://s3.us-east-1.amazonaws.com/ai-generated-audios/www.psychiatrictimes.com/44956733-1804-4d62-a070-7b321a182b25_1739546524337.034ae4e6-fdf9-4437-96af-0f95c956a329.mp3","body":[{"widthP":50,"disableLightBox":true,"_type":"figure","disableTextWrap":false,"imgcaption":[{"children":[{"_type":"span","marks":[],"text":"Tasty Cat/AdobeStock","_key":"27f138be2a71"}],"_type":"block","style":"normal","_key":"b7eb0c05f200","markDefs":[]}],"_key":"1289f6d0c0a5","alignment":"left","asset":{"_ref":"image-10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748-jpg","_type":"reference"},"alt":"Tasty Cat/AdobeStock"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"CONFERENCE REPORTER","_key":"060f0dce88cc"}],"_type":"block","style":"normal","_key":"98fae02a782f"},{"style":"normal","_key":"65463d0288eb","markDefs":[],"children":[{"_type":"span","marks":[],"text":"A 52-week, open-label phase 3 trial (EMERGENT-5) has confirmed the long-term efficacy, safety, and tolerability of xanomeline and trospium in adults with schizophrenia. The results, derived from a large, multicenter outpatient study, show that the treatment leads to sustained symptom improvement while maintaining a favorable safety profile with minimal adverse effects. The new information was presented via poster session at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.","_key":"31f28595797b"}],"_type":"block"},{"markDefs":[],"children":[{"text":"Sustained Symptom Improvement Over 52 Weeks","_key":"82f77602ed00","_type":"span","marks":["strong"]}],"_type":"block","style":"normal","_key":"a8ae6f93a6e0"},{"children":[{"text":"The EMERGENT-5 trial followed 277 participants, all of whom had stable schizophrenia symptoms with no prior exposure to xanomeline and trospium. The study found significant and durable improvements in key clinical measures, including the Positive and Negative Syndrome Scale (PANSS) total score, Clinical Global Impression–Severity scale, and PANSS subscale scores. By week 52, 30% of participants achieved at least a 30% reduction in PANSS total scores, supporting xanomeline and trospium’s effectiveness in managing schizophrenia symptoms.","_key":"8af6affc4932","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"b6bff1a5afd9","markDefs":[]},{"_key":"fd8558acf6a5","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"A Novel Mechanism of Action","_key":"241f1fe543fd"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"Xanomeline functions as an M1/M4-preferring muscarinic receptor agonist, while trospium chloride reduces peripheral side effects. This offers a new approach for treating schizophrenia, reducing the risk of common adverse effects associated with conventional treatments.","_key":"44f99b3fc79d","_type":"span"}],"_type":"block","style":"normal","_key":"2dd4731f76b9"},{"children":[{"_key":"9952e39e077e","_type":"span","marks":["strong"],"text":"Favorable Safety and Tolerability Profile"}],"_type":"block","style":"normal","_key":"4849ad7eed7d","markDefs":[]},{"_key":"3d38f4ade0bf","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Long-term treatment with xanomeline and trospium was generally well tolerated. The most common treatment-emergent adverse events were mild to moderate gastrointestinal issues, including nausea (21.4%), vomiting (17.8%), and constipation (16.8%). Serious adverse events were rare, with only 1.6% of participants experiencing severe events. The treatment was not associated with significant weight gain or metabolic disturbances, with participants experiencing an average weight reduction of 2.2 kg over 52 weeks. Additionally, there were no significant changes in prolactin levels or movement-related adverse effects, such as tardive dyskinesia.","_key":"4e556496bd40"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Study Design and Participant Demographics","_key":"f02d3bd543e6"}],"_type":"block","style":"normal","_key":"8ee789bde97d"},{"style":"normal","_key":"c81fa330ca8d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The study enrolled a diverse population, with 66.3% male and 33.7% female participants. Racial and ethnic diversity was also represented, with 68.7% identifying as Black or African American, 29% as White, and 21% as Hispanic or Latino. All participants initiated treatment with a twice-daily regimen, titrating from 50 mg xanomeline and 20 mg trospium chloride to a maximum dose of 125 mg xanomeline and30 mg trospium chloride over the course of the trial.","_key":"9eb3ba0c4bc1"}],"_type":"block"},{"style":"normal","_key":"52b3355f6978","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Future Implications for Schizophrenia Treatment","_key":"7819c358fe12"}],"_type":"block"},{"_key":"63596df6755c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"With the US Food and Drug Administration approval of xanomeline and trospium for schizophrenia, the EMERGENT-5 trial provides long-term data supporting its efficacy and safety. The findings reinforce the treatment’s potential as an alternative to conventional antipsychotics.","_key":"e19594910bc8"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"7559351f9b59","_type":"span"}],"_type":"block","style":"normal","_key":"35490f22d99c"},{"children":[{"_type":"span","marks":["em"],"text":"For complete conference coverage, click ","_key":"d9b97dbb79f3"},{"marks":["743a14389965","em"],"text":"here","_key":"ecf9b5f153ca","_type":"span"},{"_type":"span","marks":["em"],"text":".","_key":"fe5555e1ee9d"}],"_type":"block","style":"normal","_key":"d9e37efac6e0","markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/latest-conference","_key":"743a14389965"}]},{"_key":"69ed509bdffe","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"c809ef5ef601"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Reference","_key":"0f6fbf5664c2"}],"_type":"block","style":"normal","_key":"65e0241f51bb"},{"style":"normal","_key":"a76fd10a7d97","markDefs":[],"children":[{"_type":"span","marks":[],"text":"1. Kaul I, Claxton A, Sauder C, et al. Long-term safety, tolerability, and efficacy of xanomeline and trospium chloride in people with schizophrenia: results from the 52-week, open-label EMERGENT-5 trial. Presented at: Nevada Psychiatric Association 30th Annual Psychopharmacology Update; February 13, 2025.","_key":"f1009a9a1401"}],"_type":"block"},{"_type":"block","style":"normal","_key":"6ec53b0cb1e1","markDefs":[],"children":[{"marks":[],"text":"","_key":"a6ce97ed917c","_type":"span"}]}],"factCheckAuthorMapping":null,"authorMapping":[{"authorType":"author","_id":"0dd98119-9102-491d-98b5-9cd27b8be6f7","biography":[{"markDefs":[],"children":[{"marks":["strong"],"text":"Ms McSweeney","_key":"67ccf07444ee","_type":"span"},{"_type":"span","marks":[],"text":" ","_key":"3e163b408efc"},{"_type":"span","marks":["em"],"text":"is an assistant editor at ","_key":"b70df96f70e5"},{"_type":"span","marks":[],"text":"Psychiatric Times","_key":"52d2e41075d5"},{"_type":"span","marks":["em"],"text":".","_key":"85b80e6c3bc5"}],"_type":"block","style":"normal","_key":"37d6c0564341"}],"url":{"current":"megan-mcsweeney","_type":"slug"},"lastName":"McSweeney","displayName":"Megan McSweeney","_createdAt":"2024-11-25T16:17:55Z","_rev":"HG9itg5Um8jvM5zF8KyjU8","_type":"author","_updatedAt":"2024-11-25T16:17:55Z","firstName":"Megan"}],"published":"2025-02-14T15:45:38.972Z","_updatedAt":"2025-02-14T15:22:08Z","authors":[{"displayName":"Megan McSweeney","url":"megan-mcsweeney"}],"factCheckAuthors":null,"targeting":{"content_placement":["topics/psychopharmacology","conferences"],"document_url":["long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings"],"document_group":null,"rootDocumentGroup":[],"issue_url":"","publication_url":""},"relatedArticles":[{"title":"Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update","url":{"_type":"slug","current":"conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update"},"thumbnail":{"_type":"mainImage","alt":"MADNI/AdobeStock","caption":"MADNI/AdobeStock","asset":{"_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg","_type":"reference"}},"published":"2025-02-17T21:45:27.773Z"},{"title":"Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings","url":{"current":"long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Tasty Cat/AdobeStock","caption":"Tasty Cat/AdobeStock","asset":{"_ref":"image-10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748-jpg","_type":"reference"}},"published":"2025-02-14T15:45:38.972Z"},{"title":"Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment","url":{"_type":"slug","current":"xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment"},"thumbnail":{"_type":"mainImage","alt":"LFK/AdobeStock","caption":"LFK/AdobeStock","asset":{"_ref":"image-0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584-jpg","_type":"reference"}},"published":"2025-02-13T21:57:15.688Z"},{"title":"The Importance of Sports Psychiatry in an Athlete's Well-Being","url":{"current":"the-importance-of-sports-psychiatry-in-an-athletes-well-being","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Venusvi/AdobeStock","caption":"Venusvi/AdobeStock","asset":{"_ref":"image-bda231a36f0ee9d80203c625f705adfcebe7f717-5376x3584-jpg","_type":"reference"}},"published":"2025-02-13T21:45:58.157Z"},{"title":"Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis","url":{"current":"xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Berit Kessler/AdobeStock","caption":"Berit Kessler/AdobeStock","asset":{"_ref":"image-200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956-jpg","_type":"reference"}},"published":"2025-02-13T19:30:34.622Z"},{"title":"FDA Breakthrough Therapy Designation and the Future of MM120","url":{"_type":"slug","current":"fda-breakthrough-therapy-designation-and-the-future-of-mm120"},"thumbnail":{"_type":"mainImage","alt":"RolfImages/AdobeStock","caption":"RolfImages/AdobeStock","asset":{"_ref":"image-1c9a595620a6a6f3ac7d40400744f9429b1cdbda-3998x3000-jpg","_type":"reference"}},"published":"2025-02-12T21:45:54.521Z"}]},{"_updatedAt":"2025-02-13T21:51:47Z","gptTakeaways":"• Xanomeline and trospium offer an alternative mechanism of action, targeting muscarinic receptors rather than dopamine D2 receptors in schizophrenia treatment.\n\n• The EMERGENT-4 trial showed sustained symptom improvement, with 68.6% of participants achieving significant PANSS score reductions by week 52.\n\n• Long-term treatment was well tolerated, with gastrointestinal issues as the most common adverse events and minimal severe adverse effects.\n\n• Participants experienced an average weight reduction of 1.9 kg, with no significant increases in prolactin levels or movement-related side effects.\n\n• The trial supports xanomeline and trospium as a promising long-term therapy, recently approved by the FDA for schizophrenia treatment.","body":[{"imgcaption":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"LFK/AdobeStock","_key":"520cde7a59a6"}],"_type":"block","style":"normal","_key":"8256f19a7098"}],"asset":{"_ref":"image-0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584-jpg","_type":"reference"},"alignment":"left","widthP":50,"_type":"figure","alt":"LFK/AdobeStock","_key":"dcb08e762030","disableTextWrap":false,"disableLightBox":true},{"_key":"92a1448d1eff","markDefs":[],"children":[{"text":"CONFERENCE REPORTER","_key":"7511993c8653","_type":"span","marks":["strong"]}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"b1c83cb37180","markDefs":[],"children":[{"_type":"span","marks":[],"text":"A 52-week open-label extension trial (EMERGENT-4) has confirmed that long-term treatment with xanomeline and trospium is both effective and well tolerated in individuals with schizophrenia.","_key":"3b2b9d3517ed"},{"marks":["sup"],"text":"1","_key":"6052e420dd09","_type":"span"},{"_type":"span","marks":[],"text":"The new information was presented via poster session at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.","_key":"167fcd39c22e"}]},{"_type":"block","style":"normal","_key":"65fb83b6d4e5","markDefs":[],"children":[{"marks":["strong"],"text":"Mechanism of Action","_key":"ca1129147ee1","_type":"span"}]},{"children":[{"marks":[],"text":"Xanomeline and trospium do not directly block dopamine D2 receptors. Instead, xanomeline acts as an M","_key":"4dcd2d974f65","_type":"span"},{"_type":"span","marks":["sub"],"text":"1","_key":"00a863180a10"},{"_type":"span","marks":[],"text":"/M","_key":"b55744843cd5"},{"_type":"span","marks":["sub"],"text":"4","_key":"166cc2b99c1c"},{"_type":"span","marks":[],"text":" preferring muscarinic receptor agonist, while trospium chloride, a peripherally restricted muscarinic receptor antagonist, helps reduce side effects.","_key":"06382ec18a6c"},{"_type":"span","marks":["sup"],"text":"1","_key":"576f920744f5"},{"text":" This differentiates xanomeline and trospium from conventional schizophrenia treatments, offering an alternative approach to managing symptoms.","_key":"3dfc44c9037e","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"f7f59129a730","markDefs":[]},{"style":"normal","_key":"f8b4b8a57445","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Trial Design and Participant Demographics","_key":"fde11e17d50f"}],"_type":"block"},{"_key":"6d7b074bfb11","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The study included participants who had previously completed either EMERGENT-2 or EMERGENT-3. Participants were required to be between 18 and 65 years old, with a primary diagnosis of schizophrenia and a Positive and Negative Syndrome Scale (PANSS) total score of 80 to 120 at the time of enrollment in the acute trials.","_key":"d8b1008ec362"},{"_type":"span","marks":["sup"],"text":"1","_key":"2931f11ccdce"},{"_type":"span","marks":[],"text":" Overall, 122 of the 156 enrolled participants discontinued the trial, most due to withdrawal of consent, failure to adhere to treatment protocols, and lost to follow-up.","_key":"8aad13e2ff71"}],"_type":"block","style":"normal"},{"style":"normal","_key":"514f92928c05","markDefs":[],"children":[{"text":"Sustained Symptom Improvement","_key":"0ba2f71e35da","_type":"span","marks":["strong"]}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Results showed that treatment with xanomeline and trospium led to continued, durable improvements in PANSS total scores, Clinical Global Impression–Severity scores, and both PANSS positive and negative subscale scores. By week 52, 68.6% of participants had achieved at least a 30% reduction in PANSS total scores from baseline, demonstrating long-term efficacy.","_key":"b50536dbcb57"},{"text":"1","_key":"1e381b90a97a","_type":"span","marks":["sup"]}],"_type":"block","style":"normal","_key":"ca3e99a16898"},{"_key":"8ddc6c59c00f","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Manageable Safety Profile with Few Severe Adverse Events","_key":"669c7e6cc10b"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"a6444d03bf4f","markDefs":[],"children":[{"text":"Long-term treatment was generally well tolerated. The most common treatment-emergent adverse events were gastrointestinal-related, including nausea (9.2%), vomiting (7.9%), dyspepsia (5.9%), and dry mouth (5.3%).","_key":"7f5594bed60e","_type":"span","marks":[]},{"_type":"span","marks":["sup"],"text":"1","_key":"08ebf4076002"},{"_type":"span","marks":[],"text":" Serious adverse effects were rare, with only 1.3% of participants experiencing treatment-related severe events, primarily associated with worsening schizophrenia rather than the medication itself.","_key":"969ffe5f13fc"},{"text":"1","_key":"656372672498","_type":"span","marks":["sup"]}]},{"style":"normal","_key":"4d4501519c87","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Xanomeline and trospium did not lead to clinically meaningful weight gain. Instead, participants experienced an average weight reduction of 1.9 kg over 52 weeks. Additionally, there were no significant increases in prolactin levels, extrapyramidal symptoms, or tardive dyskinesia, further supporting the treatment’s favorable safety profile.","_key":"4f1b5217cebb"}],"_type":"block"},{"style":"normal","_key":"3bb0d65b673a","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Potential for a New Standard in Schizophrenia Treatment","_key":"ee3d521af6d8"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"With the US Food and Drug Administration recently approving xanomeline and trospium for the treatment of schizophrenia in adults, the EMERGENT-4 trial adds valuable long-term data supporting its efficacy and safety. Xanomeline and trospium maintained symptom improvement without significant metabolic or movement-related adverse effects.","_key":"f75441542627"}],"_type":"block","style":"normal","_key":"1a92e2fb9e54"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The findings from EMERGENT-4 reinforce xanomeline and trospium’s role as an effective long-term therapy, offering a new form of treatment for schizophrenia.","_key":"b5fe6a059e88"}],"_type":"block","style":"normal","_key":"10c6ff337613"},{"children":[{"_type":"span","marks":["em"],"text":"For complete conference coverage, click ","_key":"8f888b95920b"},{"text":"here","_key":"d36707574fca","_type":"span","marks":["62d41ea070ce","em"]},{"_type":"span","marks":["em"],"text":".","_key":"c0a0bf5f93dc"}],"_type":"block","style":"normal","_key":"9146318ca02e","markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/latest-conference","_key":"62d41ea070ce"}]},{"_type":"block","style":"normal","_key":"58bb36be7d96","markDefs":[],"children":[{"_key":"215ec9c34fca","_type":"span","marks":["strong"],"text":"Reference"}]},{"markDefs":[],"children":[{"_key":"6177f47a51a2","_type":"span","marks":[],"text":"1. Kaul I, Claxton A, Sauder C, et al. Long-term safety and efficacy of xanomeline and trospium chloride in schizophrenia: results from the 52-week, open-label EMERGENT-4 trial. Presented at: Nevada Psychiatric Association 30th Annual Psychopharmacology Update; February 13, 2025."}],"_type":"block","style":"normal","_key":"7426363818e7"}],"_rev":"sqn82GeejNhxQc9beNDZwN","summary":"A 52-week study presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update offered a promising new approach to schizophrenia treatment.","articleType":"News","is_visible":true,"_id":"083cfed7-1e88-4c77-bc81-fbfc8bb41b47","_createdAt":"2025-02-13T21:42:07Z","drugMentions":"{\"drug_mentions\": [\"xanomeline\", \"trospium\"]}","taxonomyMapping":[{"_createdAt":"2020-03-26T06:11:21Z","pixelTrackingCode":null,"perKeywordMapping":["Psychiatry","Neurology","New Drugs"],"_updatedAt":"2023-03-31T19:23:25Z","identifier":"topics/psychopharmacology","_rev":"4roekEga8ZReQAdH6zkAp9","_id":"pst_taxonomy_336_psychopharmacology","cmeType":"per","_type":"taxonomy","name":"Psychopharmacology","parent":{"_createdAt":"2020-03-26T06:11:21Z","_rev":"uvXJooXtzvjNOyx50HTt8m","_id":"pst_taxonomy_53202_clinical","_updatedAt":"2023-03-31T19:15:59Z","identifier":"topics","isMainTopic":true,"_type":"taxonomy","name":"Topics","parent":null}},{"name":"Conferences","_updatedAt":"2020-09-11T15:24:41Z","parent":null,"_createdAt":"2020-03-26T06:11:21Z","_rev":"A1SshklVZqV0BxeqIqEcIX","_type":"taxonomy","identifier":"conferences","_id":"pst_taxonomy_439_conferences","pixelTrackingCode":null}],"authors":[{"displayName":"Megan McSweeney","url":"megan-mcsweeney"}],"factCheckAuthorMapping":null,"factCheckAuthors":null,"authorMapping":[{"lastName":"McSweeney","authorType":"author","_id":"0dd98119-9102-491d-98b5-9cd27b8be6f7","biography":[{"children":[{"marks":["strong"],"text":"Ms McSweeney","_key":"67ccf07444ee","_type":"span"},{"_type":"span","marks":[],"text":" ","_key":"3e163b408efc"},{"_type":"span","marks":["em"],"text":"is an assistant editor at ","_key":"b70df96f70e5"},{"_type":"span","marks":[],"text":"Psychiatric Times","_key":"52d2e41075d5"},{"_type":"span","marks":["em"],"text":".","_key":"85b80e6c3bc5"}],"_type":"block","style":"normal","_key":"37d6c0564341","markDefs":[]}],"url":{"current":"megan-mcsweeney","_type":"slug"},"firstName":"Megan","displayName":"Megan McSweeney","_createdAt":"2024-11-25T16:17:55Z","_rev":"HG9itg5Um8jvM5zF8KyjU8","_type":"author","_updatedAt":"2024-11-25T16:17:55Z"}],"gptSummary":"A 52-week open-label extension trial, EMERGENT-4, demonstrated that long-term treatment with xanomeline and trospium is effective and well-tolerated in schizophrenia patients. Unlike conventional treatments, xanomeline acts as an M1/M4 muscarinic receptor agonist, while trospium reduces side effects. The trial showed sustained symptom improvement, with 68.6% of participants achieving significant PANSS score reductions. The treatment had a manageable safety profile, with minimal severe adverse events and no significant weight gain or movement-related side effects. These findings support xanomeline and trospium as a promising long-term therapy for schizophrenia.","ExcludeFromPubMedXML":false,"title":"Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment","url":"xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment","contentCategory":{"_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","_updatedAt":"2020-02-25T09:35:56Z","_createdAt":"2020-02-06T09:15:47Z"},"audioUrl":"https://s3.us-east-1.amazonaws.com/ai-generated-audios/www.psychiatrictimes.com/083cfed7-1e88-4c77-bc81-fbfc8bb41b47_1739483249901.6e42b4ef-c28d-49e5-bd60-63904f9f57f0.mp3","published":"2025-02-13T21:57:15.688Z","documentGroup":null,"documentGroupMapping":null,"_type":"article","thumbnail":{"caption":"LFK/AdobeStock","asset":{"_ref":"image-0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584-jpg","_type":"reference"},"_type":"mainImage","alt":"LFK/AdobeStock"},"targeting":{"content_placement":["topics/psychopharmacology","conferences"],"document_url":["xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment"],"document_group":null,"rootDocumentGroup":[],"issue_url":"","publication_url":""},"relatedArticles":[{"title":"Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update","url":{"_type":"slug","current":"conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update"},"thumbnail":{"_type":"mainImage","alt":"MADNI/AdobeStock","caption":"MADNI/AdobeStock","asset":{"_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg","_type":"reference"}},"published":"2025-02-17T21:45:27.773Z"},{"title":"Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings","url":{"current":"long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Tasty Cat/AdobeStock","caption":"Tasty Cat/AdobeStock","asset":{"_ref":"image-10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748-jpg","_type":"reference"}},"published":"2025-02-14T15:45:38.972Z"},{"title":"Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment","url":{"_type":"slug","current":"xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment"},"thumbnail":{"_type":"mainImage","alt":"LFK/AdobeStock","caption":"LFK/AdobeStock","asset":{"_ref":"image-0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584-jpg","_type":"reference"}},"published":"2025-02-13T21:57:15.688Z"},{"title":"The Importance of Sports Psychiatry in an Athlete's Well-Being","url":{"current":"the-importance-of-sports-psychiatry-in-an-athletes-well-being","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Venusvi/AdobeStock","caption":"Venusvi/AdobeStock","asset":{"_ref":"image-bda231a36f0ee9d80203c625f705adfcebe7f717-5376x3584-jpg","_type":"reference"}},"published":"2025-02-13T21:45:58.157Z"},{"title":"Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis","url":{"current":"xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Berit Kessler/AdobeStock","caption":"Berit Kessler/AdobeStock","asset":{"_ref":"image-200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956-jpg","_type":"reference"}},"published":"2025-02-13T19:30:34.622Z"},{"title":"FDA Breakthrough Therapy Designation and the Future of MM120","url":{"_type":"slug","current":"fda-breakthrough-therapy-designation-and-the-future-of-mm120"},"thumbnail":{"_type":"mainImage","alt":"RolfImages/AdobeStock","caption":"RolfImages/AdobeStock","asset":{"_ref":"image-1c9a595620a6a6f3ac7d40400744f9429b1cdbda-3998x3000-jpg","_type":"reference"}},"published":"2025-02-12T21:45:54.521Z"}]},{"_updatedAt":"2025-02-13T18:58:06Z","summary":"Learn more about the findings from the first 3 EMERGENT trials, and their use in the 4th and 5th trials, presented at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.","drugMentions":"{\"drug_mentions\": [\"xanomeline\", \"trospium\"]}","gptSummary":"A post hoc pooled analysis of the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials revealed that xanomeline and trospium significantly enhance social functioning and life engagement in individuals with schizophrenia. Conducted over five weeks, these double-blind, placebo-controlled studies involved 640 participants with acute schizophrenia exacerbations. The treatment group showed notable improvements in PANSS-derived measures, particularly in prosocial and life engagement factors. These findings suggest xanomeline and trospium could offer a novel approach to schizophrenia management, focusing on both clinical symptoms and social reintegration.","authors":[{"displayName":"Megan McSweeney","url":"megan-mcsweeney"}],"published":"2025-02-13T19:30:34.622Z","url":"xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis","_id":"53a0a614-3ee5-452e-b9dc-bf963dbc6465","documentGroup":null,"_createdAt":"2025-02-13T18:50:26Z","ExcludeFromPubMedXML":false,"thumbnail":{"caption":"Berit Kessler/AdobeStock","asset":{"_type":"reference","_ref":"image-200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956-jpg"},"_type":"mainImage","alt":"Berit Kessler/AdobeStock"},"_rev":"sqn82GeejNhxQc9beLuuUh","title":"Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis","_type":"article","gptTakeaways":"• Xanomeline and trospium significantly improved social functioning in schizophrenia patients, with a notable reduction in prosocial factor scores compared to placebo.\n\n• The treatment also enhanced life engagement, showing significant improvements in motivation and social interaction over five weeks.\n\n• The EMERGENT trials involved 640 participants, with a double-blind, placebo-controlled design, highlighting the robustness of the findings.\n\n• These results suggest a promising new approach to schizophrenia management, addressing both clinical symptoms and social reintegration.","authorMapping":[{"lastName":"McSweeney","authorType":"author","_id":"0dd98119-9102-491d-98b5-9cd27b8be6f7","biography":[{"markDefs":[],"children":[{"marks":["strong"],"text":"Ms McSweeney","_key":"67ccf07444ee","_type":"span"},{"_type":"span","marks":[],"text":" ","_key":"3e163b408efc"},{"_type":"span","marks":["em"],"text":"is an assistant editor at ","_key":"b70df96f70e5"},{"_type":"span","marks":[],"text":"Psychiatric Times","_key":"52d2e41075d5"},{"_type":"span","marks":["em"],"text":".","_key":"85b80e6c3bc5"}],"_type":"block","style":"normal","_key":"37d6c0564341"}],"url":{"current":"megan-mcsweeney","_type":"slug"},"firstName":"Megan","displayName":"Megan McSweeney","_createdAt":"2024-11-25T16:17:55Z","_rev":"HG9itg5Um8jvM5zF8KyjU8","_type":"author","_updatedAt":"2024-11-25T16:17:55Z"}],"factCheckAuthorMapping":null,"factCheckAuthors":null,"documentGroupMapping":null,"body":[{"asset":{"_ref":"image-200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956-jpg","_type":"reference"},"disableLightBox":true,"_type":"figure","imgcaption":[{"_type":"block","style":"normal","_key":"e9b73a14e8c4","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Berit Kessler/AdobeStock","_key":"f470599d73e2"}]}],"alignment":"left","disableTextWrap":false,"_key":"6860d76512fc","widthP":50,"alt":"Berit Kessler/AdobeStock"},{"markDefs":[],"children":[{"marks":["strong"],"text":"CONFERENCE REPORTER","_key":"bae6f74bdc75","_type":"span"}],"_type":"block","style":"normal","_key":"6e1742f4053c"},{"children":[{"_type":"span","marks":[],"text":"A post hoc pooled analysis of the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials has demonstrated that xanomeline and trospium significantly improves social functioning and life engagement in individuals with schizophrenia. The findings were presented via poster session at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.","_key":"9234599ca34b"},{"_key":"db6547875e9c","_type":"span","marks":["sup"],"text":"1"}],"_type":"block","style":"normal","_key":"f0479dc5e761","markDefs":[]},{"style":"normal","_key":"8a1d922daff4","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Study Design and Participant Demographics","_key":"d296048578ba"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The first 3 EMERGENT trials were 5-week, double-blind, placebo-controlled studies enrolling 640 participants with acute schizophrenia exacerbations. Participants were randomized to receive xanomeline and trospium (314 participants) or placebo (326 participants), with dosing titrated up to 125 mg of xanomeline and 30 mg trospium 2 times daily.","_key":"827b31fce6a1"},{"_type":"span","marks":["sup"],"text":"1","_key":"1e0e6c825078"}],"_type":"block","style":"normal","_key":"f85bcfc16cf7"},{"markDefs":[],"children":[{"marks":["strong"],"text":"Significant Improvements in Social Functioning","_key":"cfb88e2761a2","_type":"span"}],"_type":"block","style":"normal","_key":"5ba820976889"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The EMERGENT trials assessed social functioning using PANSS-derived measures. After 5 weeks of treatment, xanomeline and trospium showed a significantly greater reduction in the prosocial factor, with a least squares mean change from baseline to week 5 at -5.9, compared with -3.1 in the placebo group.","_key":"989768aaa03e"},{"_type":"span","marks":["sup"],"text":"1","_key":"e11167f6c682"},{"_key":"b9f3ddf613bf","_type":"span","marks":[],"text":" This improvement was observed across 6 PANSS items: hallucinatory behavior, suspiciousness/persecution, emotional withdrawal, passive social withdrawal, stereotyped thinking, and active social avoidance."}],"_type":"block","style":"normal","_key":"84067ccce395"},{"_key":"af7d8ceb1f2f","markDefs":[],"children":[{"text":"Enhanced Life Engagement with Treatment","_key":"ba078b378825","_type":"span","marks":["strong"]}],"_type":"block","style":"normal"},{"_key":"e151b6f482c5","markDefs":[],"children":[{"marks":[],"text":"Beyond social functioning, the study evaluated life engagement, a factor encompassing motivation and social interaction. By week 5, xanomeline and trospium demonstrated significantly greater reductions in the PANSS-derived life engagement factor compared with placebo.","_key":"c8bda45d6c2b","_type":"span"},{"_type":"span","marks":["sup"],"text":"1","_key":"0b2afb3baef1"},{"_type":"span","marks":[],"text":" Dosed patients had a least square mean of -7 compared with -3.8 in the placebo group.","_key":"4c50bafc2779"},{"_type":"span","marks":["sup"],"text":"1","_key":"c6b70a878afd"},{"marks":[],"text":" Improvements were seen in 10 of 11 PANSS life engagement items, with notable changes in emotional withdrawal, depression, and disturbance of volition.","_key":"583365728339","_type":"span"}],"_type":"block","style":"normal"},{"children":[{"_key":"629f5e2a76e2","_type":"span","marks":["strong"],"text":"Future Implications for Schizophrenia Treatment"}],"_type":"block","style":"normal","_key":"6addba44be71","markDefs":[]},{"style":"normal","_key":"276ca50fb7b4","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The study findings highlight xanomeline and trospium’s potential in enhancing patient well-being through improved social and functional outcomes. The results suggest a new approach to schizophrenia management, addressing both clinical symptoms and social reintegration.","_key":"8d80ed4037fa"}],"_type":"block"},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/latest-conference","_key":"1d128b51ba88"}],"children":[{"_type":"span","marks":["em"],"text":"For complete conference coverage, click ","_key":"70647549d1e6"},{"_type":"span","marks":["1d128b51ba88","em"],"text":"here","_key":"88430df964bf"},{"_type":"span","marks":["em"],"text":".","_key":"19951130143e"}],"_type":"block","style":"normal","_key":"e5af7de215bb"},{"_type":"block","style":"normal","_key":"f8633cd5826e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"e19dbb75109f"}]},{"_key":"6e2c65e3999d","markDefs":[],"children":[{"text":"Reference","_key":"654d3dee969b","_type":"span","marks":["strong"]}],"_type":"block","style":"normal"},{"_key":"e0627ef16a2f","markDefs":[],"children":[{"_type":"span","marks":[],"text":"1. Correll C, Zitnik G, Vuocolo S, et al. Effect of xanomeline and trospium chloride on social functioning and life engagement in schizophrenia: post hoc pooled analysis from the EMERGENT trials. Presented at: Nevada Psychiatric Association 30th Annual Psychopharmacology Update; February 13, 2025.","_key":"3b349ad98fab"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"","_key":"7c9e0737c630"}],"_type":"block","style":"normal","_key":"f480052f95a4","markDefs":[]}],"contentCategory":{"_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","_updatedAt":"2020-02-25T09:35:56Z","_createdAt":"2020-02-06T09:15:47Z"},"articleType":"News","taxonomyMapping":[{"_createdAt":"2020-03-26T06:11:21Z","_updatedAt":"2023-03-31T19:23:25Z","perKeywordMapping":["Psychiatry","Neurology","New Drugs"],"_type":"taxonomy","name":"Psychopharmacology","identifier":"topics/psychopharmacology","cmeType":"per","_id":"pst_taxonomy_336_psychopharmacology","pixelTrackingCode":null,"parent":{"_rev":"uvXJooXtzvjNOyx50HTt8m","_updatedAt":"2023-03-31T19:15:59Z","identifier":"topics","_createdAt":"2020-03-26T06:11:21Z","parent":null,"_type":"taxonomy","name":"Topics","_id":"pst_taxonomy_53202_clinical","isMainTopic":true},"_rev":"4roekEga8ZReQAdH6zkAp9"},{"_updatedAt":"2020-09-11T15:24:41Z","_createdAt":"2020-03-26T06:11:21Z","_rev":"A1SshklVZqV0BxeqIqEcIX","_type":"taxonomy","_id":"pst_taxonomy_439_conferences","parent":null,"identifier":"conferences","name":"Conferences","pixelTrackingCode":null}],"audioUrl":"https://s3.us-east-1.amazonaws.com/ai-generated-audios/www.psychiatrictimes.com/53a0a614-3ee5-452e-b9dc-bf963dbc6465_1739473083215.02121385-1ba7-42d9-bf84-3108f3a9aa27.mp3","is_visible":true,"targeting":{"content_placement":["topics/psychopharmacology","conferences"],"document_url":["xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis"],"document_group":null,"rootDocumentGroup":[],"issue_url":"","publication_url":""},"relatedArticles":[{"title":"Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update","url":{"_type":"slug","current":"conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update"},"thumbnail":{"_type":"mainImage","alt":"MADNI/AdobeStock","caption":"MADNI/AdobeStock","asset":{"_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg","_type":"reference"}},"published":"2025-02-17T21:45:27.773Z"},{"title":"Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings","url":{"current":"long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Tasty Cat/AdobeStock","caption":"Tasty Cat/AdobeStock","asset":{"_ref":"image-10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748-jpg","_type":"reference"}},"published":"2025-02-14T15:45:38.972Z"},{"title":"Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment","url":{"_type":"slug","current":"xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment"},"thumbnail":{"_type":"mainImage","alt":"LFK/AdobeStock","caption":"LFK/AdobeStock","asset":{"_ref":"image-0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584-jpg","_type":"reference"}},"published":"2025-02-13T21:57:15.688Z"},{"title":"The Importance of Sports Psychiatry in an Athlete's Well-Being","url":{"current":"the-importance-of-sports-psychiatry-in-an-athletes-well-being","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Venusvi/AdobeStock","caption":"Venusvi/AdobeStock","asset":{"_ref":"image-bda231a36f0ee9d80203c625f705adfcebe7f717-5376x3584-jpg","_type":"reference"}},"published":"2025-02-13T21:45:58.157Z"},{"title":"Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis","url":{"current":"xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Berit Kessler/AdobeStock","caption":"Berit Kessler/AdobeStock","asset":{"_ref":"image-200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956-jpg","_type":"reference"}},"published":"2025-02-13T19:30:34.622Z"},{"title":"FDA Breakthrough Therapy Designation and the Future of MM120","url":{"_type":"slug","current":"fda-breakthrough-therapy-designation-and-the-future-of-mm120"},"thumbnail":{"_type":"mainImage","alt":"RolfImages/AdobeStock","caption":"RolfImages/AdobeStock","asset":{"_ref":"image-1c9a595620a6a6f3ac7d40400744f9429b1cdbda-3998x3000-jpg","_type":"reference"}},"published":"2025-02-12T21:45:54.521Z"}]},{"is_visible":true,"_rev":"a16d4PP1Zddk6u8Hni7Nc6","title":"AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment","_updatedAt":"2025-02-12T18:25:21Z","taxonomyMapping":[{"_type":"taxonomy","_createdAt":"2020-03-26T06:11:21Z","parent":null,"pixelTrackingCode":null,"_rev":"A1SshklVZqV0BxeqIqEcIX","name":"Conferences","_id":"pst_taxonomy_439_conferences","_updatedAt":"2020-09-11T15:24:41Z","identifier":"conferences"},{"perKeywordMapping":["Psychiatry","Neurology"],"_updatedAt":"2024-02-29T16:00:14Z","_createdAt":"2020-03-26T06:11:21Z","_rev":"r4Rkjy04WvWq5fuPdnwLCI","name":"Major Depressive Disorder","_id":"pst_taxonomy_238_majordepressivedisorder","_type":"taxonomy","pixelTrackingCode":null,"identifier":"topics/major-depressive-disorder","parent":{"identifier":"topics","isMainTopic":true,"_rev":"uvXJooXtzvjNOyx50HTt8m","_type":"taxonomy","_id":"pst_taxonomy_53202_clinical","parent":null,"_createdAt":"2020-03-26T06:11:21Z","name":"Topics","_updatedAt":"2023-03-31T19:15:59Z"},"cmeType":"per"}],"_createdAt":"2025-02-12T14:21:19Z","documentGroupMapping":null,"factCheckAuthorMapping":null,"summary":"A pooled analysis of two clinical trials highlights AXS-05’s rapid and sustained effectiveness in reducing depressive symptoms, offering a promising new treatment option for major depressive disorder with a manageable safety profile.","published":"2025-02-12T15:30:27.309Z","url":"axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment","authorMapping":[{"lastName":"McSweeney","authorType":"author","_id":"0dd98119-9102-491d-98b5-9cd27b8be6f7","biography":[{"style":"normal","_key":"37d6c0564341","markDefs":[],"children":[{"marks":["strong"],"text":"Ms McSweeney","_key":"67ccf07444ee","_type":"span"},{"_type":"span","marks":[],"text":" ","_key":"3e163b408efc"},{"_type":"span","marks":["em"],"text":"is an assistant editor at ","_key":"b70df96f70e5"},{"_type":"span","marks":[],"text":"Psychiatric Times","_key":"52d2e41075d5"},{"_type":"span","marks":["em"],"text":".","_key":"85b80e6c3bc5"}],"_type":"block"}],"url":{"current":"megan-mcsweeney","_type":"slug"},"firstName":"Megan","displayName":"Megan McSweeney","_createdAt":"2024-11-25T16:17:55Z","_rev":"HG9itg5Um8jvM5zF8KyjU8","_type":"author","_updatedAt":"2024-11-25T16:17:55Z"}],"drugMentions":"{\"drug_mentions\": [\"AXS-05\", \"dextromethorphan\", \"bupropion\", \"Auvelity\"]}","_id":"b9fe7ac6-d513-4e94-827e-dba2ea50536f","gptSummary":"AXS-05, a novel treatment for major depressive disorder (MDD), combines dextromethorphan and bupropion, showing rapid efficacy in reducing depressive symptoms within the first week. The pooled analysis from two clinical trials, GEMINI and ASCEND, demonstrated significant symptom improvement across diverse patient demographics, with a greater reduction in Montgomery-Åsberg Depression Rating Scale scores compared to placebo or bupropion. AXS-05 maintained a manageable safety profile, with common adverse events resolving quickly and a low discontinuation rate due to side effects, indicating its potential as a new treatment option for MDD.","factCheckAuthors":null,"documentGroup":null,"body":[{"imgcaption":[{"_type":"block","style":"normal","_key":"522961e84379","markDefs":[],"children":[{"marks":[],"text":"Sebastien Montier/AdobeStock","_key":"b70ae44d765b","_type":"span"}]}],"asset":{"_ref":"image-23b63d5745365091b73bc1cfc08e2d806bfd17e3-5824x3264-jpg","_type":"reference"},"disableTextWrap":false,"alt":"Sebastien Montier/AdobeStock","alignment":"left","_type":"figure","_key":"f5720ed93aec","widthP":50,"disableLightBox":true},{"children":[{"_type":"span","marks":["strong"],"text":"CONFERENCE REPORTER","_key":"be7417cb1aa8"}],"_type":"block","style":"normal","_key":"6f9db7474a30","markDefs":[]},{"markDefs":[],"children":[{"marks":[],"text":"A pooled analysis of 2 clinical trials evaluating AXS-05, an investigational treatment for major depressive disorder (MDD), shows that the drug is effective in reducing depressive symptoms while maintaining a manageable safety profile. The findings, presented at the Nevada Psychiatric Association’s 30th Annual National Psychopharmacology Update, highlight AXS-05’s potential as a new treatment option for patients struggling with MDD.","_key":"99d74261ab82","_type":"span"},{"_type":"span","marks":["sup"],"text":"1","_key":"e021a8a25572"}],"_type":"block","style":"normal","_key":"85e866d0cd15"},{"_key":"695f00c9f60e","markDefs":[],"children":[{"text":"AXS-05: A Novel Approach to Depression Treatment","_key":"9b5868763c4a","_type":"span","marks":["strong"]}],"_type":"block","style":"normal"},{"style":"normal","_key":"01f2332302ca","markDefs":[],"children":[{"marks":[],"text":"AXS-05 is a combination of dextromethorphan and bupropion, acting as an ","_key":"69a0991b104c","_type":"span"},{"_type":"span","marks":["em"],"text":"N","_key":"15c80f0fd00c"},{"_type":"span","marks":[],"text":"-methyl-","_key":"ba7979b47007"},{"_key":"77f4d8d304df","_type":"span","marks":["sub"],"text":"D"},{"_key":"a3f615a5d5c6","_type":"span","marks":[],"text":"-aspartate receptor antagonist, sigma-1 receptor agonist, and aminoketone CYP2D6 inhibitor."},{"_type":"span","marks":["sup"],"text":"1 ","_key":"bef7490d00c3"},{"_type":"span","marks":[],"text":"Unlike many antidepressants that may take weeks to show benefit, AXS-05 was effective in reducing depression symptoms within the first week.","_key":"63baad0f4351"}],"_type":"block"},{"_type":"block","style":"normal","_key":"4880d0a6c5ad","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Effective Symptom Reduction Across Diverse Patient Groups","_key":"e3c4122d02cd"}]},{"children":[{"_type":"span","marks":[],"text":"AXS-05 demonstrated significant improvement in depressive symptoms across different demographic groups, including sex, race, and prior antidepressant therapy history.","_key":"f8e576c3b2ea"},{"_type":"span","marks":["sup"],"text":"1","_key":"8e4f6a1371f9"},{"_key":"c4f429e16e70","_type":"span","marks":[],"text":" The study pooled data from 2 6-week, double-blind, randomized controlled trials (GEMINI and ASCEND), in which 327 patients with moderate to severe MDD were enrolled."}],"_type":"block","style":"normal","_key":"21adb8cf690b","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"The primary efficacy measure was the Montgomery-Åsberg Depression Rating Scale (MADRS) total score, which showed a greater reduction in symptoms among AXS-05-treated patients compared with placebo or bupropion. Symptom relief was evident as early as week 1, and superiority over the control group was maintained through week 6.","_key":"3ba795c284b4"},{"_type":"span","marks":["sup"],"text":"1","_key":"eb63bc522440"}],"_type":"block","style":"normal","_key":"31a3c01d0bbc","markDefs":[]},{"_type":"block","style":"normal","_key":"f037ec4f25b0","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Manageable Adverse Effects with Early Onset and Resolution","_key":"17d30dbb34bc"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The most common treatment-emergent adverse events associated with AXS-05 were dizziness (17.1%), nausea (13.8%), and headache (8.1%).","_key":"c42ee178cda1"},{"_type":"span","marks":["sup"],"text":"1","_key":"72e1cdb0ac2d"},{"_type":"span","marks":[],"text":" Most treatment-emergent adverse events appeared within the first week of treatment and resolved within 2.5 to 16 days. The study found that only 7.6% of patients discontinued treatment due to adverse effects, indicating that AXS-05 was generally well tolerated.","_key":"7b59d7dd0a63"},{"marks":["sup"],"text":"1","_key":"3976b0f5e4f0","_type":"span"}],"_type":"block","style":"normal","_key":"af98abc60e68"},{"_key":"33d8a469be18","markDefs":[],"children":[{"text":"Other less common adverse effects included dry mouth (6.7%), somnolence (5.7%), anxiety (5.7%), and decreased appetite (5.2%). Sexual dysfunction was reported in 5.2% of participants, but its onset was later than other adverse effects.","_key":"e95cfc6ab18f","_type":"span","marks":[]},{"marks":["sup"],"text":"1","_key":"cfd738c947c9","_type":"span"},{"_key":"dd4b5b49a8af","_type":"span","marks":[],"text":" Serious or severe adverse events were rare, with a total of 5."}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"ec3a5542da3e","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Study Findings","_key":"a4e23792e04b"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The study demonstrated AXS-05 was effective in reducing depressive symptoms while maintaining a manageable safety profile. MADRS scores reduced consistently over 6 weeks and showed an improvement in score after week 1. This remained true across all demographics given AXS-05.","_key":"ab14ee6f354f"}],"_type":"block","style":"normal","_key":"cfb56827cb24"},{"_key":"028e99093174","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"54a2ef430cb7"}],"_type":"block","style":"normal"},{"_key":"be0d45337f17","markDefs":[{"blank":true,"_type":"link","href":"https://www.psychiatrictimes.com/latest-conference","_key":"7444cc385d78"}],"children":[{"text":"For complete conference coverage, click ","_key":"b29e32a8fc5c","_type":"span","marks":["em"]},{"_type":"span","marks":["em","7444cc385d78"],"text":"here","_key":"dae4dc750651"},{"_type":"span","marks":["em"],"text":".","_key":"33c5c1124484"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"dab261079582","_type":"span"}],"_type":"block","style":"normal","_key":"364e57b97ba4"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Reference","_key":"f78e699bcfff"}],"_type":"block","style":"normal","_key":"7269690e5163"},{"markDefs":[],"children":[{"_key":"6cc6b9b38033","_type":"span","marks":[],"text":"1. Chepke C, Iosifescu D, Eglit GML, et al. AXS-05 (Auvelity®) in major depressive disorder: pooled data from two six-week controlled trials (GEMINI and ASCEND). Presented at: Nevada Psychiatric Association 30"},{"marks":["sup"],"text":"th","_key":"852a0534d6ed","_type":"span"},{"marks":[],"text":" Annual Psychopharmacology Update; February 13, 2025.","_key":"935431ea72dd","_type":"span"}],"_type":"block","style":"normal","_key":"cf2bc0705d23"}],"audioUrl":"https://s3.us-east-1.amazonaws.com/ai-generated-audios/www.psychiatrictimes.com/b9fe7ac6-d513-4e94-827e-dba2ea50536f_1739370595115.e3dd0063-d360-4f9c-9336-100127ffb31c.mp3","thumbnail":{"_type":"mainImage","alt":"Sebastien Montier/AdobeStock","caption":"Sebastien Montier/AdobeStock","asset":{"_ref":"image-23b63d5745365091b73bc1cfc08e2d806bfd17e3-5824x3264-jpg","_type":"reference"}},"authors":[{"displayName":"Megan McSweeney","url":"megan-mcsweeney"}],"_type":"article","gptTakeaways":"• AXS-05, combining dextromethorphan and bupropion, acts as an NMDA receptor antagonist and sigma-1 receptor agonist.\n\n• Rapid symptom reduction was observed within the first week, with sustained efficacy over six weeks.\n\n• Significant improvement in depressive symptoms was consistent across diverse demographic groups.\n\n• Common adverse events included dizziness, nausea, and headache, resolving within 2.5 to 16 days.\n\n• AXS-05 was generally well tolerated, with a low discontinuation rate due to adverse effects.","ExcludeFromPubMedXML":false,"articleType":"News","contentCategory":{"_updatedAt":"2020-02-25T09:35:56Z","_createdAt":"2020-02-06T09:15:47Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb"},"targeting":{"content_placement":["conferences","topics/major-depressive-disorder"],"document_url":["axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment"],"document_group":null,"rootDocumentGroup":[],"issue_url":"","publication_url":""},"relatedArticles":[{"title":"Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update","url":{"current":"conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"MADNI/AdobeStock","caption":"MADNI/AdobeStock","asset":{"_type":"reference","_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg"}},"published":"2025-02-17T21:45:27.773Z"},{"title":"Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings","url":{"current":"long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Tasty Cat/AdobeStock","caption":"Tasty Cat/AdobeStock","asset":{"_ref":"image-10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748-jpg","_type":"reference"}},"published":"2025-02-14T15:45:38.972Z"},{"title":"Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment","url":{"current":"xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment","_type":"slug"},"thumbnail":{"asset":{"_ref":"image-0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584-jpg","_type":"reference"},"_type":"mainImage","alt":"LFK/AdobeStock","caption":"LFK/AdobeStock"},"published":"2025-02-13T21:57:15.688Z"},{"title":"Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis","url":{"current":"xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Berit Kessler/AdobeStock","caption":"Berit Kessler/AdobeStock","asset":{"_ref":"image-200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956-jpg","_type":"reference"}},"published":"2025-02-13T19:30:34.622Z"},{"title":"AXS-05 Demonstrates Efficacy and Manageable Adverse Effects in Major Depressive Disorder Treatment","url":{"current":"axs-05-demonstrates-efficacy-and-manageable-adverse-effects-in-major-depressive-disorder-treatment","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"Sebastien Montier/AdobeStock","caption":"Sebastien Montier/AdobeStock","asset":{"_ref":"image-23b63d5745365091b73bc1cfc08e2d806bfd17e3-5824x3264-jpg","_type":"reference"}},"published":"2025-02-12T15:30:27.309Z"},{"title":"SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms","url":{"current":"spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms","_type":"slug"},"thumbnail":{"alt":"Yuparet/AdobeStock","caption":"Yuparet/AdobeStock","asset":{"_ref":"image-ab7da8966014ad1be562e621a9f5b7a2397b9d28-5824x3264-jpg","_type":"reference"},"_type":"mainImage"},"published":"2025-02-12T14:30:50.177Z"}]},{"articleType":"News","documentGroupMapping":[{"_rev":"wprjukSzaYWKhfPX4FSqef","name":"Conferences","_id":"pst_documentGroup_53201_conferences","_updatedAt":"2021-10-07T14:43:42Z","_type":"documentGroup","identifier":{"_type":"slug","current":"conferences"},"_createdAt":"2020-03-26T06:12:02Z","parent":null,"pixelTrackingCode":null}],"audioUrl":"https://s3.us-east-1.amazonaws.com/ai-generated-audios/www.psychiatrictimes.com/143be4a0-11f7-465a-aab6-52eef0aafb3f_1739369226754.42697ef7-e5fa-42da-a4a0-dd36c46be7e6.mp3","summary":"A new phase 2 trial reveals a novel antidepressant delivers rapid symptom relief for major depressive disorder, with patients experiencing significant improvement within just hours of their first dose.","documentGroup":null,"published":"2025-02-12T14:30:50.177Z","body":[{"_key":"4f324b740360","disableTextWrap":false,"asset":{"_ref":"image-ab7da8966014ad1be562e621a9f5b7a2397b9d28-5824x3264-jpg","_type":"reference"},"widthP":50,"disableLightBox":true,"imgcaption":[{"_type":"block","style":"normal","_key":"d5d61780be8c","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Yuparet/AdobeStock","_key":"7e8a755f127c"}]}],"_type":"figure","alignment":"left","alt":"Yuparet/AdobeStock"},{"_type":"block","style":"normal","_key":"98b5f205f0c5","markDefs":[],"children":[{"marks":["strong"],"text":"CONFERENCE REPORTER","_key":"6eac6ae47114","_type":"span"}]},{"children":[{"text":"A new phase 2, open-label clinical trial has demonstrated that SPN-820, a novel antidepressant, provides rapid and substantial improvement in adults with major depressive disorder (MDD).","_key":"bdae7aacba2b","_type":"span","marks":[]},{"text":"1","_key":"be92106c7c17","_type":"span","marks":["sup"]},{"marks":[],"text":" Patients taking SPN-820 alongside their existing antidepressant medication showed significant symptom relief within hours of administration, with continued progress over the study period. SPN-820 is an oral formulation of NV-5138 with a novel mechanism of action. The new information was presented via poster session at the 30th Annual Nevada Psychiatric Association National Psychopharmacology Update.","_key":"aa1a91a4990d","_type":"span"},{"_type":"span","marks":["sup"],"text":"1","_key":"8db05b12d2f3"}],"_type":"block","style":"normal","_key":"c04caab05bdf","markDefs":[]},{"style":"normal","_key":"a3eb5b12e15a","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Study Design and Patient Response","_key":"a6a034d922cf"}],"_type":"block"},{"markDefs":[],"children":[{"marks":[],"text":"This 10-day phase 2 study evaluated SPN-820 as an adjunct treatment for MDD in patients who had not achieved full symptom relief from conventional antidepressants. The trial included 40 participants aged 18 to 65 with moderate to severe MDD symptoms.","_key":"2d98511265b6","_type":"span"}],"_type":"block","style":"normal","_key":"e988afa7445e"},{"_type":"block","style":"normal","_key":"c705f20f50e1","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Patients received 2400 mg of SPN-820 every 3 days, administered orally. The study’s primary efficacy measures were the HAM-D6 and MADRS score changes, while safety outcomes included adverse events, vital sign monitoring, and assessments for dissociative symptoms, hallucinations, and suicidality.","_key":"05c9f804bf0d"}]},{"_key":"5a1038e0995b","markDefs":[],"children":[{"_key":"2baa8549aa5d","_type":"span","marks":[],"text":"By day 10, more than half of the participants achieved symptom remission, a result that suggests SPN-820 could be an effective alternative for patients who do not fully respond to traditional antidepressants."}],"_type":"block","style":"normal"},{"_key":"37c50ef84133","markDefs":[],"children":[{"text":"Rapid Reduction in Depression Symptoms","_key":"75e787988b90","_type":"span","marks":["strong"]}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"5f93969e5e98","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Preclinical research shows SPN-820 increases neuroplasticity by acting intracellularly to enhance activity of Mechanistic Target of Rapamycin Complex 1.","_key":"4b684b24649a"},{"_key":"7087e6962db5","_type":"span","marks":["sup"],"text":"1 "},{"_key":"22848c65176b","_type":"span","marks":[],"text":"The study results show that SPN-820 produced meaningful symptom relief within just 4 hours of the first dose. Patients experienced an average 50% reduction in Montgomery–Åsberg Depression Rating Scale (MADRS) scores. By day 10, 84.2% of participants met the MADRS response criteria, and 63.2% achieved remission, demonstrating the potential long-term benefits of this novel treatment."},{"_type":"span","marks":["sup"],"text":"1","_key":"4cd089ecd861"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Additionally, the Hamilton Depression Rating Scale (HAM-D6) scores showed significant improvement early in treatment, reinforcing SPN-820’s rapid-acting antidepressant properties.","_key":"84bc745537f8"}],"_type":"block","style":"normal","_key":"277f06179721"},{"children":[{"marks":[],"text":"","_key":"c59aa4d08669","_type":"span"}],"_type":"block","style":"normal","_key":"4dacd45d9d94","markDefs":[]},{"style":"normal","_key":"774860c14cf8","markDefs":[],"children":[{"text":"Safety and Tolerability Profile","_key":"ae334d203132","_type":"span","marks":["strong"]}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"SPN-820 was well tolerated, with no serious adverse events reported. Only 1 patient discontinued treatment due to worsening hypertension, which was deemed unrelated to the study drug.","_key":"a16856621117"}],"_type":"block","style":"normal","_key":"6c1fb8177d8d","markDefs":[]},{"style":"normal","_key":"9749d8cdb52a","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Common mild-to-moderate adverse events included headache, nausea, somnolence, dizziness, and fatigue, occurring in a minority of participants. Notably, there were no reports of dissociative effects, hallucinations, or psychosis, side effects commonly associated with other rapid-acting antidepressants such as ketamine-derived treatments.","_key":"7b42de612e17"}],"_type":"block"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Suicidal ideation among participants also decreased significantly during the trial, further highlighting the potential mental health benefits of SPN-820.","_key":"65197617bce8"}],"_type":"block","style":"normal","_key":"bc10e8a192ac"},{"_type":"block","style":"normal","_key":"d7c38229fe87","markDefs":[{"_type":"link","href":"https://www.psychiatrictimes.com/latest-conference","_key":"dfc86a0e7bf4","blank":true}],"children":[{"_type":"span","marks":["em"],"text":"For complete conference coverage, click ","_key":"a336a66da566"},{"_key":"0d2eeb4b7992","_type":"span","marks":["em","dfc86a0e7bf4"],"text":"here"},{"_type":"span","marks":["em"],"text":".","_key":"9f52061ee389"}]},{"children":[{"_type":"span","marks":[],"text":"","_key":"af13f9b6c79a"}],"_type":"block","style":"normal","_key":"615eda99e3d1","markDefs":[]},{"markDefs":[],"children":[{"marks":["strong"],"text":"Reference","_key":"ee0a09493400","_type":"span"}],"_type":"block","style":"normal","_key":"3d40c08926e6"},{"_key":"62a6ffc15c36","markDefs":[],"children":[{"_type":"span","marks":[],"text":"1. Ceresoli-Borroni G, Targum SD, Alleyne N, et al. Efficacy and safety of SPN-820 for adults with major depressive disorder: Primary results from a phase 2, open-label trial. Presented at: Nevada Psychiatric Association 30","_key":"b6da85e3fa85"},{"_type":"span","marks":["sup"],"text":"th","_key":"b3511e321ed6"},{"_key":"0db62850b853","_type":"span","marks":[],"text":" Annual Psychopharmacology Update; February 13, 2025."}],"_type":"block","style":"normal"}],"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","_updatedAt":"2020-02-25T09:35:56Z","_createdAt":"2020-02-06T09:15:47Z","_rev":"snQqhhB4O8T5bi1viURsgs"},"gptSummary":"A phase 2 clinical trial has shown that SPN-820, a novel antidepressant, offers rapid and significant improvement in major depressive disorder (MDD) symptoms. Administered alongside existing antidepressants, SPN-820 provided symptom relief within hours, with continued progress over 10 days. The trial involved 40 participants with moderate to severe MDD, showing a 50% reduction in MADRS scores and 63.2% achieving remission. SPN-820 was well tolerated, with no serious adverse events, and reduced suicidal ideation. This suggests SPN-820 as a promising alternative for treatment-resistant MDD.","gptTakeaways":"• SPN-820 demonstrated rapid and substantial symptom relief in MDD patients, with effects seen within hours and sustained over 10 days.\n\n• The trial showed a 50% reduction in MADRS scores, with 63.2% of participants achieving remission by day 10.\n\n• SPN-820 was well tolerated, with no serious adverse events and a favorable safety profile compared to other rapid-acting antidepressants.\n\n• The novel mechanism of SPN-820 enhances neuroplasticity, potentially offering long-term benefits for treatment-resistant MDD.","title":"SPN-820 Shows Rapid and Significant Improvement in Major Depressive Disorder Symptoms","authors":[{"displayName":"Megan McSweeney","url":"megan-mcsweeney"}],"factCheckAuthorMapping":null,"_type":"article","url":"spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms","thumbnail":{"_type":"mainImage","alt":"Yuparet/AdobeStock","caption":"Yuparet/AdobeStock","asset":{"_ref":"image-ab7da8966014ad1be562e621a9f5b7a2397b9d28-5824x3264-jpg","_type":"reference"}},"is_visible":true,"_updatedAt":"2025-02-12T18:25:50Z","authorMapping":[{"_updatedAt":"2024-11-25T16:17:55Z","firstName":"Megan","displayName":"Megan McSweeney","_createdAt":"2024-11-25T16:17:55Z","_rev":"HG9itg5Um8jvM5zF8KyjU8","_type":"author","lastName":"McSweeney","authorType":"author","_id":"0dd98119-9102-491d-98b5-9cd27b8be6f7","biography":[{"style":"normal","_key":"37d6c0564341","markDefs":[],"children":[{"marks":["strong"],"text":"Ms McSweeney","_key":"67ccf07444ee","_type":"span"},{"_type":"span","marks":[],"text":" ","_key":"3e163b408efc"},{"_type":"span","marks":["em"],"text":"is an assistant editor at ","_key":"b70df96f70e5"},{"_type":"span","marks":[],"text":"Psychiatric Times","_key":"52d2e41075d5"},{"_type":"span","marks":["em"],"text":".","_key":"85b80e6c3bc5"}],"_type":"block"}],"url":{"current":"megan-mcsweeney","_type":"slug"}}],"drugMentions":"{\"drug_mentions\": [\"SPN-820\", \"NV-5138\", \"ketamine\"]}","_createdAt":"2025-02-12T13:58:45Z","_rev":"a16d4PP1Zddk6u8Hni7UhL","_id":"143be4a0-11f7-465a-aab6-52eef0aafb3f","taxonomyMapping":[{"pixelTrackingCode":null,"_createdAt":"2020-03-26T06:11:21Z","_rev":"r4Rkjy04WvWq5fuPdnwLCI","perKeywordMapping":["Psychiatry","Neurology"],"_id":"pst_taxonomy_238_majordepressivedisorder","_updatedAt":"2024-02-29T16:00:14Z","identifier":"topics/major-depressive-disorder","_type":"taxonomy","parent":{"_rev":"uvXJooXtzvjNOyx50HTt8m","_type":"taxonomy","_id":"pst_taxonomy_53202_clinical","identifier":"topics","isMainTopic":true,"name":"Topics","_updatedAt":"2023-03-31T19:15:59Z","_createdAt":"2020-03-26T06:11:21Z","parent":null},"cmeType":"per","name":"Major Depressive Disorder"},{"_createdAt":"2020-03-26T06:11:21Z","_id":"pst_taxonomy_336_psychopharmacology","cmeType":"per","pixelTrackingCode":null,"_type":"taxonomy","perKeywordMapping":["Psychiatry","Neurology","New Drugs"],"parent":{"_createdAt":"2020-03-26T06:11:21Z","_type":"taxonomy","name":"Topics","_id":"pst_taxonomy_53202_clinical","_updatedAt":"2023-03-31T19:15:59Z","identifier":"topics","isMainTopic":true,"parent":null,"_rev":"uvXJooXtzvjNOyx50HTt8m"},"_updatedAt":"2023-03-31T19:23:25Z","identifier":"topics/psychopharmacology","_rev":"4roekEga8ZReQAdH6zkAp9","name":"Psychopharmacology"},{"_id":"pst_taxonomy_439_conferences","identifier":"conferences","_rev":"A1SshklVZqV0BxeqIqEcIX","_type":"taxonomy","parent":null,"name":"Conferences","_updatedAt":"2020-09-11T15:24:41Z","_createdAt":"2020-03-26T06:11:21Z","pixelTrackingCode":null}],"factCheckAuthors":null,"ExcludeFromPubMedXML":false,"targeting":{"content_placement":["topics/major-depressive-disorder","topics/psychopharmacology","conferences"],"document_url":["spn-820-shows-rapid-and-significant-improvement-in-major-depressive-disorder-symptoms"],"document_group":null,"rootDocumentGroup":[],"issue_url":"","publication_url":""},"relatedArticles":[{"title":"Conference Recap: 30th Annual Nevada Psychiatric Association National Psychopharmacology Update","url":{"current":"conference-recap-30th-annual-nevada-psychiatric-association-national-psychopharmacology-update","_type":"slug"},"thumbnail":{"asset":{"_ref":"image-d96ac7d10334dfdc16e1b4c5e8dc9b56c8dbab08-6144x3072-jpg","_type":"reference"},"_type":"mainImage","alt":"MADNI/AdobeStock","caption":"MADNI/AdobeStock"},"published":"2025-02-17T21:45:27.773Z"},{"title":"Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings","url":{"current":"long-term-efficacy-and-safety-of-xanomeline-and-trospium-in-schizophrenia-emergent-5-trial-findings","_type":"slug"},"thumbnail":{"asset":{"_ref":"image-10dc2b18d26be8aebd7afbd522c57e9de56e3eeb-4158x2748-jpg","_type":"reference"},"_type":"mainImage","alt":"Tasty Cat/AdobeStock","caption":"Tasty Cat/AdobeStock"},"published":"2025-02-14T15:45:38.972Z"},{"title":"Xanomeline and Trospium Show Long-Term Efficacy and Safety in Schizophrenia Treatment","url":{"current":"xanomeline-and-trospium-show-long-term-efficacy-and-safety-in-schizophrenia-treatment","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"LFK/AdobeStock","caption":"LFK/AdobeStock","asset":{"_ref":"image-0a9ef5105fc74db5697b1fa463322248ba615dc9-5376x3584-jpg","_type":"reference"}},"published":"2025-02-13T21:57:15.688Z"},{"title":"The Importance of Sports Psychiatry in an Athlete's Well-Being","url":{"_type":"slug","current":"the-importance-of-sports-psychiatry-in-an-athletes-well-being"},"thumbnail":{"_type":"mainImage","alt":"Venusvi/AdobeStock","caption":"Venusvi/AdobeStock","asset":{"_ref":"image-bda231a36f0ee9d80203c625f705adfcebe7f717-5376x3584-jpg","_type":"reference"}},"published":"2025-02-13T21:45:58.157Z"},{"title":"Xanomeline and Trospium Improves Social Functioning and Life Engagement in Schizophrenia: EMERGENT Trials Analysis","url":{"current":"xanomeline-and-trospium-improves-social-functioning-and-life-engagement-in-schizophrenia-emergent-trials-analysis","_type":"slug"},"thumbnail":{"asset":{"_ref":"image-200884f3861b9a5997942bff0db4dd3e19fa1c49-6291x3956-jpg","_type":"reference"},"_type":"mainImage","alt":"Berit Kessler/AdobeStock","caption":"Berit Kessler/AdobeStock"},"published":"2025-02-13T19:30:34.622Z"},{"title":"FDA Breakthrough Therapy Designation and the Future of MM120","url":{"current":"fda-breakthrough-therapy-designation-and-the-future-of-mm120","_type":"slug"},"thumbnail":{"_type":"mainImage","alt":"RolfImages/AdobeStock","caption":"RolfImages/AdobeStock","asset":{"_ref":"image-1c9a595620a6a6f3ac7d40400744f9429b1cdbda-3998x3000-jpg","_type":"reference"}},"published":"2025-02-12T21:45:54.521Z"}]}],"relatedVideos":[{"thumbnail":{"asset":{"_ref":"image-ad60c6a7f35f5eb08bccf5e65acba3191272fade-6720x4375-jpg","_type":"reference"},"_type":"mainImage","alt":"tardive dyskinesia","caption":"GoodIdeas/AdobeStock"},"contentCategory":{"_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Videos","_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z"},"factCheckAuthors":null,"factCheckAuthorMapping":null,"url":"examples-of-quality-of-life-improvement-for-patients-with-tardive-dyskinesia","published":"2025-01-23T16:00:00.000Z","_id":"b26e41be-4bf7-4a99-ad64-55e840da0a7d","title":"Examples of Quality of Life Improvement for Patients With Tardive Dyskinesia","summary":"Check out 2 high-level examples of patient quality of life improvement following treatment for tardive dyskinesia. ","authorMapping":[{"firstName":"Erin","displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","_rev":"w14ZFqLK3vmAl22uSW8PAZ","_type":"author","_id":"2270b229-89a6-41ec-bc1d-24c4f25de7bd","biography":[{"_key":"fc856dc557ca","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ms Crown","_key":"08477e92955d0"},{"_type":"span","marks":[],"text":" ","_key":"0d2add315389"},{"_type":"span","marks":["em"],"text":"is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials. ","_key":"910c2addcd00"}],"_type":"block","style":"normal"}],"_updatedAt":"2025-01-20T19:12:03Z","url":{"current":"erin-crown-mhs-pa-c","_type":"slug"},"lastName":"Crown","authorType":"author","_createdAt":"2023-11-13T16:47:10Z"}],"authors":[{"displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","url":"erin-crown-mhs-pa-c"}]},{"factCheckAuthorMapping":null,"published":"2025-01-22T18:00:34.466Z","_id":"f68fd66d-1108-4cdd-917e-a5240fa9ee96","authorMapping":[{"_createdAt":"2023-11-13T16:47:10Z","_type":"author","_id":"2270b229-89a6-41ec-bc1d-24c4f25de7bd","biography":[{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ms Crown","_key":"08477e92955d0"},{"_type":"span","marks":[],"text":" ","_key":"0d2add315389"},{"_type":"span","marks":["em"],"text":"is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials. ","_key":"910c2addcd00"}],"_type":"block","style":"normal","_key":"fc856dc557ca"}],"_updatedAt":"2025-01-20T19:12:03Z","url":{"current":"erin-crown-mhs-pa-c","_type":"slug"},"lastName":"Crown","authorType":"author","_rev":"w14ZFqLK3vmAl22uSW8PAZ","firstName":"Erin","displayName":"Erin Crown, MHS, PA-C, Psych-CAQ"}],"contentCategory":{"_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Videos","_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z","_createdAt":"2020-02-10T10:49:36Z"},"authors":[{"displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","url":"erin-crown-mhs-pa-c"}],"factCheckAuthors":null,"url":"designing-an-effective-treatment-strategy-for-tardive-dyskinesia","title":"Designing an Effective Treatment Strategy for Tardive Dyskinesia","summary":"What are the signs of increased struggle with tardive dyskinesia? Here's what Erin Crown, MHS, PA-C, Psych-CAQ, picks up on during patient visits. ","thumbnail":{"alt":"tardive dyskinesia","caption":"Uladzislau/AdobeStock","asset":{"_type":"reference","_ref":"image-647c4feb1336c4441a62c8168309482962a587f5-5944x3871-jpg"},"_type":"mainImage"}},{"contentCategory":{"_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z","_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Videos"},"authorMapping":[{"firstName":"Erin","displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","_rev":"w14ZFqLK3vmAl22uSW8PAZ","_updatedAt":"2025-01-20T19:12:03Z","url":{"current":"erin-crown-mhs-pa-c","_type":"slug"},"lastName":"Crown","authorType":"author","_createdAt":"2023-11-13T16:47:10Z","_type":"author","_id":"2270b229-89a6-41ec-bc1d-24c4f25de7bd","biography":[{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ms Crown","_key":"08477e92955d0"},{"_type":"span","marks":[],"text":" ","_key":"0d2add315389"},{"_type":"span","marks":["em"],"text":"is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials. ","_key":"910c2addcd00"}],"_type":"block","style":"normal","_key":"fc856dc557ca"}]}],"factCheckAuthorMapping":null,"url":"teasing-out-tardive-dyskinesia","factCheckAuthors":null,"published":"2025-01-22T16:30:00.060Z","_id":"007f4866-c8c4-4885-9379-5e5df7c054d3","title":"Teasing Out Tardive Dyskinesia","summary":"Tardive dyskinesia can be difficult to discern...","thumbnail":{"_type":"mainImage","alt":"tardive dyskinesia","caption":"Richelle/AdobeStock","asset":{"_type":"reference","_ref":"image-808b4a905dec1e7bc23681e028cd3a49e4fae1b2-6000x4000-jpg"}},"authors":[{"displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","url":"erin-crown-mhs-pa-c"}]},{"_id":"2eb494b5-42eb-4301-97a7-67471cdc06b6","summary":"Here's how to address medication side effects with patients. ","contentCategory":{"name":"Videos","_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z","_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory"},"url":"managing-medication-side-effects-what-to-share-with-your-patients","authors":[{"displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","url":"erin-crown-mhs-pa-c"}],"factCheckAuthorMapping":null,"factCheckAuthors":null,"published":"2025-01-22T15:15:00.722Z","title":"Managing Medication Side Effects: What to Share With Your Patients","thumbnail":{"_type":"mainImage","alt":"meds pills","caption":"Leo/AdobeStock","asset":{"_ref":"image-bb01cc1bd0cfb7e65295fd3d0f1aa484deafa56e-8064x5376-jpg","_type":"reference"}},"authorMapping":[{"authorType":"author","_createdAt":"2023-11-13T16:47:10Z","_type":"author","_id":"2270b229-89a6-41ec-bc1d-24c4f25de7bd","biography":[{"children":[{"_type":"span","marks":["strong"],"text":"Ms Crown","_key":"08477e92955d0"},{"_type":"span","marks":[],"text":" ","_key":"0d2add315389"},{"_type":"span","marks":["em"],"text":"is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials. ","_key":"910c2addcd00"}],"_type":"block","style":"normal","_key":"fc856dc557ca","markDefs":[]}],"_updatedAt":"2025-01-20T19:12:03Z","url":{"current":"erin-crown-mhs-pa-c","_type":"slug"},"lastName":"Crown","displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","_rev":"w14ZFqLK3vmAl22uSW8PAZ","firstName":"Erin"}]},{"published":"2025-01-21T21:00:47.382Z","summary":"COVID-19 increased the usage of telemedicine drastically, but is that always a good thing? ","contentCategory":{"name":"Videos","_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z","_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory"},"factCheckAuthorMapping":null,"factCheckAuthors":null,"_id":"e8fb026a-3229-4ab6-a805-adf59ff8914b","title":"COVID-19: The Advent of Virtual Psychiatry","thumbnail":{"_type":"mainImage","alt":"covid","caption":"jijomathai/AdobeStock","asset":{"_ref":"image-fa6af06ba6f9bfb9e1ef56a588728adedf345251-1500x643-jpg","_type":"reference"}},"authorMapping":[{"displayName":"John J. Miller, MD","_createdAt":"2020-02-21T11:23:21Z","_type":"author","_updatedAt":"2024-03-27T15:40:23Z","url":{"_type":"slug","current":"john-j-miller-md"},"_rev":"iETXi7W7pY87NNzCpcZa11","_id":"pst_author_324713","biography":[{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Dr Miller","_key":"1caa3e4a631c0"},{"_key":"1caa3e4a631c1","_type":"span","marks":[],"text":" "},{"marks":["em"],"text":"is Medical Director, Brain Health, Exeter, New Hampshire; Editor in Chief,","_key":"1caa3e4a631c2","_type":"span"},{"_type":"span","marks":[],"text":" Psychiatric Times","_key":"1caa3e4a631c3"},{"_type":"span","marks":["em"],"text":"; Staff Psychiatrist, Seacoast Mental Health Center, Exeter; and Consulting Psychiatrist, Insight Meditation Society, Barre, Massachusetts.","_key":"1caa3e4a631c4"}],"_type":"block","style":"normal","_key":"b9bc238502dd"}],"profileImage":{"_type":"mainImage","asset":{"_ref":"image-a429e28c06070418331e927699954a278efa97c9-1500x2100-jpg","_type":"reference"}}}],"authors":[{"displayName":"John J. Miller, MD","url":"john-j-miller-md"}],"url":"covid-19-the-advent-of-virtual-psychiatry"},{"url":"factors-when-choosing-an-adhd-treatment","published":"2025-01-21T13:00:00.000Z","summary":"What 5 factors should you look at when selecting ADHD treatment? ","thumbnail":{"_type":"mainImage","alt":"ADHD","caption":"TA design/AdobeStock","asset":{"_ref":"image-4c94906465b48a9c3f4a9a2281bb33d7b58c9fec-2697x2025-jpg","_type":"reference"}},"authorMapping":[{"_id":"2270b229-89a6-41ec-bc1d-24c4f25de7bd","biography":[{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ms Crown","_key":"08477e92955d0"},{"_type":"span","marks":[],"text":" ","_key":"0d2add315389"},{"_type":"span","marks":["em"],"text":"is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials. ","_key":"910c2addcd00"}],"_type":"block","style":"normal","_key":"fc856dc557ca"}],"_updatedAt":"2025-01-20T19:12:03Z","url":{"current":"erin-crown-mhs-pa-c","_type":"slug"},"lastName":"Crown","authorType":"author","_createdAt":"2023-11-13T16:47:10Z","_type":"author","firstName":"Erin","displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","_rev":"w14ZFqLK3vmAl22uSW8PAZ"}],"factCheckAuthorMapping":null,"_id":"dbbc741c-4208-4d9e-8e42-14c4fcca8e5d","title":"Factors When Choosing an ADHD Treatment","contentCategory":{"_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Videos","_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z"},"authors":[{"displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","url":"erin-crown-mhs-pa-c"}],"factCheckAuthors":null},{"published":"2025-01-20T21:44:42.537Z","thumbnail":{"_type":"mainImage","alt":"covid-19","caption":"Parradee/AdobeStock","asset":{"_type":"reference","_ref":"image-4e6ae26c40a11072254511ecb5197dd4527d5370-4310x2669-jpg"}},"contentCategory":{"_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z","_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Videos"},"authorMapping":[{"_createdAt":"2023-08-11T15:09:51Z","_rev":"KyvDj08oX3Dy2f7SBrYmgE","_type":"author","_id":"cbba7907-0968-4178-84ef-7d5d6d35c52d","biography":[{"children":[{"marks":["strong"],"text":"Mr Asbach","_key":"213db04bf39b0","_type":"span"},{"text":" ","_key":"77085cb0e057","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"is a psychiatric physician associate and serves as associate director of interventional psychiatry at DENT Neurologic Institute.","_key":"8333e174d7c2"}],"_type":"block","style":"normal","_key":"f79e5efc94e7","markDefs":[]}],"_updatedAt":"2023-08-11T15:09:51Z","url":{"current":"michael-asbach-dmsc-pa-c-psych-caq","_type":"slug"},"displayName":"Michael Asbach, DMSc, PA-C, Psych-CAQ"}],"authors":[{"displayName":"Michael Asbach, DMSc, PA-C, Psych-CAQ","url":"michael-asbach-dmsc-pa-c-psych-caq"}],"url":"research-on-pause-covid-19-s-impact-on-drug-development","_id":"270fb0b4-af0d-4ec1-abe9-092b0bb58a25","title":"Research on Pause: COVID-19's Impact on Drug Development","summary":"Let's explore COVID-19's impact on psychiatric research... ","factCheckAuthorMapping":null,"factCheckAuthors":null},{"_id":"5017b18d-2e9f-4406-9b03-2912bfe45e03","summary":"Let's define success for patients with ADHD...","thumbnail":{"_type":"mainImage","alt":"ADHD","caption":"BillionPhotos.com/AdobeStock","asset":{"_ref":"image-d8ac56994505f64acb8a96030cedacd7d9404054-5750x3830-jpg","_type":"reference"}},"contentCategory":{"_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Videos","_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z"},"authorMapping":[{"biography":[{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ms Crown","_key":"08477e92955d0"},{"_type":"span","marks":[],"text":" ","_key":"0d2add315389"},{"_type":"span","marks":["em"],"text":"is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials. ","_key":"910c2addcd00"}],"_type":"block","style":"normal","_key":"fc856dc557ca"}],"_updatedAt":"2025-01-20T19:12:03Z","url":{"current":"erin-crown-mhs-pa-c","_type":"slug"},"lastName":"Crown","authorType":"author","_createdAt":"2023-11-13T16:47:10Z","_type":"author","_id":"2270b229-89a6-41ec-bc1d-24c4f25de7bd","firstName":"Erin","displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","_rev":"w14ZFqLK3vmAl22uSW8PAZ"}],"factCheckAuthors":null,"url":"gauging-adhd-treatment-success-improvement-in-quality-of-life","published":"2025-01-20T21:32:58.500Z","authors":[{"displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","url":"erin-crown-mhs-pa-c"}],"factCheckAuthorMapping":null,"title":"Gauging ADHD Treatment Success: Improvement in Quality of Life"},{"authorMapping":[{"_type":"author","_id":"cbba7907-0968-4178-84ef-7d5d6d35c52d","biography":[{"markDefs":[],"children":[{"marks":["strong"],"text":"Mr Asbach","_key":"213db04bf39b0","_type":"span"},{"text":" ","_key":"77085cb0e057","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"is a psychiatric physician associate and serves as associate director of interventional psychiatry at DENT Neurologic Institute.","_key":"8333e174d7c2"}],"_type":"block","style":"normal","_key":"f79e5efc94e7"}],"_updatedAt":"2023-08-11T15:09:51Z","url":{"current":"michael-asbach-dmsc-pa-c-psych-caq","_type":"slug"},"displayName":"Michael Asbach, DMSc, PA-C, Psych-CAQ","_createdAt":"2023-08-11T15:09:51Z","_rev":"KyvDj08oX3Dy2f7SBrYmgE"}],"authors":[{"displayName":"Michael Asbach, DMSc, PA-C, Psych-CAQ","url":"michael-asbach-dmsc-pa-c-psych-caq"}],"factCheckAuthorMapping":null,"url":"the-importance-of-mattering-in-the-wake-of-the-pandemic","published":"2025-01-20T21:04:00.303Z","_id":"e3c17284-0fbe-4caa-91db-9b3fb5e58fd8","title":"The Importance of \"Mattering\" in the Wake of the Pandemic","thumbnail":{"caption":"jirsak/AdobeStock","asset":{"_ref":"image-a9c1ca867d5768ee3663eaac0fab5c7c22b73970-5616x3744-jpg","_type":"reference"},"_type":"mainImage","alt":"covid"},"summary":"\"Who are you important to? If you passed tomorrow, who would show up at your funeral?\" ","contentCategory":{"_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z","_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Videos"},"factCheckAuthors":null},{"published":"2025-01-20T19:04:25.870Z","_id":"250ea84c-5ea9-4119-9d75-9211f3a6f6b6","title":"Whole Person Care: Choosing an ADHD Treatment ","summary":"When a patient has comorbidities like anxiety, substance use, and depression, how can you best select a treatment? ","contentCategory":{"_id":"42000fd0-0d05-4832-9f2c-62c21079b76c","_updatedAt":"2020-02-25T09:35:54Z","_createdAt":"2020-02-10T10:49:36Z","_rev":"snQqhhB4O8T5bi1viURsgs","_type":"contentCategory","name":"Videos"},"authorMapping":[{"_rev":"w14ZFqLK3vmAl22uSW8PAZ","firstName":"Erin","displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","_createdAt":"2023-11-13T16:47:10Z","_type":"author","_id":"2270b229-89a6-41ec-bc1d-24c4f25de7bd","biography":[{"_type":"block","style":"normal","_key":"fc856dc557ca","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Ms Crown","_key":"08477e92955d0"},{"_type":"span","marks":[],"text":" ","_key":"0d2add315389"},{"_type":"span","marks":["em"],"text":"is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials. ","_key":"910c2addcd00"}]}],"_updatedAt":"2025-01-20T19:12:03Z","url":{"current":"erin-crown-mhs-pa-c","_type":"slug"},"lastName":"Crown","authorType":"author"}],"authors":[{"displayName":"Erin Crown, MHS, PA-C, Psych-CAQ","url":"erin-crown-mhs-pa-c"}],"factCheckAuthorMapping":null,"factCheckAuthors":null,"url":"whole-person-care-choosing-an-adhd-treatment","thumbnail":{"_type":"mainImage","alt":"ADHD","caption":"Feng Yu/AdobeStock","asset":{"_ref":"image-25b1fa5a7736e85e3488981af4900fef2b499081-5616x3744-jpg","_type":"reference"}}}],"relatedTopics":[{"id":"pst_taxonomy_439_conferences","name":"Conferences","type":"taxonomy","url":"/conferences"},{"id":"pst_taxonomy_51523_expertinterviews","name":"Videos","type":"taxonomy","url":"/videos/expert-interviews"},{"id":"416d7790-5dab-4702-b1f8-76ddf93117f9","name":"ASCP","type":"documentGroup","url":"/conferences/ascp"}],"algoliaData":{"algoliaDocGroup":[{"id":"416d7790-5dab-4702-b1f8-76ddf93117f9","name":"ASCP","type":"documentGroup","url":"/conferences/ascp"}],"algoliaTax":[{"id":"pst_taxonomy_439_conferences","name":"Conferences","type":"taxonomy","url":"/conferences"},{"id":"pst_taxonomy_51523_expertinterviews","name":"Videos","type":"taxonomy","url":"/videos/expert-interviews"}],"excludeIDs":["72fc8e94-b0c8-4e74-a8fb-6f7e390a234d"],"articleCategoryID":"8bdaa7fc-960a-4b57-b076-75fdce3741bb","podcastsCategoryID":"93d57b69-2d72-45fe-8b8a-d18e7e7e5f20","videoCategoryID":"42000fd0-0d05-4832-9f2c-62c21079b76c"}},"targeting":{"content_placement":[],"document_url":["research-and-opportunities-at-the-2024-ascp-annual-meeting"],"document_group":["ascp"],"content_group":[],"rootDocumentGroup":["conferences"],"issue_url":[],"publication_url":[],"tags":[],"hostname":"www.psychiatrictimes.com"},"mediaSeries":null,"videoData":{}},"queryString":{"slug":["view","research-and-opportunities-at-the-2024-ascp-annual-meeting"]}},"host":"www.psychiatrictimes.com"},"__N_SSG":true},"page":"/view/[...slug]","query":{"slug":["research-and-opportunities-at-the-2024-ascp-annual-meeting","?utm_source=www.psychiatrictimes.com\u0026utm_medium=relatedContent"]},"buildId":"aMxshKRZGxbHXjz6zV8Pm","isFallback":false,"gsp":true,"appGip":true,"scriptLoader":[]}</script></body></html>